<!DOCTYPE html>
<!-- Created by pdf2htmlEX (https://github.com/pdf2htmlEX/pdf2htmlEX) -->
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>

<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
<style type="text/css">
/*! 
 * Base CSS for pdf2htmlEX
 * Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> 
 * https://github.com/pdf2htmlEX/pdf2htmlEX/blob/master/share/LICENSE
 */#sidebar{position:absolute;top:0;left:0;bottom:0;width:250px;padding:0;margin:0;overflow:auto}#page-container{position:absolute;top:0;left:0;margin:0;padding:0;border:0}@media screen{#sidebar.opened+#page-container{left:250px}#page-container{bottom:0;right:0;overflow:auto}.loading-indicator{display:none}.loading-indicator.active{display:block;position:absolute;width:64px;height:64px;top:50%;left:50%;margin-top:-32px;margin-left:-32px}.loading-indicator img{position:absolute;top:0;left:0;bottom:0;right:0}}@media print{@page{margin:0}html{margin:0}body{margin:0;-webkit-print-color-adjust:exact}#sidebar{display:none}#page-container{width:auto;height:auto;overflow:visible;background-color:transparent}.d{display:none}}.pf{position:relative;background-color:white;overflow:hidden;margin:0;border:0}.pc{position:absolute;border:0;padding:0;margin:0;top:0;left:0;width:100%;height:100%;overflow:hidden;display:block;transform-origin:0 0;-ms-transform-origin:0 0;-webkit-transform-origin:0 0}.pc.opened{display:block}.bf{position:absolute;border:0;margin:0;top:0;bottom:0;width:100%;height:100%;-ms-user-select:none;-moz-user-select:none;-webkit-user-select:none;user-select:none}.bi{position:absolute;border:0;margin:0;-ms-user-select:none;-moz-user-select:none;-webkit-user-select:none;user-select:none}@media print{.pf{margin:0;box-shadow:none;page-break-after:always;page-break-inside:avoid}@-moz-document url-prefix(){.pf{overflow:visible;border:1px solid #fff}.pc{overflow:visible}}}.c{position:absolute;border:0;padding:0;margin:0;overflow:hidden;display:block}.t{position:absolute;white-space:pre;font-size:1px;transform-origin:0 100%;-ms-transform-origin:0 100%;-webkit-transform-origin:0 100%;unicode-bidi:bidi-override;-moz-font-feature-settings:"liga" 0}.t:after{content:''}.t:before{content:'';display:inline-block}.t span{position:relative;unicode-bidi:bidi-override}._{display:inline-block;color:transparent;z-index:-1}::selection{background:rgba(255,255,0,1.0)}::-moz-selection{background:rgba(255,255,0,1.0)}.pi{display:none}.d{position:absolute;transform-origin:0 100%;-ms-transform-origin:0 100%;-webkit-transform-origin:0 100%}.it{border:0;background-color:rgba(255,255,255,0.0)}.ir:hover{cursor:pointer}</style>
<style type="text/css">
/*! 
 * Fancy styles for pdf2htmlEX
 * Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> 
 * https://github.com/pdf2htmlEX/pdf2htmlEX/blob/master/share/LICENSE
 */@keyframes fadein{from{opacity:0}to{opacity:1}}@-webkit-keyframes fadein{from{opacity:0}to{opacity:1}}@keyframes swing{0{transform:rotate(0)}10%{transform:rotate(0)}90%{transform:rotate(720deg)}100%{transform:rotate(720deg)}}@-webkit-keyframes swing{0{-webkit-transform:rotate(0)}10%{-webkit-transform:rotate(0)}90%{-webkit-transform:rotate(720deg)}100%{-webkit-transform:rotate(720deg)}}@media screen{#sidebar{background-color:#2f3236;background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSI0IiBoZWlnaHQ9IjQiPgo8cmVjdCB3aWR0aD0iNCIgaGVpZ2h0PSI0IiBmaWxsPSIjNDAzYzNmIj48L3JlY3Q+CjxwYXRoIGQ9Ik0wIDBMNCA0Wk00IDBMMCA0WiIgc3Ryb2tlLXdpZHRoPSIxIiBzdHJva2U9IiMxZTI5MmQiPjwvcGF0aD4KPC9zdmc+")}#outline{font-family:Georgia,Times,"Times New Roman",serif;font-size:13px;margin:2em 1em}#outline ul{padding:0}#outline li{list-style-type:none;margin:1em 0}#outline li>ul{margin-left:1em}#outline a,#outline a:visited,#outline a:hover,#outline a:active{line-height:1.2;color:#e8e8e8;text-overflow:ellipsis;white-space:nowrap;text-decoration:none;display:block;overflow:hidden;outline:0}#outline a:hover{color:#0cf}#page-container{background-color:#ffffff;-webkit-transition:left 500ms;transition:left 500ms}.pf{margin:13px auto;box-shadow:1px 1px 3px 1px #cccccc;border-collapse:separate}.pc.opened{-webkit-animation:fadein 100ms;animation:fadein 100ms}.loading-indicator.active{-webkit-animation:swing 1.5s ease-in-out .01s infinite alternate none;animation:swing 1.5s ease-in-out .01s infinite alternate none}.checked{background:no-repeat url(data:image/png;base64,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)}}</style>
<style type="text/css">
.ff0{font-family:sans-serif;visibility:hidden;}
@font-face{font-family:ff1;src:url('data:application/font-woff;base64,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')format("woff");}.ff1{font-family:ff1;line-height:0.748000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2;src:url('data:application/font-woff;base64,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')format("woff");}.ff2{font-family:ff2;line-height:0.911000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff3;src:url('data:application/font-woff;base64,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')format("woff");}.ff3{font-family:ff3;line-height:1.000000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff4;src:url('data:application/font-woff;base64,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')format("woff");}.ff4{font-family:ff4;line-height:0.911000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff5;src:url('data:application/font-woff;base64,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')format("woff");}.ff5{font-family:ff5;line-height:0.868000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff6;src:url('data:application/font-woff;base64,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')format("woff");}.ff6{font-family:ff6;line-height:0.913000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff7;src:url('data:application/font-woff;base64,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')format("woff");}.ff7{font-family:ff7;line-height:0.714000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff8;src:url('data:application/font-woff;base64,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')format("woff");}.ff8{font-family:ff8;line-height:0.990000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff9;src:url('data:application/font-woff;base64,d09GRgABAAAAABMcAA0AAAAAGpQAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAATAAAAABoAAAAc22AvXEdERUYAABLgAAAAHgAAAB4AKQAvT1MvMgAAAaQAAABDAAAAVlXXXvNjbWFwAAACiAAAAMYAAAGyrqYEUWdhc3AAABLYAAAACAAAAAj//wADZ2x5ZgAAA6QAAA0AAAARqFm7kP9oZWFkAAABMAAAAC8AAAA2WwWj2WhoZWEAAAFgAAAAIgAAACQGnALNaG10eAAAAegAAACfAAAApFLrBFhsb2NhAAADUAAAAFQAAABUTtxTlm1heHAAAAGEAAAAHgAAACAAbgBIbmFtZQAAEKQAAAHVAAAD2P+36aZwb3N0AAASfAAAAFwAAAB0BCkEu3icY2BkAAPdbVdc4vltvjJwM78A8WtUNzTA6P+b/vMxv2J6BuRyMDCBRAFYCQzRAHicY2BkYGB69p+PgYF5xv9N/2cxv2JIYRBnQAaaAK8xB20AAHicY2BkYGDQZHBlYGYAASYgZmQAiTmA+QwADY4AtwAAeJxjYGSSZ5zAwMrAwNTFtIdBnqEHRP+fyviAwZCRCSjKwMrMAAOMDEggIM01BUgpMFQyPfvPB1T5jOETTA0AKB4MdAB4nB2JsQpBcRjFz3f+brISZVLKiK7tDjeTQbqUrsGC6Q4mo9GijFLKc9g8AE9gsHoEGe/tfr6c+p1O54c3/pHIyrYcMJUSuixrzo0+uIXjGROm8BjDuSI8mRsrvbqLZkyNj/nE/M6ooskFEvpoyA0djtCSO9ry1ZRLBBJiKD0E7og+10YdPseoyQkD2aMiM0T2h5IjZkEzeerrBx6lJ3QAeJzNj1kOAVEQRU+3Nk9taPPQZj8SsQMfEguwAZ8SH+JD2IWFSLAJG7GQUt0IduAm9e6tV/Xq1gMCPKOGgYeTZoafWxyVs9h6Y+IyYcaCFRt2HES05jJiypwla7bsReQOcvPGyFUucvYn2RolxrxhEXypEAmSpHyd1r6MukGOPA4FVUV9V1auUNV9MEK8llQ29TD5hfH8yscp6Jv8IByJxuKQSKpt2s5kyeWd73qBYqlMpap+9UbTbdHudHt9BkP+Ag+57xiWAAAAAAAAAAAAAAAAAA4AJABeAJwA7AEgAWIBqgH+AigCVAKsAvYDJANoA74EAgQwBG4EmATkBRwFfgW+BfQGGgZ0BrQG5gckB1QHkAe6B/QIKgiECNR4nHVXa2wb15Wee4czQ4nk8M0ZvoYajsihKIkSnyOKEmkqoiUr1suSLFm2ZFm25UcdP+vIseMmtlvXTtLYjtskTdts0+3DBdJX1kmKLVq0aVoU6KKLNl1skP2zXSyChbtYbFMni2ZX1J47pB4JdmVI5gyG93zfd875zhkKUTuot9EUkiiaopxpTll4n38fSVsp+EFUx+p96tvUKcpEUUI4ms3k0imP28Ue9oWag/BrbvKGIrIQisKzq1WKwj58h4pQVAtSi0gromxGCXOssvFNHnMs/EuncpqAvlY9ZPIcOvbQ4vx0h9HtCF3YvfNoYHtnbyPz9cSHctgrNZbODg2d33rmM16/u3Pf5FhbpdyksPTeOXczS/Dh1V/CnxP4LhWkwhQlKyVURB1IgRAhxOlXWs6P0k4JhZCJ3MdHPmCzNhMW/jk4ZA1o7B9YWZQF+s6dgSED74m+qeBz8SCDbe43sjfCNBMMGrAvyqAIUle+KQuYRi4UfXuExKaJXvhR/Bpo46ZSIEA6peWymagSZjlaoVkPkMxmkA7CmYt2IC2dE4h4ViQhooSCrOXZZKG/lPQybjVvDPfPz1d9bJfDyTzMNtoL7J8ezZf2zqMt02LhkZ3oaqRjIFswC9X3V6mwdHjo6epXgix2ezHvc2E2iJXIeHHORJvHB5vLfTHI3ejqn/Bb+OeUTFGRNMlCgs5mICmQCIFTcgCU4wEIwYmXpOTk8uCJSpu9P/n9y/lHY82SYfvu56aUyEOzU/v+9q/iSn5kJP7U8bGlgPfZqYmnu58fOHl2TM8BxZBEQA7slAoqEPY6dyJGgt7MX04JhDnHyuiVvgj7CBfvePhWosz6EzNVEXg7mGWmAXgjy3en4m0PnKvex7fM3pV7IdfY9k98NpgqJ+SVk0EWeYCzV0BMcFA5Ubp08FXgSnJxCzAkoIZlIJdArYDEClwhepqwbUUc6xF0YGlO3kD1HPowKjFMtvcRi8mQv9LW7uGlhEQHilfSRmyy713YGZHSKx8APDt7jm109OC732ovBEyOv9hC0d9m5X9SpAZLZtf3AZfbh22QCwPgAU3oXYCnExSRtRwhb0U8AmmgMOvRZdBp42rjGWRFI5nGpgKHHJzmcLDnTHKBrf4HSz4Xqq90A4j163ObnkMX3u2gDcEggzy+lff0jwQTwtWqV0T1K8yvP0PVcKKXAaeb9OzHgRCwSNAjORmCYjMiOE0Q108TRT0i8YzVV1avo7twpkByUT+IlJ+ahZqoif4ScnLk0LNN27r2mzyjiQ75IQZo4btBA/KI1YbrGRV7jfG2p9HvBQ9i9HP/BzS9B+dmKCpd7+0a2rRHcKadkNd6sE2qKkghvciRe//270xI9DU47POEyht8axf9g3PZN2uMaqL+py7qBbp6IXAO77Ex2ONTgzR2CKkh9EI7zQYf/Gn1j4h/fTfAFEBkUUBsXVfTynfxjuqRwYzHiel1vNOAt5X4qkdHWLMBKyIeSCtYXYNGvCpXp/PMTyZfNuyA2G6/ygDkdt5hP1n+4Tw9X8Ozdo+wwHd/VH0CHR3MCDaSB9qgpoaqTvTsr6tLNSD1ezp40qvEE94DT7BQAdKrHKv3v+5bKvFncATdrbUc+oenx4sLE18b7ti768qLpc4vnL/5hcoJ/NU7V24sHfvV+UcPHVKeuX3x9PShL1+6dvaHaz5wFfj6qZaPVlM6pfsex+o9GEJOmgcL1O0RzBLJ1X9l16qKu3e6NJ7tHL411A4ZqTT10sjk9x06+WyzUC/fBLhyc2KpayHY8QsiPx6v/pfVZKGPHrnCb/jRZcDRTnWRCkyR0G7J4GYF4nthNZpTo2q0jmVT+zl1RLp/v4D4d07N+SKORoRtjmLDyKyJQTTrc3X1aB9pP4B8bsvisYFc1s/iuy9tO2DBnD/QEZbGfEE2OBz7rDlstfzZ58YwSljsquGv/m7PTK/Gi9B/YciHBPloh2woOQjtdkm0UJsPXDiqaun6HImqCZimRUzMG30YdDy55UGHs93lHxn0aUtbC+cDvqBhYWhgrFSubBdT88Xk/hA2fHlQ86iiZOJjc32tQ+Uoao98ce+R6e78oCxPlsN9vRG/WJvzS6DZm6CZbyNzRAdFWzNTvavQt6t/x5U9buZyZVtFlKK4C6yTzfaULrNm1zbSEyLeog1/ixjkyk8FMB2Sj9DqfZxGH1BmUhcI9OWx20WKTkvTrL4JkKIrwXjWS69IQ72gn4gR7WAx0lY+MJiaPGr1OjNOMTCVHZbD+NKlzk5/99hyf6uEfuwZO7PcuvX5Y29UT2lbm/nS+MnT/1JJtRw8NpN3A6/E6n30W4jthxkokPMz+vyDkiCFAFBqAxBdF2ee6pmoXJvq2tbm8tHGTNtoWzQ19ILz9vY7Xz2ejgqyNLZwva93K/CJrP4ZH8DvQg8lKUpz6aNO02khTdhgxEZrlOqMoMGh+a+lIrOxbT5PR9f+gowirzAv8qJObRJiWGX82LUD3q7hT/ZlmnCUZR09Jwdnyg9fc42dOYvTIrPyqRpHVMguv/vp6MKR6S47fkm0Ib2324HrP+pcm+tsE5h0ss6XrF1E9SJWyVpGqhzdFGY+500kgxN7HiuU4yO/Qbv9yTb/H5dPNPm6Dz7numFpqqSuLp3ujufig3Gu4Um3Glr07u/2ybfJ/rP636s87sUU5DVP9RM3Wdsm4PgSEqyoLjPxGKH2meyBWlb3Fy27VtA0+Yaqfxkl23o8barWn5q+xcqT7tNLYVdb7oHvPXF034W53oEpA5ZynvaZ7pEnCyOvRvsn0VuFgeZo576BRJSJNZTM/vjoAdoUcPls8TOjM2N9+YoJy/GIghE2lZLBnu7ISqFbm/Ox+WSuj9R9HmpzO+SSLLB0Wq8NblNRkmlFioSDVUIfXCWEek/Sqdv93bJ71O7XU7cjORHa0WAXY/Nlu69l+hmWc+bZu/gP1dzex3cWqh/WcnYMBULq1MG2vhfM+MmgA3OCCDnbBjkbxL+mXFQTeNXm8glHa6PSmdqQbt9rzEP1VphIq17zJGd05V8XQkpQDCnonQBTPV4Llm1HeZ8TMagh4JciQb8vVuOKHgSuzo9HqgW6/TfMSxbB3uUUfdOp7eJ1zujM499A0V3M9Uf53olF3EJg1/yitHqf/hTUWjfMYq6ujMDVBISti/wvIe7jbNakhM/EXdhnpw9xBnsv+ypTorNXH8iEBJdB+3RfLI4ah+s8oS/8lp2NTq+6q+T2JqZ9Q55M1+Mhpxl9EdyfEQPM3+87MzxY2n8qVo6taZ1JoGhTdMdisvuvzYtInHxxNFnDjGcAs/p/YP5/oD43c8TI2ovs60yZ7rxR6Q67R9ZwZVUfv7PB7o3Olt2hDTTvzF3eyHlXHEWC8YmDnUOkP5MQvxHi8yTXqO6CRdjJ1ZSESYfW7Q/t7BhJeGfVvrhk3iEXtKbS+K3dc9aW0jH01tDxE61H8xOLw+IRxR4ZTJ7c//jihLR9YSRbm30e6MkhiGEhLCPQ7fqIheaHrDiLaDNnGDE0dCcy5vckvbnYfjUpKQd2PWVARnMRMpKntes9J+yJvtOVwWZhcvmoMrHQP/2MtGLGj9ntFp3sW4dOXfVPnpgre0hNVKC+fgaxg7q+Hw3m4fQaJlh49KWde2pRXmbacWyhVRBQ0GFTrcF+f0MzSOm0mfXjvzm2W3B7Yt7lxabbcL4Tzv8cnE+myCYLB3vRB+b6a6ZQ3y1Ucon43r6Q3WUMJf3KQCo+P/rAhOQRGsypQFOsMgPlkAq4va5KzJvpbtka3zLdo7hlSW2PKUVtoFKaJLyGIe7n8WGyz8I2+ZE6UbS0ThFdv7jL7HcXPR55b1ezaJmdMI1b9pnDj6E3q5/vrETsxVGtFR2PJoe5Zb1/eqEW9gEXeGtFGjlzfQhuNCScXIuWQ+/t+gTvl4picDo9HJJx583KkWiFY6AyX2MWhM78w2oQ3TNXD+eOWnt3HDs9d+kWMsL4JSJWb8zcnCX2TE1CTBvEDNX735P2wJzPqDnSq25S7uumM/sDZtrocsUODhnMYdVgNaNy+vHT7WADLGMr6k5zMdyM9j/fNxF3e6KOjtuV75T74MVsfVeHWE6IVSKTiNQZHKpwvGE9RzAnSgh2GitStRBKkym1nlFOz2ARo7d9VrfS5muO2Bw45rQoYsQVVERno2SzSEOBZiPPP0h/g43htnJ/2mc3u6wWZbzJ7uAbXaLpCT6kdAjd5ZE+ydPhcAQ9zpC14WLnLdkBsqQMd/oPt7oCRuPNK5VWa8RFML+9yqO/AOacrg8s7KB8XRwXz3CwkK3h11LC2huuTqH5jtHH0+edVhxpMRhZ1sb7bWEuUEgb5FC73Optamly2h2Cw6rwosxabP3ol52G69Xf/64/N+m1+G1GQfYn/Jq5fWmGy6e3eB1htyeCxJDa1N33yXstAYSp/wX0eFpCeJylkk9q20AUxj/JTkopZFHcrt/SIZGRBQlRdsZgcMgi2CTdVrEmioisESMl4Bukl+gRuugl2kuUHqB02X2/GQ+FQimlsZl5v3nzvnl/EIA9fECA7e9dMPAcYBB89hziWfDdcw9x+MZzH4Pwo+cdvAi/et7FoPeKkUH/OR966VSWAwyD955D7AVfPPfwNvjhuY9h+Oh5B6/DT5536f+GKTQabGBQosAtOgiGWGGfdowUJ1yHnlPugglyaq6hyEsqW2oU1rSCOWpqNV9r3J65uxwj3lllxb9g8StX606KVjH6wcde8sZWVVIv3G2UJcP7wp07F2+jhWzz5K6GjHxHn8bNf1eKqW42pixuOxmu9mWcnqSH3NOxTHJ9rWS5aTu1bmVer7RptMk6lY9EJlUlC6tqZaFaZR7ovex0U2ZStpKJUUVJoVG5dCbL1Tozd6Jv/vYoOIlznLH2KS5w8NtcInbQ0VY8rRh4fracXhxsE0bzLqtKehduYPcMsoPBQhX3VUaY8Zma8plrvXADSth6THvK9a9pt9EJdRGOuSwlOGICXXczbQolySiWU/lTeXQncXQcJXFy9OROr9wH0TLEdmY/V9sNrpRpS13LeBQ/NcVPOGi9rgAAAHicbcvbCYJgAIDRky5QD26gXSjBimqBUKmgG5lSazZZA9Q/gB+cx0/E7xt8rPQ1CwYisaGRRCozNjE1t5ArLMO5trG1s1eq1A6OTs4urm7uHhpPrc7L+w+5zAzjAAAAAf//AAIAAQAAAAwAAAAWAAAAAgABAAMAKAABAAQAAAACAAAAAHicY2BgYGQAgsci56JBdI3qhgYYDQA++gXEAAA=')format("woff");}.ff9{font-family:ff9;line-height:0.984000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffa;src:url('data:application/font-woff;base64,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')format("woff");}.ffa{font-family:ffa;line-height:0.748000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffb;src:url('data:application/font-woff;base64,d09GRgABAAAAABTUAA0AAAAAHRgAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAAUuAAAABoAAAAc22AvXEdERUYAABSYAAAAHgAAAB4AKQBMT1MvMgAAAaAAAABEAAAAVlcenjdjbWFwAAACtAAAAOwAAAGwOK6qbmdhc3AAABSQAAAACAAAAAj//wADZ2x5ZgAABDAAAA3SAAAS3MKFwydoZWFkAAABMAAAAC8AAAA2WxmkCGhoZWEAAAFgAAAAIAAAACQGjAN4aG10eAAAAeQAAADNAAABGKHGCfVsb2NhAAADoAAAAI4AAACOo0aeYG1heHAAAAGAAAAAHgAAACAAjQA/bmFtZQAAEgQAAAIGAAAEPk3MAilwb3N0AAAUDAAAAIIAAACuB1QG9XicY2BkAIMY471e8fw2Xxm4mV+A+DWqGxpg9P+3/72YDzPdBHI5GJhAogBLZwyvAHicY2BkYGC6+d+LgYH59/+3/98wH2YAiqAANwC/aAgIeJxjYGRgYHBjsGFgZQABJiBmZACJOYD5DAAP6gDNAAB4nGNgZEpgVmBgZWBg6mLaw8DA0AOhGR8wGDIyAUUZOJkZYIDRgQEBAtJcU4CUwm9Gppv/vYAqbzJsA6kByQEAwtILQXicNY+9DgFBFIXPvVsRlQIbxBYkIootbQijFoVOv5VW4Q0k+wYKiQeQeAeJN/AOSqVsRGScGUzy5dw599z5kSH8kjlhHbwwky7a0rW5jDCVHWKnukGHrEhEKqT1U+ePSNPVPrtErGeb6xVGc/SI0RNMUGT2hjHvMbpAg7XRlP6BM/R9/59zs3tUNUNZM/sILoDu7Z1ejbPuroQa+fekiGSNErXufL5/wp5Xnp34bOqziRzZ66MuWxS4H2ho38GUZ4f2+YV/ylD6AN9kNzEAAAB4nLWPOU5CURSGvws8AXFAEUUFfQ6oDCKCI4qKQtyAsbCzJDTGkkW4EJcClJAYW5dBcTzvPQ2xsuJL7hn//CcX8OO9JAaHd+2M2wd405wgqpMQNgUqVGnwwBNNXmgPjYgqbNIUdVPjnkeeafHqbOQL5FM+ZCB9rXrSlY5Vd70X+cVmRMCNFhNuDurNMBmyWufIg9G5+ZEanwYffzHeRxwfS7XBUJjJyNT0zGx0bj62AHHn8lJieYXVZGpt3d7Y3NpO7+zukcmSy3se+4WD4mGpfHTMyenZeeWCy+rV9U3t9q7O+Gn8q/gGebUm4gAAAAAAAAAAAAAAXAB2AJAAqAC2AMIBAgEWAUoBiAGkAdICDAIsAnwCugLMAuAC/AMwA1gDdgOMA7wD0gPeA/oEFAQkBEIEWgR6BJgExgT8BUIFVAVqBYwFpAW6BgAGLAZSBn4GqgbKBwwHLgdAB1gHZAeWB7YH1AgCCB4IbgiSCLQIygjsCQQJKglACW4AAHicbVcLdBPnlZ7/l6zxC9uyNCMT27KksV6WLFkajWT5IUu28RMbI2QbYvMIBBOMMQGCQ4IpxmRJYBPqFvAJENbgxiF1k9BQ2lItSZM0NK1zcnqyDjmbXU7PafcknN2EbHJ28+Dh8d5/RjLQreeMRpL/e//v3v+7372iUqjW+U8Vr+OPqGxKQxVRDqqSonK1euwNYZ8Lm7KQhkN8SgjxXpbRqqwqy73v/fcufAunLbbkpWGclmdZnDa1AR3bMNeBumNdnbHu7hjOWnj72H0LcZ4z386y9nz5MXcB//e/dPX3PbjqEYQ2/8/Cu8H7VlGIKp6PIg/+hMqgKA2v0ql0nAtZQ+js2A6lcsdYpALjCvzJ59eufj5yZc/IexT8ofnvwEYp2yh4PdJlIZrzW/1p8vIIMcWfjLw3sufKyOdXr0k2VGQ+St2m4lQmRfECz2izMC2EUCASL66sNNjMKfEpvq2EVXSkO23S+jLqD2gTWkkpKMpsFIxok/hHFPjDmOwLXokvhewrEo/H4RtMmee/w1H8DpVHOcHKG1IIPpeSM2VhRqtX6kwuLPhCCt6rx7A7qjS42EUYq7Lz7PkWr1aF6ew8G9M0ECrKLQmtrmh5tNZgqH10v95W7youtAYtZo2tpdpZYC+3mjWHK/uGm4ObemutFX17x/b2VcoxboaXd/FvqFR4cgLrD/BqDuWcWzGU8txF9Mpe3LB0rpGsMwDYZYATnnbkD4RwIIQEn4Uz0ZzFL7ECsqOCy4iXzX2It+QHe1WlLo99B55IfX5023iBv8K6SBV1otZne3W2gFIvGG3u50bP7OwvbfLb82gl75DwsJCPGOxTAh8ELxvwSpvAERPu6RGQj2YIBTmTJcCrWN7rF3ycCSFan7o96PAF0YTi6GO1j0Z51+Pndo5O0hO4JlwWGc5GviGMmo1mn3v7MNdT51mWiov2D+44OBIKORxrKeksiuClE3KRTmXB7jzDMZxgFBCPeIFDt3p6psU/ofKfiD+9gJFj7NSpCbRP3PGXBOZ2sCukqABwS8IkZUZjZIw0L6eHIGan0ZISb22Fr810sh5dEt9/APOdAz+Y2Lfn+X+1loW8vhoBHR7b5318YPjgFuo+fmRQVvCuZZPOVWbOYiXPe/wTspAPf6r2+Gpryt0h9OREar62sK5eiUuH1h4483jLthr9qfF1B264QjVOvrbuM7M6Y0tDy8F1uw9V9j3ZcPqDh8gZVMHGAYgnB+pLMDJQKioa8g8nHhCq0O0HegyN+NcKl8OwUouLTh5iDzSd+FXjxVjT7iwMmBVUIWB+EDCnwyn6waFJxWhZCXeKzx8QXEAc6TSxdJrkULMQQS8vlCNE1Z4l9evrIuJrrZWewIrtNe7upa6gq7qhe7gl8FCXFxW5qqpLHeEQqvCVeTxlXrewtXpNOs5s90V6illnm9cThU8rI80P21l3N7pgtTusdrvNdl9O7YAumVDYmuZZHdk/wBFAFimbEjwMn5BPqAkL7nD17ISqYDEXDikw2+nZNPrCtvX/UGlq2L18/T7UHfGU1USc3tpJgzpnQ7vFfHDT4HNrxh9qP9BfuU46T0kHMA1ZoiG7QDA1qMHteBzT8fjcTSIKGHQkiG3obXkNYoxCCtzYJqai7+F+e2zs+zEQFTz/HbzM4BlYB6qGaN6aBlzlrByN1i6fXCaOo4w3UMY7zpulWHnr1twdPDPnHxmB1WGwexW/T6kolnBew/BQZRxSG/3ykZCQjQomQbVbxx9+WHwdtfOx9lLeEawV/+v0WKHbYUTBFzti4nt4BmWbWwV3K5vTW/1nXHHIyBUbZW0pmf8afwSaqyPa4oKMqqTTDfBSdnMIVfFHcbqtKhaNxsKtKXH6l4cnrlyZGP49el8I7rmwpyH0zAtXUejqMbkWCO4PId5UwkxebZRpr1DzRIq4MOJfjP9m6omV/T1X8Mzll16L4xJxCPdueZtgIbYHwDZDsmSSVxgHxf1ojTiJDuGZ43vHnjkDa82AexZwQz0jNWddQAtt494wOAHP7s4wbS0nmNuf2ZgaV3YESSj1K1NH0dPiE+1lpQS974nOUgGiqfQclvMSAiznkljki4MrFP8mHv8Gz4h3kHLOjyziv8m4qVvSGUtrw3FyivB9AWDMge9zCEYtAKwGwZKLR41zbj2987yZMxnBWd7Xz44U1XIWhxddS+Thxt29NXwa4hQ0E45/fl38Htmvv7UUbL5EueJ1cRlydlxL5q4RbFJkG8haHLUBjo/PUMneplgN/8+WcqvhNUYSjwIudQTl7sF7UO55PH5kHIPrYnRtzo/1c38ldyIXLy3g0Ui5ALvQb7/H5+EGiyZ0CbLxhliX0MOv8adwNjTZzZ/jN7A5KgMm8uKzmMyXUdPly+IlHH05Gn35XVQ7Oyu+OYs+uLAH0n+XQ8dhvzRKvcAhI8eopRqwAIlWbDsqiif2Pux34ZlHh779Egu/XlXmSuz9K2nvRVQ+9GraqpJ4YQAPtDmgI8UiUyOA/9q5vmnNi5cJnFXiZysaDARQjM3OWrnOPEtgnT29aUt3vbB8FUGmTOC6DLgKqGIZV7LX6VggnVJwKRxoMVpAOVC3taXC37MojbmUQisVMFBpS4qee6FLsOMZ6+olVesZzB7/R5bW6XWF2OB05Yl3sHA2ZrGS89JBDp+CODykX8l661JYXQpZlmE/v6yHeoVOr0iony6eMuqu03q4Fbml4QjXu69p6ByK43pPsZ9x29pYZyRs8vX0hw6e/2pbsTk3n81gUhYVuJrcLX32XdtL7YWGnLzczFxVZqG7yRVZJyz+gcydXIh7COKWlI5UAVTV0NX4VTxzZu5jXHKGzG7fwJqjiTXAKmCJBh+9/vFf3nkWP0vKAe4bWCP7Iw3odzIXyVousZ5cit9dia/H6994O74Rbz6/GW8ktugLUQvPb3E6ueVZ8Qbsd17SGSoNBECN+HyEz4t34uKd2SNHgJJh8VuUjt4S/4xMZM+8hLakkdkOweTHICOThwbFl3GTeAg99Tz68Zkxse8M4VAh5N6FWeB7WbKfW8nkFOD8ASIxikKk1UFrV0n9J6RMjlnv2Yqq3IoMk3tRQ/qEsi280RapdeZrf6ZSVg+2b9CXNAZWMHkMX9R8XF/YtJxOS1Ooz64pLU5lLTWO/+i15xjDHW32SqMuNVOZotXl5xMsQcASA9xqYB2pPiYxShDBs3KMhnBAbgLBaSysfWSna6C9l8f99ppNPq8Hz9xpOrm1bW+stQodq20eX1UdjMpnYAC/AsS4oPuSMCVkXx5RcNkU8hgHeW9s0VTGWP/QyWPDfT9CzQbHifKOVX27jg3t/actUs0RX5WAMZ1gTA4IgEgDROHIzIMkhzpIvNfv9fo3eq5OYr63fcC185G1AkbHosHQyh+Fosg/569qje1t23qy8XbCbxtgVFEPkF8RkqynGKXh7T6gM7M4WOKsQLvEA7haMAiZE+wPV+8/9ZNdTx9BQWeo4of+sD6/s/vo/qFTF0js8FsB7QK8WpJRTuAlcAypp0IyUarXRKPdg2h5HmvU9/WhE4PbYordCo1RNyhukuLNn2/BbokfpeApOZgAKo1am6UAWNbEjFKN7hlSSPhHPILP7fHwvrO0nu9b0v901rRKx9gDJqxrsW/f+WT/mlKM1OWtrQG+sR45xHKD0OItblxrzMwIVXqKbUceG/hxR4TEEAQgoWQMPGmvvJeBYHzSwMmogQ2anrJ/nqaza0rdUA7fWt1/FH9xu1VbFnaLn8o6WwOv/yn1LVryAtrFCTXT05ieu4lnRkeT+/Tc7UUBntZwVpoJTp+68ubHH+xzguuxV98V3/jQ8ZLEq7s+pfU104leCH4UGyFnXILFBK9OKiZArfbJyYc30jM4hfPa3TvMNRvcDRZWNW0BqZ0Ou22YbrS5YrHCkrCfE2eQp8Rd1ywi64aa9rm7OWETOWH+f06msK53ISd04/0pkflWB/ZS38pN9Cvs83tZrco04xnwegf+/cRXJ09+hUJDnV2PdYs3vzh9+osXKLlOo1Cn7D01kJiREyUrtQqpZNESuTbFt+4vgkR5zr2Jf5ksgs+oZE7RNFbLE1Uyd4wcU80U1kQDOrW5oKoe0z0en/JUeqNPnCd2+RBPLmCqJD1Eq0t0EZpzpYBqYTLc6zgpN3IbWZjx8ycL8qx6ryKVzkpV0zCqLLVUFuqcLW0lrvbGEnya1ZqadW5rfXZDqH1L2BNrdf7MzOTmF6gy02iVMgUrlTnpi/W8qTRiys4uXlJWlLXImsXkpGUqsmIltV3GXNtSKa60+dtoB35R0iD4ISeVEM+YVNKkBHUJUzfasVlfRBemZobVAy1dXUDNwS8KGbw3ZemW64OnT8v5KYc4q2Fe10qzoJCoOWBfctaqBj6tdPV3TZeUcBWE3XD027eicnHW6/CHEAv9BAiEC8DHvf2r4LV3X319LV4n1QMt/hR13+1fEUz/3f4VmXwlipe/MvlKN26ZXAo/VcEWrRLPgf3PUQfM6Mvk/nUT9jOAD6grTmPldYnCoi9OXW5uvjh56fKDnSjnu+Hh/xVvjI+T9cAvYyJGRRZyIEE+TWyVsRo/KFy9tqNSb8nIzMUHL0IPhZ3f7yg7XJSfbjO5U9Bm8TWU0H4W9laCL7kXcnIvZJHiS/R7cQ6xTyE0ul+8Myr9TgStxM0JjQBmGxMqgf6ebqKJ6Wnxt/eKZ1JJoIf/rYz+H7gPZRcAAHictZLLahsxFIb/GSeBttBNoYt0kbMpJE3sTMaJsbMpJuQGxpAEvJc9ijNkPBpGY4Ofo/Q1+hBd9om67C9FhCzaTWlHSOeTzlVnBOAtviHC0/c1OggcYTv6GTjGZrwTuIVe/CXwBrZbCLyJN61u4C2eL2kZbbyi+pP3chzhOPoeOMbr+F3gFor4Y+ANHMc/Am/ifetD4C0ctz7jDAYV1qiRY44HNBDsYoY9yiMM0Oc4CDxA8oK7pCEy+k+hyXeMYumvsaAUXKNkHMPIlV+V12XoUOc8Cw7B7XNe63eaUtN6FWyvKAu/a2g5YxShdLaOGh838zkV+ZFnBvdcR7QqyQ2rqqhvh0iFz33p/Ut6HvraXMynCiyWvI/lPuNUvi+upg5wZqp1nc8fGtmd7cnRoN8/4DpI/NqVYWamWu7WttELK9flzNSVqVWjs47IsCjk1vlaudVW1yueXulipZt8piS3oqSpVaYXqn4Ucy+jvDTNutJtGhUyvBRVZoemlpwB7HJq8yxXda4ty5rwruecNxhj/zf9GpOXzx1Q1K3pNDof3Yz3n0sY66XLpVbUvTALJxdsUsmAF75Zc/+7U7YkoTzl/JsSnjxTxmijx+koxQmTmbK5MPVcS9pJ5FT+XCqVadLutdMkPfkPfZj4h+iegru9e/buxpjo2uamlKNO8u+T/gLy3dCdAAB4nG3MW0+BAQCA4Qc3tmy0UA5tLhLLIcealjtKmNBCDj+z+/4Z37r2bO/tK+zf8VfLOW9BIWERURdi4hIuXUlKSbt2IyMrJ+9WwZ2ieyVlDyqqauoeNTSDe1tH15NnPS9e9Q0Mg/+7kQ9jE1Mzn+YWlr58W1nb+LG1s3fwdwL1YBBJAAAAAAAB//8AAgABAAAADAAAABYAAAACAAEAAwBFAAEABAAAAAIAAAAAeJxjYGBgZACCxyLnokF0jeqGBhgNAD76BcQAAA==')format("woff");}.ffb{font-family:ffb;line-height:0.911000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffc;src:url('data:application/font-woff;base64,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')format("woff");}.ffc{font-family:ffc;line-height:0.748000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffd;src:url('data:application/font-woff;base64,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')format("woff");}.ffd{font-family:ffd;line-height:0.708000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffe;src:url('data:application/font-woff;base64,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')format("woff");}.ffe{font-family:ffe;line-height:0.000000;font-style:normal;font-weight:normal;visibility:visible;}
.m0{transform:matrix(0.285000,0.000000,0.000000,0.300000,0,0);-ms-transform:matrix(0.285000,0.000000,0.000000,0.300000,0,0);-webkit-transform:matrix(0.285000,0.000000,0.000000,0.300000,0,0);}
.m2{transform:matrix(0.285000,0.000000,0.000000,0.300000,0,0);-ms-transform:matrix(0.285000,0.000000,0.000000,0.300000,0,0);-webkit-transform:matrix(0.285000,0.000000,0.000000,0.300000,0,0);}
.m3{transform:matrix(0.291000,0.000000,0.000000,0.300000,0,0);-ms-transform:matrix(0.291000,0.000000,0.000000,0.300000,0,0);-webkit-transform:matrix(0.291000,0.000000,0.000000,0.300000,0,0);}
.m5{transform:matrix(0.291002,0.000000,0.000000,0.300000,0,0);-ms-transform:matrix(0.291002,0.000000,0.000000,0.300000,0,0);-webkit-transform:matrix(0.291002,0.000000,0.000000,0.300000,0,0);}
.m1{transform:matrix(0.300000,0.000000,0.000000,0.300000,0,0);-ms-transform:matrix(0.300000,0.000000,0.000000,0.300000,0,0);-webkit-transform:matrix(0.300000,0.000000,0.000000,0.300000,0,0);}
.m4{transform:matrix(1.200000,0.000000,0.000000,1.200000,0,0);-ms-transform:matrix(1.200000,0.000000,0.000000,1.200000,0,0);-webkit-transform:matrix(1.200000,0.000000,0.000000,1.200000,0,0);}
.v0{vertical-align:0.000000px;}
.ls12{letter-spacing:-3.600000px;}
.lsc{letter-spacing:-2.664000px;}
.ls11{letter-spacing:-1.296000px;}
.ls7{letter-spacing:-0.648000px;}
.ls2{letter-spacing:-0.468000px;}
.ls10{letter-spacing:-0.432000px;}
.ls3{letter-spacing:-0.360000px;}
.ls9{letter-spacing:-0.288000px;}
.ls4{letter-spacing:-0.209880px;}
.ls8{letter-spacing:-0.180000px;}
.lsa{letter-spacing:-0.167904px;}
.ls13{letter-spacing:-0.108000px;}
.ls14{letter-spacing:-0.062964px;}
.ls0{letter-spacing:0.000000px;}
.lse{letter-spacing:0.062964px;}
.lsf{letter-spacing:0.104940px;}
.lsd{letter-spacing:0.108000px;}
.ls1{letter-spacing:0.180000px;}
.lsb{letter-spacing:0.209880px;}
.ls6{letter-spacing:0.360000px;}
.ls15{letter-spacing:0.640000px;}
.ls5{letter-spacing:0.720000px;}
.sc_{text-shadow:none;}
.sc0{text-shadow:-0.015em 0 transparent,0 0.015em transparent,0.015em 0 transparent,0 -0.015em  transparent;}
@media screen and (-webkit-min-device-pixel-ratio:0){
.sc_{-webkit-text-stroke:0px transparent;}
.sc0{-webkit-text-stroke:0.015em transparent;text-shadow:none;}
}
.wseb{word-spacing:-3.600000px;}
.ws164{word-spacing:-3.096000px;}
.wsc8{word-spacing:-2.808000px;}
.ws48{word-spacing:-2.052000px;}
.ws17e{word-spacing:-1.920000px;}
.ws16d{word-spacing:-1.908000px;}
.ws12b{word-spacing:-1.872000px;}
.wsc4{word-spacing:-1.836000px;}
.ws141{word-spacing:-1.764000px;}
.wsb{word-spacing:-1.692000px;}
.ws161{word-spacing:-1.656000px;}
.wsc6{word-spacing:-1.584000px;}
.ws134{word-spacing:-1.512000px;}
.wsc5{word-spacing:-1.476000px;}
.wsb2{word-spacing:-1.368000px;}
.ws47{word-spacing:-1.332000px;}
.ws140{word-spacing:-1.296000px;}
.ws89{word-spacing:-1.260000px;}
.ws37{word-spacing:-1.152000px;}
.wsb9{word-spacing:-1.116000px;}
.wsb7{word-spacing:-1.080000px;}
.ws17a{word-spacing:-1.044000px;}
.wsa2{word-spacing:-0.900000px;}
.wsa5{word-spacing:-0.864000px;}
.ws115{word-spacing:-0.828000px;}
.ws139{word-spacing:-0.792000px;}
.ws11{word-spacing:-0.756000px;}
.ws128{word-spacing:-0.720000px;}
.ws1e{word-spacing:-0.684000px;}
.ws146{word-spacing:-0.648000px;}
.ws17c{word-spacing:-0.640000px;}
.wsec{word-spacing:-0.612000px;}
.ws10d{word-spacing:-0.576000px;}
.ws4a{word-spacing:-0.540000px;}
.ws14c{word-spacing:-0.468000px;}
.ws94{word-spacing:-0.432000px;}
.ws13a{word-spacing:-0.396000px;}
.ws87{word-spacing:-0.360000px;}
.ws77{word-spacing:-0.324000px;}
.wse7{word-spacing:-0.288000px;}
.wsa6{word-spacing:-0.252000px;}
.ws13b{word-spacing:-0.216000px;}
.wsb8{word-spacing:-0.209880px;}
.ws2f{word-spacing:-0.180000px;}
.wsca{word-spacing:-0.144000px;}
.ws32{word-spacing:-0.108000px;}
.ws136{word-spacing:-0.104940px;}
.ws11f{word-spacing:-0.072000px;}
.ws17d{word-spacing:-0.064000px;}
.wsdf{word-spacing:-0.062964px;}
.ws0{word-spacing:0.000000px;}
.ws175{word-spacing:0.062964px;}
.wsfd{word-spacing:0.072000px;}
.ws4{word-spacing:0.108000px;}
.wsac{word-spacing:0.167904px;}
.wsd{word-spacing:0.180000px;}
.ws50{word-spacing:0.209880px;}
.ws4d{word-spacing:0.216000px;}
.wsae{word-spacing:0.288000px;}
.ws3{word-spacing:0.324000px;}
.ws4f{word-spacing:0.360000px;}
.wsd4{word-spacing:0.468000px;}
.ws156{word-spacing:0.504000px;}
.ws122{word-spacing:0.540000px;}
.ws12d{word-spacing:0.576000px;}
.ws154{word-spacing:0.612000px;}
.ws162{word-spacing:0.648000px;}
.wsc0{word-spacing:0.720000px;}
.ws132{word-spacing:0.756000px;}
.wsaf{word-spacing:0.792000px;}
.wsc7{word-spacing:0.864000px;}
.wse{word-spacing:0.900000px;}
.wsee{word-spacing:0.936000px;}
.ws6a{word-spacing:1.044000px;}
.ws170{word-spacing:1.080000px;}
.ws20{word-spacing:1.116000px;}
.wsbf{word-spacing:1.152000px;}
.ws16c{word-spacing:1.188000px;}
.ws137{word-spacing:1.224000px;}
.ws13{word-spacing:1.260000px;}
.ws129{word-spacing:1.296000px;}
.ws5b{word-spacing:1.332000px;}
.ws55{word-spacing:1.368000px;}
.ws33{word-spacing:1.404000px;}
.ws106{word-spacing:1.440000px;}
.ws10c{word-spacing:1.476000px;}
.ws165{word-spacing:1.512000px;}
.ws12a{word-spacing:1.548000px;}
.wsf2{word-spacing:1.584000px;}
.ws7c{word-spacing:1.620000px;}
.ws10e{word-spacing:1.656000px;}
.ws8c{word-spacing:1.728000px;}
.ws98{word-spacing:1.764000px;}
.ws150{word-spacing:1.836000px;}
.ws5{word-spacing:1.872000px;}
.wsf9{word-spacing:1.908000px;}
.wsa3{word-spacing:1.944000px;}
.wscd{word-spacing:1.980000px;}
.ws3b{word-spacing:2.016000px;}
.ws110{word-spacing:2.052000px;}
.wsb3{word-spacing:2.088000px;}
.ws14a{word-spacing:2.196000px;}
.ws67{word-spacing:2.232000px;}
.wsfc{word-spacing:2.268000px;}
.wse3{word-spacing:2.304000px;}
.wse8{word-spacing:2.340000px;}
.ws3f{word-spacing:2.448000px;}
.ws107{word-spacing:2.484000px;}
.wsbe{word-spacing:2.664000px;}
.ws96{word-spacing:2.700000px;}
.wsa4{word-spacing:2.772000px;}
.wsd9{word-spacing:2.808000px;}
.ws147{word-spacing:2.844000px;}
.ws8d{word-spacing:2.880000px;}
.ws4c{word-spacing:2.952000px;}
.ws1d{word-spacing:3.060000px;}
.ws56{word-spacing:3.096000px;}
.ws100{word-spacing:3.132000px;}
.wsea{word-spacing:3.168000px;}
.ws10{word-spacing:3.204000px;}
.ws93{word-spacing:3.240000px;}
.ws111{word-spacing:3.276000px;}
.ws36{word-spacing:3.312000px;}
.ws44{word-spacing:3.384000px;}
.ws4e{word-spacing:3.420000px;}
.wse4{word-spacing:3.456000px;}
.ws79{word-spacing:3.492000px;}
.ws34{word-spacing:3.528000px;}
.wsdc{word-spacing:3.564000px;}
.ws163{word-spacing:3.636000px;}
.ws6{word-spacing:3.672000px;}
.ws97{word-spacing:3.708000px;}
.wsf5{word-spacing:3.744000px;}
.wsed{word-spacing:3.780000px;}
.ws90{word-spacing:3.852000px;}
.ws135{word-spacing:3.888000px;}
.ws5f{word-spacing:3.924000px;}
.ws21{word-spacing:3.996000px;}
.ws138{word-spacing:4.032000px;}
.wsf7{word-spacing:4.068000px;}
.wsc9{word-spacing:4.104000px;}
.wsf6{word-spacing:4.140000px;}
.ws27{word-spacing:4.176000px;}
.wse0{word-spacing:4.248000px;}
.ws2{word-spacing:4.284000px;}
.wsc3{word-spacing:4.320000px;}
.ws28{word-spacing:4.392000px;}
.ws40{word-spacing:4.428000px;}
.ws7{word-spacing:4.464000px;}
.ws7d{word-spacing:4.500000px;}
.wscb{word-spacing:4.536000px;}
.ws16f{word-spacing:4.572000px;}
.wsf{word-spacing:4.608000px;}
.ws8{word-spacing:4.644000px;}
.ws7b{word-spacing:4.752000px;}
.ws118{word-spacing:4.788000px;}
.ws159{word-spacing:4.824000px;}
.ws52{word-spacing:4.860000px;}
.ws133{word-spacing:4.896000px;}
.ws9{word-spacing:4.932000px;}
.ws158{word-spacing:4.968000px;}
.ws23{word-spacing:5.004000px;}
.ws41{word-spacing:5.076000px;}
.ws16e{word-spacing:5.112000px;}
.ws14f{word-spacing:5.148000px;}
.ws102{word-spacing:5.220000px;}
.ws14{word-spacing:5.256000px;}
.ws13d{word-spacing:5.292000px;}
.ws101{word-spacing:5.364000px;}
.ws149{word-spacing:5.400000px;}
.wsc{word-spacing:5.436000px;}
.ws6f{word-spacing:5.472000px;}
.ws22{word-spacing:5.508000px;}
.wscc{word-spacing:5.544000px;}
.ws60{word-spacing:5.580000px;}
.ws9e{word-spacing:5.616000px;}
.ws57{word-spacing:5.652000px;}
.ws142{word-spacing:5.688000px;}
.ws13e{word-spacing:5.724000px;}
.ws9b{word-spacing:5.760000px;}
.ws8e{word-spacing:5.796000px;}
.ws131{word-spacing:5.832000px;}
.wse9{word-spacing:5.868000px;}
.ws99{word-spacing:5.904000px;}
.wsa{word-spacing:5.976000px;}
.ws168{word-spacing:6.084000px;}
.ws64{word-spacing:6.120000px;}
.ws7e{word-spacing:6.156000px;}
.ws3d{word-spacing:6.192000px;}
.wse1{word-spacing:6.228000px;}
.ws12{word-spacing:6.264000px;}
.ws8a{word-spacing:6.300000px;}
.wsb1{word-spacing:6.336000px;}
.ws12f{word-spacing:6.372000px;}
.ws16b{word-spacing:6.408000px;}
.wsef{word-spacing:6.444000px;}
.ws15b{word-spacing:6.480000px;}
.ws15{word-spacing:6.516000px;}
.ws109{word-spacing:6.552000px;}
.ws54{word-spacing:6.624000px;}
.wsad{word-spacing:6.660000px;}
.ws4b{word-spacing:6.696000px;}
.wsbd{word-spacing:6.732000px;}
.ws169{word-spacing:6.768000px;}
.ws160{word-spacing:6.840000px;}
.ws5a{word-spacing:6.876000px;}
.wsa8{word-spacing:6.984000px;}
.ws42{word-spacing:7.020000px;}
.wse6{word-spacing:7.128000px;}
.ws63{word-spacing:7.164000px;}
.ws3a{word-spacing:7.200000px;}
.ws10b{word-spacing:7.236000px;}
.ws26{word-spacing:7.272000px;}
.ws25{word-spacing:7.344000px;}
.ws75{word-spacing:7.380000px;}
.wsd8{word-spacing:7.416000px;}
.ws68{word-spacing:7.452000px;}
.ws53{word-spacing:7.524000px;}
.wsf8{word-spacing:7.560000px;}
.ws103{word-spacing:7.596000px;}
.ws178{word-spacing:7.668000px;}
.ws82{word-spacing:7.704000px;}
.wsb5{word-spacing:7.740000px;}
.ws124{word-spacing:7.776000px;}
.ws51{word-spacing:7.884000px;}
.wsfa{word-spacing:7.992000px;}
.ws3c{word-spacing:8.028000px;}
.ws6e{word-spacing:8.208000px;}
.ws15d{word-spacing:8.280000px;}
.ws174{word-spacing:8.316000px;}
.wsf4{word-spacing:8.352000px;}
.wsc1{word-spacing:8.424000px;}
.ws121{word-spacing:8.460000px;}
.ws38{word-spacing:8.496000px;}
.ws74{word-spacing:8.532000px;}
.ws14e{word-spacing:8.568000px;}
.wsdb{word-spacing:8.712000px;}
.ws1c{word-spacing:8.748000px;}
.ws45{word-spacing:8.856000px;}
.ws173{word-spacing:8.964000px;}
.ws78{word-spacing:9.000000px;}
.ws71{word-spacing:9.036000px;}
.ws12c{word-spacing:9.072000px;}
.wsda{word-spacing:9.108000px;}
.ws69{word-spacing:9.144000px;}
.ws29{word-spacing:9.180000px;}
.wsba{word-spacing:9.288000px;}
.ws43{word-spacing:9.324000px;}
.ws9c{word-spacing:9.360000px;}
.wsa7{word-spacing:9.432000px;}
.ws85{word-spacing:9.468000px;}
.ws2e{word-spacing:9.504000px;}
.wsb4{word-spacing:9.540000px;}
.ws167{word-spacing:9.612000px;}
.wsf1{word-spacing:9.648000px;}
.ws1a{word-spacing:9.756000px;}
.ws46{word-spacing:9.828000px;}
.ws19{word-spacing:9.900000px;}
.ws16a{word-spacing:9.972000px;}
.ws179{word-spacing:10.008000px;}
.wsd2{word-spacing:10.044000px;}
.wsbb{word-spacing:10.080000px;}
.ws72{word-spacing:10.188000px;}
.ws13f{word-spacing:10.260000px;}
.wsd0{word-spacing:10.296000px;}
.wsb0{word-spacing:10.332000px;}
.ws92{word-spacing:10.440000px;}
.wse5{word-spacing:10.476000px;}
.ws151{word-spacing:10.548000px;}
.ws17b{word-spacing:10.560000px;}
.wse2{word-spacing:10.584000px;}
.ws15f{word-spacing:10.656000px;}
.ws3e{word-spacing:10.692000px;}
.ws112{word-spacing:10.872000px;}
.ws31{word-spacing:10.908000px;}
.ws8f{word-spacing:10.944000px;}
.ws11e{word-spacing:11.052000px;}
.ws11c{word-spacing:11.124000px;}
.ws13c{word-spacing:11.268000px;}
.ws9f{word-spacing:11.304000px;}
.ws12e{word-spacing:11.412000px;}
.ws70{word-spacing:11.592000px;}
.ws9d{word-spacing:11.628000px;}
.ws7a{word-spacing:11.700000px;}
.ws152{word-spacing:11.844000px;}
.ws7f{word-spacing:12.024000px;}
.ws127{word-spacing:12.096000px;}
.ws119{word-spacing:12.132000px;}
.wsd5{word-spacing:12.168000px;}
.ws8b{word-spacing:12.348000px;}
.ws148{word-spacing:12.384000px;}
.ws35{word-spacing:12.420000px;}
.ws6b{word-spacing:12.456000px;}
.wsd3{word-spacing:12.564000px;}
.ws10a{word-spacing:12.600000px;}
.ws123{word-spacing:12.744000px;}
.wsb6{word-spacing:12.780000px;}
.wsab{word-spacing:12.816000px;}
.ws11b{word-spacing:12.852000px;}
.wscf{word-spacing:12.924000px;}
.ws14d{word-spacing:13.068000px;}
.ws116{word-spacing:13.104000px;}
.ws2c{word-spacing:13.176000px;}
.ws11d{word-spacing:13.356000px;}
.wsaa{word-spacing:13.428000px;}
.ws125{word-spacing:13.500000px;}
.ws15e{word-spacing:13.608000px;}
.wsfe{word-spacing:13.644000px;}
.ws105{word-spacing:13.752000px;}
.wsd6{word-spacing:13.968000px;}
.wsd1{word-spacing:14.184000px;}
.ws30{word-spacing:14.256000px;}
.ws2d{word-spacing:14.292000px;}
.ws80{word-spacing:14.364000px;}
.ws61{word-spacing:14.472000px;}
.ws17{word-spacing:14.508000px;}
.wsa9{word-spacing:14.580000px;}
.ws114{word-spacing:14.616000px;}
.ws1b{word-spacing:14.652000px;}
.ws120{word-spacing:14.724000px;}
.wsff{word-spacing:14.760000px;}
.wsdd{word-spacing:14.868000px;}
.ws62{word-spacing:15.012000px;}
.ws88{word-spacing:15.048000px;}
.ws117{word-spacing:15.084000px;}
.wsfb{word-spacing:15.156000px;}
.ws9a{word-spacing:15.264000px;}
.ws177{word-spacing:15.336000px;}
.ws1f{word-spacing:15.516000px;}
.ws143{word-spacing:15.624000px;}
.wsc2{word-spacing:15.696000px;}
.wsce{word-spacing:15.732000px;}
.ws73{word-spacing:15.912000px;}
.ws130{word-spacing:15.984000px;}
.ws66{word-spacing:16.056000px;}
.ws2a{word-spacing:16.164000px;}
.wsf0{word-spacing:16.488000px;}
.ws2b{word-spacing:16.632000px;}
.ws6c{word-spacing:16.704000px;}
.ws155{word-spacing:16.776000px;}
.ws15c{word-spacing:16.812000px;}
.ws81{word-spacing:16.920000px;}
.ws24{word-spacing:17.064000px;}
.ws84{word-spacing:17.208000px;}
.ws18{word-spacing:17.244000px;}
.wsa0{word-spacing:17.280000px;}
.ws86{word-spacing:17.424000px;}
.ws65{word-spacing:17.640000px;}
.ws5c{word-spacing:17.748000px;}
.ws172{word-spacing:17.856000px;}
.ws6d{word-spacing:17.964000px;}
.ws14b{word-spacing:18.072000px;}
.ws126{word-spacing:18.288000px;}
.ws15a{word-spacing:18.396000px;}
.ws10f{word-spacing:18.432000px;}
.ws95{word-spacing:18.684000px;}
.wsbc{word-spacing:19.044000px;}
.ws58{word-spacing:19.116000px;}
.ws166{word-spacing:19.476000px;}
.ws144{word-spacing:19.620000px;}
.ws113{word-spacing:19.692000px;}
.wsf3{word-spacing:19.944000px;}
.wsa1{word-spacing:20.052000px;}
.ws5e{word-spacing:20.196000px;}
.ws1{word-spacing:20.216000px;}
.ws176{word-spacing:21.168000px;}
.ws104{word-spacing:21.240000px;}
.ws153{word-spacing:21.312000px;}
.ws39{word-spacing:21.852000px;}
.ws5d{word-spacing:21.924000px;}
.ws11a{word-spacing:22.284000px;}
.ws157{word-spacing:22.356000px;}
.ws76{word-spacing:22.392000px;}
.ws171{word-spacing:22.500000px;}
.ws49{word-spacing:23.940000px;}
.ws59{word-spacing:24.948000px;}
.ws16{word-spacing:25.056000px;}
.wsde{word-spacing:25.524000px;}
.wsd7{word-spacing:27.360000px;}
.ws145{word-spacing:28.692000px;}
.ws108{word-spacing:28.980000px;}
.ws83{word-spacing:30.456000px;}
.ws91{word-spacing:32.112000px;}
._2{margin-left:-21.164400px;}
._3{margin-left:-19.267600px;}
._e{margin-left:-11.808000px;}
._13{margin-left:-9.216000px;}
._2a{margin-left:-7.308000px;}
._7{margin-left:-5.293600px;}
._5{margin-left:-3.728400px;}
._0{margin-left:-2.667600px;}
._4{margin-left:-1.456000px;}
._8{width:1.224000px;}
._6{width:2.523200px;}
._12{width:4.051753px;}
._11{width:5.767464px;}
._f{width:6.768000px;}
._b{width:9.180000px;}
._10{width:10.929600px;}
._a{width:19.180000px;}
._9{width:21.918400px;}
._29{width:56.047753px;}
._17{width:64.943505px;}
._16{width:72.158351px;}
._1f{width:84.143258px;}
._1b{width:89.950186px;}
._d{width:99.628289px;}
._14{width:101.951258px;}
._21{width:107.742763px;}
._28{width:129.215340px;}
._27{width:197.004701px;}
._25{width:379.327753px;}
._1c{width:439.195188px;}
._26{width:460.209155px;}
._c{width:487.501443px;}
._24{width:498.463340px;}
._15{width:515.647588px;}
._1e{width:535.775588px;}
._18{width:541.151175px;}
._1a{width:551.231753px;}
._19{width:552.991588px;}
._1d{width:556.234940px;}
._22{width:558.911753px;}
._20{width:568.415340px;}
._23{width:571.935340px;}
._1{width:631.663600px;}
.fc3{color:transparent;}
.fc2{color:rgb(34,76,137);}
.fc1{color:rgb(35,31,32);}
.fc0{color:rgb(255,255,255);}
.fsa{font-size:16.324000px;}
.fs6{font-size:20.988000px;}
.fs2{font-size:28.000000px;}
.fs5{font-size:30.000000px;}
.fs8{font-size:32.000000px;}
.fs0{font-size:36.000000px;}
.fs3{font-size:40.000000px;}
.fs9{font-size:44.000000px;}
.fs1{font-size:48.000000px;}
.fs4{font-size:80.000000px;}
.fs7{font-size:103.226800px;}
.y0{bottom:0.000000px;}
.y3{bottom:38.759880px;}
.y48{bottom:65.700000px;}
.y1b{bottom:65.802000px;}
.y273{bottom:66.000000px;}
.y231{bottom:66.708000px;}
.y8d{bottom:67.500000px;}
.y189{bottom:67.524000px;}
.y1e1{bottom:67.620000px;}
.y1c3{bottom:67.764000px;}
.yf7{bottom:67.788000px;}
.y137{bottom:67.908000px;}
.ybf{bottom:68.052000px;}
.yff{bottom:71.096400px;}
.y272{bottom:78.000000px;}
.y230{bottom:78.828000px;}
.y47{bottom:80.100000px;}
.y1a{bottom:81.402000px;}
.y8c{bottom:81.900000px;}
.y188{bottom:81.924000px;}
.y1df{bottom:82.020000px;}
.y1c2{bottom:82.164000px;}
.yf6{bottom:82.188000px;}
.y136{bottom:82.308000px;}
.ybe{bottom:82.452000px;}
.y1e0{bottom:85.616400px;}
.y271{bottom:90.000000px;}
.y22f{bottom:90.948000px;}
.y19{bottom:91.602000px;}
.y46{bottom:94.500000px;}
.y8b{bottom:96.300000px;}
.y187{bottom:96.324000px;}
.y1de{bottom:96.420000px;}
.y1c1{bottom:96.564000px;}
.yf4{bottom:96.588000px;}
.y135{bottom:96.708000px;}
.ybd{bottom:96.852000px;}
.yf5{bottom:100.184400px;}
.y18{bottom:101.802000px;}
.y270{bottom:102.000000px;}
.y22e{bottom:103.068000px;}
.y45{bottom:108.900000px;}
.y89{bottom:110.700000px;}
.y186{bottom:110.724000px;}
.y1dd{bottom:110.820000px;}
.y1c0{bottom:110.964000px;}
.yf3{bottom:110.988000px;}
.y133{bottom:111.108000px;}
.ybc{bottom:111.252000px;}
.y26f{bottom:114.000000px;}
.y8a{bottom:114.296400px;}
.y134{bottom:114.704400px;}
.y22d{bottom:115.188000px;}
.y44{bottom:123.300000px;}
.y88{bottom:125.100000px;}
.y185{bottom:125.124000px;}
.y1db{bottom:125.220000px;}
.y1bf{bottom:125.364000px;}
.yf2{bottom:125.388000px;}
.y132{bottom:125.508000px;}
.ybb{bottom:125.652000px;}
.y26e{bottom:126.000000px;}
.y22c{bottom:127.308000px;}
.y1dc{bottom:128.816400px;}
.y1fa{bottom:128.844000px;}
.y17{bottom:132.402000px;}
.yf1{bottom:136.191600px;}
.y43{bottom:137.700000px;}
.y26d{bottom:138.000000px;}
.y22b{bottom:139.428000px;}
.y87{bottom:139.500000px;}
.y184{bottom:139.524000px;}
.y1da{bottom:139.620000px;}
.y1be{bottom:139.764000px;}
.yf0{bottom:139.788000px;}
.y131{bottom:139.908000px;}
.yba{bottom:140.052000px;}
.y4a{bottom:141.296400px;}
.y16{bottom:142.602000px;}
.y26c{bottom:150.000000px;}
.y22a{bottom:151.548000px;}
.y41{bottom:152.100000px;}
.y86{bottom:153.900000px;}
.y183{bottom:153.924000px;}
.y1d9{bottom:154.020000px;}
.y1f9{bottom:154.044000px;}
.y1bd{bottom:154.164000px;}
.yef{bottom:154.188000px;}
.y130{bottom:154.308000px;}
.yb9{bottom:154.452000px;}
.y42{bottom:155.696400px;}
.y26b{bottom:162.000000px;}
.y229{bottom:163.668000px;}
.y40{bottom:166.500000px;}
.y85{bottom:168.300000px;}
.y182{bottom:168.324000px;}
.y1d8{bottom:168.420000px;}
.y1f8{bottom:168.444000px;}
.y1bc{bottom:168.564000px;}
.yee{bottom:168.588000px;}
.y12f{bottom:168.708000px;}
.yb7{bottom:168.852000px;}
.yb8{bottom:172.448400px;}
.y26a{bottom:174.000000px;}
.y228{bottom:175.788000px;}
.yed{bottom:179.391600px;}
.y3f{bottom:180.900000px;}
.y84{bottom:182.700000px;}
.y181{bottom:182.724000px;}
.y1d7{bottom:182.820000px;}
.y1f7{bottom:182.844000px;}
.y1ba{bottom:182.964000px;}
.yec{bottom:182.988000px;}
.y12e{bottom:183.108000px;}
.yb6{bottom:183.252000px;}
.y269{bottom:186.000000px;}
.y1bb{bottom:186.560400px;}
.y14b{bottom:186.704400px;}
.y227{bottom:187.908000px;}
.y3e{bottom:195.300000px;}
.y83{bottom:197.100000px;}
.y180{bottom:197.124000px;}
.y1d5{bottom:197.220000px;}
.y1f6{bottom:197.244000px;}
.y1b9{bottom:197.364000px;}
.yeb{bottom:197.388000px;}
.y12d{bottom:197.508000px;}
.yb5{bottom:197.652000px;}
.y268{bottom:198.000000px;}
.y49{bottom:198.896400px;}
.y226{bottom:200.028000px;}
.y1d6{bottom:200.816400px;}
.y3d{bottom:209.700000px;}
.y267{bottom:210.000000px;}
.y82{bottom:211.500000px;}
.y17f{bottom:211.524000px;}
.y1d4{bottom:211.620000px;}
.y1f5{bottom:211.644000px;}
.y1b8{bottom:211.764000px;}
.yea{bottom:211.788000px;}
.y12c{bottom:211.908000px;}
.yb4{bottom:212.052000px;}
.y225{bottom:212.148000px;}
.y266{bottom:222.000000px;}
.y3c{bottom:224.100000px;}
.y224{bottom:224.268000px;}
.y81{bottom:225.900000px;}
.y17e{bottom:225.924000px;}
.y1d3{bottom:226.020000px;}
.y1f4{bottom:226.044000px;}
.y1b7{bottom:226.164000px;}
.ye9{bottom:226.188000px;}
.y12b{bottom:226.308000px;}
.yb3{bottom:226.452000px;}
.yfe{bottom:229.496400px;}
.y19a{bottom:229.520400px;}
.y14a{bottom:229.764000px;}
.y265{bottom:234.000000px;}
.y223{bottom:236.388000px;}
.y3b{bottom:238.500000px;}
.y80{bottom:240.300000px;}
.y17d{bottom:240.324000px;}
.y1d2{bottom:240.420000px;}
.y1f2{bottom:240.444000px;}
.y1b6{bottom:240.564000px;}
.ye7{bottom:240.588000px;}
.y12a{bottom:240.708000px;}
.yb2{bottom:240.852000px;}
.y1f3{bottom:244.040400px;}
.ye8{bottom:244.184400px;}
.y264{bottom:246.000000px;}
.y222{bottom:248.508000px;}
.y39{bottom:252.900000px;}
.y7e{bottom:254.700000px;}
.y17c{bottom:254.724000px;}
.y1d1{bottom:254.820000px;}
.y1f1{bottom:254.844000px;}
.y148{bottom:254.964000px;}
.ye6{bottom:254.988000px;}
.y129{bottom:255.108000px;}
.yb1{bottom:255.252000px;}
.y263{bottom:258.000000px;}
.y7f{bottom:258.296400px;}
.y149{bottom:258.560400px;}
.y221{bottom:260.628000px;}
.y3a{bottom:267.300000px;}
.y7d{bottom:269.100000px;}
.y17b{bottom:269.124000px;}
.y1d0{bottom:269.220000px;}
.y1f0{bottom:269.244000px;}
.y147{bottom:269.364000px;}
.ye5{bottom:269.388000px;}
.y128{bottom:269.508000px;}
.yb0{bottom:269.652000px;}
.y262{bottom:270.000000px;}
.y220{bottom:272.748000px;}
.y261{bottom:282.000000px;}
.y7b{bottom:283.500000px;}
.y17a{bottom:283.524000px;}
.y1cf{bottom:283.620000px;}
.y1ef{bottom:283.644000px;}
.y146{bottom:283.764000px;}
.ye4{bottom:283.788000px;}
.y127{bottom:283.908000px;}
.yaf{bottom:284.052000px;}
.y21f{bottom:284.868000px;}
.y7c{bottom:287.096400px;}
.y260{bottom:294.000000px;}
.y21e{bottom:296.988000px;}
.y7a{bottom:297.900000px;}
.y179{bottom:297.924000px;}
.y1ce{bottom:298.020000px;}
.y1ee{bottom:298.044000px;}
.y144{bottom:298.164000px;}
.ye3{bottom:298.188000px;}
.y126{bottom:298.308000px;}
.yae{bottom:298.452000px;}
.y199{bottom:301.520400px;}
.y145{bottom:301.760400px;}
.y25f{bottom:306.000000px;}
.y21d{bottom:309.108000px;}
.y79{bottom:312.300000px;}
.y178{bottom:312.324000px;}
.y1cd{bottom:312.420000px;}
.y1ec{bottom:312.444000px;}
.y143{bottom:312.564000px;}
.ye2{bottom:312.588000px;}
.y125{bottom:312.708000px;}
.yac{bottom:312.852000px;}
.y1ed{bottom:316.040400px;}
.yad{bottom:316.448400px;}
.y25e{bottom:318.000000px;}
.y21c{bottom:321.228000px;}
.y78{bottom:326.700000px;}
.y177{bottom:326.724000px;}
.y1cc{bottom:326.820000px;}
.y1eb{bottom:326.844000px;}
.y142{bottom:326.964000px;}
.ye0{bottom:326.988000px;}
.y124{bottom:327.108000px;}
.yab{bottom:327.252000px;}
.y25d{bottom:330.000000px;}
.y1b5{bottom:330.560400px;}
.ye1{bottom:330.584400px;}
.y38{bottom:331.735200px;}
.y21b{bottom:333.348000px;}
.y77{bottom:341.100000px;}
.y176{bottom:341.124000px;}
.y1cb{bottom:341.220000px;}
.y1ea{bottom:341.244000px;}
.y140{bottom:341.364000px;}
.ydf{bottom:341.388000px;}
.y123{bottom:341.508000px;}
.yaa{bottom:341.652000px;}
.y25c{bottom:342.000000px;}
.y141{bottom:344.960400px;}
.y21a{bottom:345.468000px;}
.y25b{bottom:354.000000px;}
.y76{bottom:355.500000px;}
.y175{bottom:355.524000px;}
.y1ca{bottom:355.620000px;}
.y1e9{bottom:355.644000px;}
.y13f{bottom:355.764000px;}
.yde{bottom:355.788000px;}
.y121{bottom:355.908000px;}
.ya9{bottom:356.052000px;}
.y37{bottom:356.335200px;}
.y219{bottom:357.588000px;}
.y122{bottom:359.504400px;}
.y25a{bottom:366.000000px;}
.y36{bottom:366.538800px;}
.y218{bottom:369.708000px;}
.y74{bottom:369.900000px;}
.y174{bottom:369.924000px;}
.y1c9{bottom:370.020000px;}
.y1e8{bottom:370.044000px;}
.y35{bottom:370.135200px;}
.y13e{bottom:370.164000px;}
.ydd{bottom:370.188000px;}
.y120{bottom:370.308000px;}
.ya8{bottom:370.452000px;}
.y75{bottom:373.496400px;}
.y198{bottom:373.520400px;}
.y259{bottom:378.000000px;}
.y217{bottom:381.828000px;}
.y73{bottom:384.300000px;}
.y173{bottom:384.324000px;}
.y1c8{bottom:384.420000px;}
.y1e7{bottom:384.444000px;}
.y13d{bottom:384.564000px;}
.ydc{bottom:384.588000px;}
.y11f{bottom:384.708000px;}
.ya7{bottom:384.852000px;}
.y150{bottom:387.896400px;}
.y258{bottom:390.000000px;}
.y216{bottom:393.948000px;}
.y34{bottom:394.735200px;}
.y72{bottom:398.700000px;}
.y172{bottom:398.724000px;}
.y1c7{bottom:398.820000px;}
.y1e6{bottom:398.844000px;}
.y13c{bottom:398.964000px;}
.ydb{bottom:398.988000px;}
.y11e{bottom:399.108000px;}
.ya6{bottom:399.252000px;}
.y257{bottom:402.000000px;}
.y215{bottom:406.068000px;}
.y33{bottom:408.535200px;}
.y71{bottom:413.100000px;}
.y171{bottom:413.124000px;}
.y1c6{bottom:413.220000px;}
.y1e5{bottom:413.244000px;}
.y13a{bottom:413.364000px;}
.yda{bottom:413.388000px;}
.y11d{bottom:413.508000px;}
.ya5{bottom:413.652000px;}
.y256{bottom:414.000000px;}
.y13b{bottom:416.960400px;}
.y214{bottom:418.188000px;}
.y32{bottom:422.335200px;}
.y255{bottom:426.000000px;}
.y70{bottom:427.500000px;}
.y170{bottom:427.524000px;}
.y1c5{bottom:427.620000px;}
.y1e4{bottom:427.644000px;}
.y139{bottom:427.764000px;}
.yd9{bottom:427.788000px;}
.y213{bottom:430.188000px;}
.y1b4{bottom:431.220000px;}
.y11c{bottom:431.364000px;}
.y31{bottom:436.135200px;}
.y254{bottom:438.000000px;}
.y6f{bottom:441.900000px;}
.y16f{bottom:441.924000px;}
.y1c4{bottom:442.020000px;}
.y138{bottom:442.164000px;}
.yd8{bottom:442.188000px;}
.yfd{bottom:445.496400px;}
.y1e3{bottom:445.500000px;}
.y30{bottom:449.935200px;}
.y253{bottom:450.000000px;}
.y212{bottom:454.188000px;}
.y6e{bottom:456.300000px;}
.y16e{bottom:456.324000px;}
.y1b2{bottom:456.420000px;}
.y11b{bottom:456.564000px;}
.yd7{bottom:456.588000px;}
.y14f{bottom:459.896400px;}
.y1e2{bottom:459.900000px;}
.y1b3{bottom:460.016400px;}
.y252{bottom:462.000000px;}
.y211{bottom:466.188000px;}
.y6d{bottom:470.700000px;}
.y16d{bottom:470.724000px;}
.y1b1{bottom:470.820000px;}
.y11a{bottom:470.964000px;}
.y251{bottom:474.000000px;}
.yd6{bottom:474.444000px;}
.y2f{bottom:474.535200px;}
.y210{bottom:478.188000px;}
.y6c{bottom:485.100000px;}
.y16c{bottom:485.124000px;}
.y119{bottom:485.364000px;}
.y250{bottom:486.000000px;}
.y2e{bottom:488.335200px;}
.y197{bottom:488.720400px;}
.yd5{bottom:488.844000px;}
.y20f{bottom:490.188000px;}
.y24f{bottom:498.000000px;}
.y6b{bottom:499.500000px;}
.y16b{bottom:499.524000px;}
.y118{bottom:499.764000px;}
.ya4{bottom:501.016680px;}
.y2d{bottom:502.135200px;}
.y20e{bottom:502.188000px;}
.y14e{bottom:503.096400px;}
.y24e{bottom:510.000000px;}
.y196{bottom:510.327480px;}
.y6a{bottom:513.900000px;}
.y16a{bottom:513.924000px;}
.yd3{bottom:514.044000px;}
.y117{bottom:514.164000px;}
.y20d{bottom:514.188000px;}
.ya3{bottom:515.416680px;}
.y2c{bottom:515.935200px;}
.yfc{bottom:517.496400px;}
.yd4{bottom:517.640400px;}
.y28f{bottom:521.448000px;}
.y24d{bottom:522.000000px;}
.y1b0{bottom:525.163800px;}
.y20c{bottom:526.188000px;}
.y1af{bottom:527.961000px;}
.y69{bottom:528.300000px;}
.y169{bottom:528.324000px;}
.yd2{bottom:528.444000px;}
.y116{bottom:528.564000px;}
.y2b{bottom:529.735200px;}
.ya2{bottom:529.816680px;}
.y14d{bottom:531.896400px;}
.y195{bottom:531.920400px;}
.y28e{bottom:533.448000px;}
.y24c{bottom:534.000000px;}
.y20b{bottom:538.188000px;}
.y1ae{bottom:541.366080px;}
.y68{bottom:542.700000px;}
.y168{bottom:542.724000px;}
.yd1{bottom:542.844000px;}
.y114{bottom:542.964000px;}
.y2a{bottom:543.535200px;}
.ya1{bottom:544.216680px;}
.y28d{bottom:545.448000px;}
.y24b{bottom:546.000000px;}
.yfb{bottom:546.296400px;}
.y115{bottom:546.560400px;}
.y20a{bottom:550.188000px;}
.y67{bottom:557.100000px;}
.y167{bottom:557.124000px;}
.yd0{bottom:557.244000px;}
.y29{bottom:557.335200px;}
.y113{bottom:557.364000px;}
.y28c{bottom:557.448000px;}
.y24a{bottom:558.000000px;}
.y1ad{bottom:558.511680px;}
.ya0{bottom:558.616680px;}
.y209{bottom:562.188000px;}
.y28b{bottom:569.448000px;}
.y249{bottom:570.000000px;}
.y28{bottom:571.135200px;}
.y65{bottom:571.500000px;}
.y166{bottom:571.524000px;}
.ycf{bottom:571.644000px;}
.y9f{bottom:573.016680px;}
.y208{bottom:574.188000px;}
.y66{bottom:575.096400px;}
.y194{bottom:575.120400px;}
.y1ac{bottom:575.657280px;}
.y28a{bottom:581.448000px;}
.y248{bottom:582.000000px;}
.y27{bottom:584.935200px;}
.y64{bottom:585.900000px;}
.y165{bottom:585.924000px;}
.yce{bottom:586.044000px;}
.y207{bottom:586.188000px;}
.y9e{bottom:587.416680px;}
.yfa{bottom:589.496400px;}
.y1ab{bottom:592.802760px;}
.y289{bottom:593.448000px;}
.y247{bottom:594.000000px;}
.y15{bottom:594.593880px;}
.y63{bottom:596.703600px;}
.y206{bottom:598.188000px;}
.y26{bottom:598.735200px;}
.y62{bottom:600.300000px;}
.y164{bottom:600.324000px;}
.ycc{bottom:600.444000px;}
.y193{bottom:603.920400px;}
.ycd{bottom:604.040400px;}
.y14{bottom:604.793880px;}
.y288{bottom:605.448000px;}
.y246{bottom:606.000000px;}
.y9d{bottom:607.216680px;}
.y1aa{bottom:609.948360px;}
.y205{bottom:610.188000px;}
.y25{bottom:612.535200px;}
.y61{bottom:614.700000px;}
.y163{bottom:614.724000px;}
.ycb{bottom:614.844000px;}
.y13{bottom:614.993880px;}
.y287{bottom:617.448000px;}
.y245{bottom:618.000000px;}
.y9c{bottom:621.616680px;}
.y204{bottom:622.188000px;}
.y112{bottom:622.483440px;}
.y12{bottom:625.193880px;}
.y111{bottom:625.280640px;}
.y24{bottom:626.335200px;}
.y1a9{bottom:627.093840px;}
.y60{bottom:629.100000px;}
.y162{bottom:629.124000px;}
.yca{bottom:629.244000px;}
.y286{bottom:629.448000px;}
.y244{bottom:630.000000px;}
.y14c{bottom:632.696400px;}
.y203{bottom:634.188000px;}
.y11{bottom:635.393880px;}
.y9b{bottom:636.016680px;}
.y110{bottom:638.685840px;}
.y5f{bottom:639.903600px;}
.y23{bottom:640.135200px;}
.y285{bottom:641.448000px;}
.y243{bottom:642.000000px;}
.y5e{bottom:643.500000px;}
.y161{bottom:643.524000px;}
.yc9{bottom:643.644000px;}
.y1a8{bottom:644.239440px;}
.y10{bottom:645.593880px;}
.y202{bottom:646.188000px;}
.y10f{bottom:649.485840px;}
.y9a{bottom:650.416680px;}
.y284{bottom:653.448000px;}
.y22{bottom:653.935200px;}
.y242{bottom:654.000000px;}
.y5d{bottom:654.303600px;}
.yc8{bottom:654.447600px;}
.yf{bottom:655.793880px;}
.y5c{bottom:657.900000px;}
.y160{bottom:657.924000px;}
.yc7{bottom:658.044000px;}
.y201{bottom:658.188000px;}
.y10e{bottom:660.285840px;}
.y1a7{bottom:661.385040px;}
.y99{bottom:664.816680px;}
.y283{bottom:665.448000px;}
.y241{bottom:666.000000px;}
.y21{bottom:667.735200px;}
.y200{bottom:670.188000px;}
.y10d{bottom:671.085840px;}
.ye{bottom:671.393880px;}
.y5b{bottom:672.300000px;}
.y15f{bottom:672.324000px;}
.yc6{bottom:672.444000px;}
.y282{bottom:677.448000px;}
.y240{bottom:678.000000px;}
.y1a6{bottom:678.530520px;}
.y98{bottom:679.216680px;}
.y20{bottom:681.535200px;}
.yd{bottom:681.593880px;}
.y1ff{bottom:682.188000px;}
.y5a{bottom:686.700000px;}
.y15e{bottom:686.724000px;}
.yc5{bottom:686.844000px;}
.y10c{bottom:688.231320px;}
.y281{bottom:689.448000px;}
.y23f{bottom:690.000000px;}
.y152{bottom:690.296400px;}
.yc{bottom:691.793880px;}
.y97{bottom:693.616680px;}
.y1fe{bottom:694.188000px;}
.y1a5{bottom:695.676120px;}
.y10b{bottom:699.031320px;}
.y59{bottom:701.100000px;}
.y15d{bottom:701.124000px;}
.yc4{bottom:701.244000px;}
.y280{bottom:701.448000px;}
.yb{bottom:701.993880px;}
.y23e{bottom:702.000000px;}
.yf9{bottom:704.696400px;}
.y1f{bottom:706.135200px;}
.y96{bottom:708.016680px;}
.y1fd{bottom:709.644000px;}
.y10a{bottom:709.831320px;}
.y151{bottom:711.903600px;}
.ya{bottom:712.193880px;}
.y1a4{bottom:712.821720px;}
.y27f{bottom:713.448000px;}
.y23d{bottom:714.000000px;}
.y58{bottom:715.500000px;}
.y15c{bottom:715.524000px;}
.yc3{bottom:715.644000px;}
.y1e{bottom:719.935200px;}
.y95{bottom:722.416680px;}
.y27e{bottom:725.448000px;}
.y23c{bottom:726.000000px;}
.y109{bottom:726.976920px;}
.y9{bottom:727.793880px;}
.y56{bottom:729.900000px;}
.y15b{bottom:729.924000px;}
.y1a3{bottom:729.967200px;}
.yc2{bottom:730.044000px;}
.y192{bottom:733.380000px;}
.y57{bottom:733.496400px;}
.y1d{bottom:733.735200px;}
.y1fc{bottom:734.844000px;}
.y27d{bottom:737.448000px;}
.y108{bottom:737.776920px;}
.y8{bottom:737.993880px;}
.y23b{bottom:738.000000px;}
.y94{bottom:742.216680px;}
.y55{bottom:744.300000px;}
.y15a{bottom:744.324000px;}
.yc1{bottom:744.444000px;}
.y1fb{bottom:746.844000px;}
.y1a2{bottom:747.112800px;}
.y1c{bottom:747.535200px;}
.y7{bottom:748.193880px;}
.y107{bottom:748.576920px;}
.y27c{bottom:749.448000px;}
.y23a{bottom:750.000000px;}
.y93{bottom:756.616680px;}
.y6{bottom:758.393880px;}
.y190{bottom:758.580000px;}
.y54{bottom:758.700000px;}
.y159{bottom:758.724000px;}
.y27b{bottom:761.448000px;}
.y239{bottom:762.000000px;}
.y191{bottom:762.176400px;}
.yc0{bottom:762.300000px;}
.y1a1{bottom:764.258400px;}
.y106{bottom:765.722520px;}
.y92{bottom:771.016680px;}
.y18f{bottom:772.980000px;}
.y53{bottom:773.100000px;}
.y158{bottom:773.124000px;}
.y27a{bottom:773.448000px;}
.y238{bottom:774.000000px;}
.y105{bottom:776.522520px;}
.y19e{bottom:781.403880px;}
.y91{bottom:785.416680px;}
.y279{bottom:785.448000px;}
.y237{bottom:786.000000px;}
.y104{bottom:787.322520px;}
.y18e{bottom:787.380000px;}
.y52{bottom:787.500000px;}
.y157{bottom:787.524000px;}
.y1a0{bottom:792.203880px;}
.y278{bottom:797.448000px;}
.y236{bottom:798.000000px;}
.y90{bottom:799.816680px;}
.y18d{bottom:801.780000px;}
.y50{bottom:801.900000px;}
.y156{bottom:801.924000px;}
.y19f{bottom:803.003880px;}
.y103{bottom:804.468000px;}
.y51{bottom:805.496400px;}
.y5{bottom:807.936120px;}
.y277{bottom:809.448000px;}
.y235{bottom:810.000000px;}
.y8f{bottom:814.216680px;}
.y18c{bottom:816.180000px;}
.y4f{bottom:816.300000px;}
.y155{bottom:816.324000px;}
.y19d{bottom:819.957600px;}
.y276{bottom:821.448000px;}
.y101{bottom:821.503320px;}
.y234{bottom:822.000000px;}
.y102{bottom:825.099720px;}
.y18b{bottom:830.580000px;}
.y4e{bottom:830.700000px;}
.y154{bottom:830.724000px;}
.y8e{bottom:831.208680px;}
.y275{bottom:833.448000px;}
.y233{bottom:834.000000px;}
.yf8{bottom:834.296400px;}
.y4{bottom:834.336120px;}
.y100{bottom:834.703320px;}
.y19b{bottom:836.911200px;}
.y19c{bottom:840.507600px;}
.y18a{bottom:844.980000px;}
.y4d{bottom:845.100000px;}
.y153{bottom:845.124000px;}
.y274{bottom:845.448000px;}
.y232{bottom:846.000000px;}
.y2{bottom:884.400000px;}
.y4b{bottom:885.000000px;}
.y1{bottom:885.600000px;}
.y4c{bottom:886.200000px;}
.h10{height:12.830664px;}
.hb{height:15.699024px;}
.h8{height:16.496568px;}
.h5{height:21.870000px;}
.h11{height:22.008000px;}
.hd{height:23.220000px;}
.he{height:23.328000px;}
.h6{height:23.580000px;}
.h12{height:23.936000px;}
.hf{height:25.152000px;}
.h1{height:26.316000px;}
.ha{height:26.928000px;}
.h7{height:28.296000px;}
.h3{height:29.160000px;}
.hc{height:32.076000px;}
.h2{height:34.992000px;}
.h4{height:62.880000px;}
.h9{height:73.703935px;}
.h0{height:939.600000px;}
.w0{width:702.000000px;}
.x0{left:0.000000px;}
.x3{left:65.232000px;}
.x1{left:70.464000px;}
.x41{left:74.574000px;}
.x42{left:77.871960px;}
.x19{left:81.000000px;}
.x3d{left:83.707560px;}
.x3e{left:89.841840px;}
.x39{left:92.791320px;}
.x72{left:94.208640px;}
.x1b{left:95.812920px;}
.x1c{left:99.080400px;}
.x73{left:100.170240px;}
.x6e{left:101.393520px;}
.x82{left:107.506440px;}
.x21{left:110.118240px;}
.x3f{left:112.716240px;}
.x6b{left:114.886200px;}
.x7f{left:117.023280px;}
.x22{left:118.027440px;}
.x40{left:119.312280px;}
.x6c{left:120.847800px;}
.x80{left:122.984760px;}
.x85{left:128.827800px;}
.x3b{left:134.339760px;}
.x7b{left:137.800200px;}
.x3c{left:140.813640px;}
.x7c{left:143.761800px;}
.x6f{left:147.121680px;}
.x95{left:151.950720px;}
.x78{left:153.731160px;}
.x96{left:158.424600px;}
.x79{left:159.692640px;}
.x84{left:160.926000px;}
.x87{left:164.226240px;}
.x13{left:166.736880px;}
.x14{left:169.973880px;}
.x15{left:172.106160px;}
.x81{left:175.612800px;}
.x67{left:177.231960px;}
.x16{left:178.964160px;}
.x74{left:182.495040px;}
.x68{left:183.742560px;}
.x7a{left:184.916640px;}
.x75{left:188.822400px;}
.x7d{left:192.558120px;}
.x7e{left:198.519720px;}
.x97{left:202.394160px;}
.x65{left:204.384720px;}
.x1d{left:205.507920px;}
.x6d{left:206.845200px;}
.x1e{left:208.775400px;}
.x66{left:210.637800px;}
.x3a{left:213.608640px;}
.x76{left:215.443920px;}
.x69{left:216.925320px;}
.x77{left:221.405520px;}
.x6a{left:222.886920px;}
.x86{left:224.004480px;}
.x70{left:226.243560px;}
.x1f{left:227.825880px;}
.x20{left:231.093480px;}
.x71{left:232.570920px;}
.x23{left:236.054040px;}
.x1a{left:238.756440px;}
.x17{left:241.563000px;}
.x18{left:244.800000px;}
.x8{left:258.835320px;}
.xa{left:261.000000px;}
.x98{left:266.140800px;}
.x24{left:272.004000px;}
.x4{left:273.456000px;}
.x9{left:277.759560px;}
.x54{left:281.763240px;}
.x25{left:282.804000px;}
.xb{left:284.382120px;}
.x46{left:286.980960px;}
.x55{left:287.983920px;}
.x45{left:289.392600px;}
.x47{left:290.502840px;}
.x43{left:291.804360px;}
.xc{left:293.250120px;}
.x8f{left:307.470480px;}
.x89{left:329.924760px;}
.x44{left:334.008000px;}
.x56{left:347.070480px;}
.x50{left:351.289200px;}
.x57{left:353.291160px;}
.x51{left:357.509880px;}
.x58{left:359.874960px;}
.x59{left:368.098440px;}
.x5a{left:382.664760px;}
.x4d{left:384.803760px;}
.x83{left:385.882080px;}
.x4b{left:389.153280px;}
.x4e{left:391.024440px;}
.x4c{left:392.390280px;}
.x52{left:404.361120px;}
.x4f{left:407.606160px;}
.x7{left:409.570200px;}
.x53{left:410.581800px;}
.x26{left:413.425080px;}
.x27{left:416.662080px;}
.x90{left:420.078720px;}
.x48{left:424.514880px;}
.x49{left:427.812840px;}
.x4a{left:434.465040px;}
.x28{left:438.339120px;}
.x29{left:441.576000px;}
.xd{left:457.200000px;}
.x8c{left:468.448080px;}
.x8a{left:469.951920px;}
.x2a{left:473.400000px;}
.x8b{left:474.430680px;}
.x5f{left:478.861800px;}
.x10{left:481.514400px;}
.x5c{left:485.118120px;}
.x11{left:489.606840px;}
.x5d{left:491.592000px;}
.x35{left:493.265040px;}
.xe{left:494.462520px;}
.xf{left:497.699400px;}
.x32{left:502.822320px;}
.x2{left:506.325120px;}
.x33{left:517.388520px;}
.x2f{left:527.303880px;}
.x8d{left:530.009520px;}
.x37{left:532.667760px;}
.x8e{left:538.366800px;}
.x2b{left:541.105200px;}
.x2c{left:543.768000px;}
.x88{left:544.857480px;}
.x60{left:548.445960px;}
.x61{left:551.682960px;}
.x38{left:555.326520px;}
.x94{left:560.965320px;}
.x91{left:566.001720px;}
.x12{left:575.091600px;}
.x5b{left:578.373840px;}
.x63{left:583.904400px;}
.x62{left:592.878960px;}
.x5{left:596.360040px;}
.x30{left:598.829280px;}
.x6{left:599.860800px;}
.x5e{left:604.226400px;}
.x34{left:609.044880px;}
.x92{left:617.726640px;}
.x31{left:621.487920px;}
.x64{left:622.560480px;}
.x93{left:624.200520px;}
.x36{left:625.400400px;}
.x2d{left:630.726120px;}
.x2e{left:637.200000px;}
@media print{
.v0{vertical-align:0.000000pt;}
.ls12{letter-spacing:-4.000000pt;}
.lsc{letter-spacing:-2.960000pt;}
.ls11{letter-spacing:-1.440000pt;}
.ls7{letter-spacing:-0.720000pt;}
.ls2{letter-spacing:-0.520000pt;}
.ls10{letter-spacing:-0.480000pt;}
.ls3{letter-spacing:-0.400000pt;}
.ls9{letter-spacing:-0.320000pt;}
.ls4{letter-spacing:-0.233200pt;}
.ls8{letter-spacing:-0.200000pt;}
.lsa{letter-spacing:-0.186560pt;}
.ls13{letter-spacing:-0.120000pt;}
.ls14{letter-spacing:-0.069960pt;}
.ls0{letter-spacing:0.000000pt;}
.lse{letter-spacing:0.069960pt;}
.lsf{letter-spacing:0.116600pt;}
.lsd{letter-spacing:0.120000pt;}
.ls1{letter-spacing:0.200000pt;}
.lsb{letter-spacing:0.233200pt;}
.ls6{letter-spacing:0.400000pt;}
.ls15{letter-spacing:0.711111pt;}
.ls5{letter-spacing:0.800000pt;}
.wseb{word-spacing:-4.000000pt;}
.ws164{word-spacing:-3.440000pt;}
.wsc8{word-spacing:-3.120000pt;}
.ws48{word-spacing:-2.280000pt;}
.ws17e{word-spacing:-2.133333pt;}
.ws16d{word-spacing:-2.120000pt;}
.ws12b{word-spacing:-2.080000pt;}
.wsc4{word-spacing:-2.040000pt;}
.ws141{word-spacing:-1.960000pt;}
.wsb{word-spacing:-1.880000pt;}
.ws161{word-spacing:-1.840000pt;}
.wsc6{word-spacing:-1.760000pt;}
.ws134{word-spacing:-1.680000pt;}
.wsc5{word-spacing:-1.640000pt;}
.wsb2{word-spacing:-1.520000pt;}
.ws47{word-spacing:-1.480000pt;}
.ws140{word-spacing:-1.440000pt;}
.ws89{word-spacing:-1.400000pt;}
.ws37{word-spacing:-1.280000pt;}
.wsb9{word-spacing:-1.240000pt;}
.wsb7{word-spacing:-1.200000pt;}
.ws17a{word-spacing:-1.160000pt;}
.wsa2{word-spacing:-1.000000pt;}
.wsa5{word-spacing:-0.960000pt;}
.ws115{word-spacing:-0.920000pt;}
.ws139{word-spacing:-0.880000pt;}
.ws11{word-spacing:-0.840000pt;}
.ws128{word-spacing:-0.800000pt;}
.ws1e{word-spacing:-0.760000pt;}
.ws146{word-spacing:-0.720000pt;}
.ws17c{word-spacing:-0.711111pt;}
.wsec{word-spacing:-0.680000pt;}
.ws10d{word-spacing:-0.640000pt;}
.ws4a{word-spacing:-0.600000pt;}
.ws14c{word-spacing:-0.520000pt;}
.ws94{word-spacing:-0.480000pt;}
.ws13a{word-spacing:-0.440000pt;}
.ws87{word-spacing:-0.400000pt;}
.ws77{word-spacing:-0.360000pt;}
.wse7{word-spacing:-0.320000pt;}
.wsa6{word-spacing:-0.280000pt;}
.ws13b{word-spacing:-0.240000pt;}
.wsb8{word-spacing:-0.233200pt;}
.ws2f{word-spacing:-0.200000pt;}
.wsca{word-spacing:-0.160000pt;}
.ws32{word-spacing:-0.120000pt;}
.ws136{word-spacing:-0.116600pt;}
.ws11f{word-spacing:-0.080000pt;}
.ws17d{word-spacing:-0.071111pt;}
.wsdf{word-spacing:-0.069960pt;}
.ws0{word-spacing:0.000000pt;}
.ws175{word-spacing:0.069960pt;}
.wsfd{word-spacing:0.080000pt;}
.ws4{word-spacing:0.120000pt;}
.wsac{word-spacing:0.186560pt;}
.wsd{word-spacing:0.200000pt;}
.ws50{word-spacing:0.233200pt;}
.ws4d{word-spacing:0.240000pt;}
.wsae{word-spacing:0.320000pt;}
.ws3{word-spacing:0.360000pt;}
.ws4f{word-spacing:0.400000pt;}
.wsd4{word-spacing:0.520000pt;}
.ws156{word-spacing:0.560000pt;}
.ws122{word-spacing:0.600000pt;}
.ws12d{word-spacing:0.640000pt;}
.ws154{word-spacing:0.680000pt;}
.ws162{word-spacing:0.720000pt;}
.wsc0{word-spacing:0.800000pt;}
.ws132{word-spacing:0.840000pt;}
.wsaf{word-spacing:0.880000pt;}
.wsc7{word-spacing:0.960000pt;}
.wse{word-spacing:1.000000pt;}
.wsee{word-spacing:1.040000pt;}
.ws6a{word-spacing:1.160000pt;}
.ws170{word-spacing:1.200000pt;}
.ws20{word-spacing:1.240000pt;}
.wsbf{word-spacing:1.280000pt;}
.ws16c{word-spacing:1.320000pt;}
.ws137{word-spacing:1.360000pt;}
.ws13{word-spacing:1.400000pt;}
.ws129{word-spacing:1.440000pt;}
.ws5b{word-spacing:1.480000pt;}
.ws55{word-spacing:1.520000pt;}
.ws33{word-spacing:1.560000pt;}
.ws106{word-spacing:1.600000pt;}
.ws10c{word-spacing:1.640000pt;}
.ws165{word-spacing:1.680000pt;}
.ws12a{word-spacing:1.720000pt;}
.wsf2{word-spacing:1.760000pt;}
.ws7c{word-spacing:1.800000pt;}
.ws10e{word-spacing:1.840000pt;}
.ws8c{word-spacing:1.920000pt;}
.ws98{word-spacing:1.960000pt;}
.ws150{word-spacing:2.040000pt;}
.ws5{word-spacing:2.080000pt;}
.wsf9{word-spacing:2.120000pt;}
.wsa3{word-spacing:2.160000pt;}
.wscd{word-spacing:2.200000pt;}
.ws3b{word-spacing:2.240000pt;}
.ws110{word-spacing:2.280000pt;}
.wsb3{word-spacing:2.320000pt;}
.ws14a{word-spacing:2.440000pt;}
.ws67{word-spacing:2.480000pt;}
.wsfc{word-spacing:2.520000pt;}
.wse3{word-spacing:2.560000pt;}
.wse8{word-spacing:2.600000pt;}
.ws3f{word-spacing:2.720000pt;}
.ws107{word-spacing:2.760000pt;}
.wsbe{word-spacing:2.960000pt;}
.ws96{word-spacing:3.000000pt;}
.wsa4{word-spacing:3.080000pt;}
.wsd9{word-spacing:3.120000pt;}
.ws147{word-spacing:3.160000pt;}
.ws8d{word-spacing:3.200000pt;}
.ws4c{word-spacing:3.280000pt;}
.ws1d{word-spacing:3.400000pt;}
.ws56{word-spacing:3.440000pt;}
.ws100{word-spacing:3.480000pt;}
.wsea{word-spacing:3.520000pt;}
.ws10{word-spacing:3.560000pt;}
.ws93{word-spacing:3.600000pt;}
.ws111{word-spacing:3.640000pt;}
.ws36{word-spacing:3.680000pt;}
.ws44{word-spacing:3.760000pt;}
.ws4e{word-spacing:3.800000pt;}
.wse4{word-spacing:3.840000pt;}
.ws79{word-spacing:3.880000pt;}
.ws34{word-spacing:3.920000pt;}
.wsdc{word-spacing:3.960000pt;}
.ws163{word-spacing:4.040000pt;}
.ws6{word-spacing:4.080000pt;}
.ws97{word-spacing:4.120000pt;}
.wsf5{word-spacing:4.160000pt;}
.wsed{word-spacing:4.200000pt;}
.ws90{word-spacing:4.280000pt;}
.ws135{word-spacing:4.320000pt;}
.ws5f{word-spacing:4.360000pt;}
.ws21{word-spacing:4.440000pt;}
.ws138{word-spacing:4.480000pt;}
.wsf7{word-spacing:4.520000pt;}
.wsc9{word-spacing:4.560000pt;}
.wsf6{word-spacing:4.600000pt;}
.ws27{word-spacing:4.640000pt;}
.wse0{word-spacing:4.720000pt;}
.ws2{word-spacing:4.760000pt;}
.wsc3{word-spacing:4.800000pt;}
.ws28{word-spacing:4.880000pt;}
.ws40{word-spacing:4.920000pt;}
.ws7{word-spacing:4.960000pt;}
.ws7d{word-spacing:5.000000pt;}
.wscb{word-spacing:5.040000pt;}
.ws16f{word-spacing:5.080000pt;}
.wsf{word-spacing:5.120000pt;}
.ws8{word-spacing:5.160000pt;}
.ws7b{word-spacing:5.280000pt;}
.ws118{word-spacing:5.320000pt;}
.ws159{word-spacing:5.360000pt;}
.ws52{word-spacing:5.400000pt;}
.ws133{word-spacing:5.440000pt;}
.ws9{word-spacing:5.480000pt;}
.ws158{word-spacing:5.520000pt;}
.ws23{word-spacing:5.560000pt;}
.ws41{word-spacing:5.640000pt;}
.ws16e{word-spacing:5.680000pt;}
.ws14f{word-spacing:5.720000pt;}
.ws102{word-spacing:5.800000pt;}
.ws14{word-spacing:5.840000pt;}
.ws13d{word-spacing:5.880000pt;}
.ws101{word-spacing:5.960000pt;}
.ws149{word-spacing:6.000000pt;}
.wsc{word-spacing:6.040000pt;}
.ws6f{word-spacing:6.080000pt;}
.ws22{word-spacing:6.120000pt;}
.wscc{word-spacing:6.160000pt;}
.ws60{word-spacing:6.200000pt;}
.ws9e{word-spacing:6.240000pt;}
.ws57{word-spacing:6.280000pt;}
.ws142{word-spacing:6.320000pt;}
.ws13e{word-spacing:6.360000pt;}
.ws9b{word-spacing:6.400000pt;}
.ws8e{word-spacing:6.440000pt;}
.ws131{word-spacing:6.480000pt;}
.wse9{word-spacing:6.520000pt;}
.ws99{word-spacing:6.560000pt;}
.wsa{word-spacing:6.640000pt;}
.ws168{word-spacing:6.760000pt;}
.ws64{word-spacing:6.800000pt;}
.ws7e{word-spacing:6.840000pt;}
.ws3d{word-spacing:6.880000pt;}
.wse1{word-spacing:6.920000pt;}
.ws12{word-spacing:6.960000pt;}
.ws8a{word-spacing:7.000000pt;}
.wsb1{word-spacing:7.040000pt;}
.ws12f{word-spacing:7.080000pt;}
.ws16b{word-spacing:7.120000pt;}
.wsef{word-spacing:7.160000pt;}
.ws15b{word-spacing:7.200000pt;}
.ws15{word-spacing:7.240000pt;}
.ws109{word-spacing:7.280000pt;}
.ws54{word-spacing:7.360000pt;}
.wsad{word-spacing:7.400000pt;}
.ws4b{word-spacing:7.440000pt;}
.wsbd{word-spacing:7.480000pt;}
.ws169{word-spacing:7.520000pt;}
.ws160{word-spacing:7.600000pt;}
.ws5a{word-spacing:7.640000pt;}
.wsa8{word-spacing:7.760000pt;}
.ws42{word-spacing:7.800000pt;}
.wse6{word-spacing:7.920000pt;}
.ws63{word-spacing:7.960000pt;}
.ws3a{word-spacing:8.000000pt;}
.ws10b{word-spacing:8.040000pt;}
.ws26{word-spacing:8.080000pt;}
.ws25{word-spacing:8.160000pt;}
.ws75{word-spacing:8.200000pt;}
.wsd8{word-spacing:8.240000pt;}
.ws68{word-spacing:8.280000pt;}
.ws53{word-spacing:8.360000pt;}
.wsf8{word-spacing:8.400000pt;}
.ws103{word-spacing:8.440000pt;}
.ws178{word-spacing:8.520000pt;}
.ws82{word-spacing:8.560000pt;}
.wsb5{word-spacing:8.600000pt;}
.ws124{word-spacing:8.640000pt;}
.ws51{word-spacing:8.760000pt;}
.wsfa{word-spacing:8.880000pt;}
.ws3c{word-spacing:8.920000pt;}
.ws6e{word-spacing:9.120000pt;}
.ws15d{word-spacing:9.200000pt;}
.ws174{word-spacing:9.240000pt;}
.wsf4{word-spacing:9.280000pt;}
.wsc1{word-spacing:9.360000pt;}
.ws121{word-spacing:9.400000pt;}
.ws38{word-spacing:9.440000pt;}
.ws74{word-spacing:9.480000pt;}
.ws14e{word-spacing:9.520000pt;}
.wsdb{word-spacing:9.680000pt;}
.ws1c{word-spacing:9.720000pt;}
.ws45{word-spacing:9.840000pt;}
.ws173{word-spacing:9.960000pt;}
.ws78{word-spacing:10.000000pt;}
.ws71{word-spacing:10.040000pt;}
.ws12c{word-spacing:10.080000pt;}
.wsda{word-spacing:10.120000pt;}
.ws69{word-spacing:10.160000pt;}
.ws29{word-spacing:10.200000pt;}
.wsba{word-spacing:10.320000pt;}
.ws43{word-spacing:10.360000pt;}
.ws9c{word-spacing:10.400000pt;}
.wsa7{word-spacing:10.480000pt;}
.ws85{word-spacing:10.520000pt;}
.ws2e{word-spacing:10.560000pt;}
.wsb4{word-spacing:10.600000pt;}
.ws167{word-spacing:10.680000pt;}
.wsf1{word-spacing:10.720000pt;}
.ws1a{word-spacing:10.840000pt;}
.ws46{word-spacing:10.920000pt;}
.ws19{word-spacing:11.000000pt;}
.ws16a{word-spacing:11.080000pt;}
.ws179{word-spacing:11.120000pt;}
.wsd2{word-spacing:11.160000pt;}
.wsbb{word-spacing:11.200000pt;}
.ws72{word-spacing:11.320000pt;}
.ws13f{word-spacing:11.400000pt;}
.wsd0{word-spacing:11.440000pt;}
.wsb0{word-spacing:11.480000pt;}
.ws92{word-spacing:11.600000pt;}
.wse5{word-spacing:11.640000pt;}
.ws151{word-spacing:11.720000pt;}
.ws17b{word-spacing:11.733333pt;}
.wse2{word-spacing:11.760000pt;}
.ws15f{word-spacing:11.840000pt;}
.ws3e{word-spacing:11.880000pt;}
.ws112{word-spacing:12.080000pt;}
.ws31{word-spacing:12.120000pt;}
.ws8f{word-spacing:12.160000pt;}
.ws11e{word-spacing:12.280000pt;}
.ws11c{word-spacing:12.360000pt;}
.ws13c{word-spacing:12.520000pt;}
.ws9f{word-spacing:12.560000pt;}
.ws12e{word-spacing:12.680000pt;}
.ws70{word-spacing:12.880000pt;}
.ws9d{word-spacing:12.920000pt;}
.ws7a{word-spacing:13.000000pt;}
.ws152{word-spacing:13.160000pt;}
.ws7f{word-spacing:13.360000pt;}
.ws127{word-spacing:13.440000pt;}
.ws119{word-spacing:13.480000pt;}
.wsd5{word-spacing:13.520000pt;}
.ws8b{word-spacing:13.720000pt;}
.ws148{word-spacing:13.760000pt;}
.ws35{word-spacing:13.800000pt;}
.ws6b{word-spacing:13.840000pt;}
.wsd3{word-spacing:13.960000pt;}
.ws10a{word-spacing:14.000000pt;}
.ws123{word-spacing:14.160000pt;}
.wsb6{word-spacing:14.200000pt;}
.wsab{word-spacing:14.240000pt;}
.ws11b{word-spacing:14.280000pt;}
.wscf{word-spacing:14.360000pt;}
.ws14d{word-spacing:14.520000pt;}
.ws116{word-spacing:14.560000pt;}
.ws2c{word-spacing:14.640000pt;}
.ws11d{word-spacing:14.840000pt;}
.wsaa{word-spacing:14.920000pt;}
.ws125{word-spacing:15.000000pt;}
.ws15e{word-spacing:15.120000pt;}
.wsfe{word-spacing:15.160000pt;}
.ws105{word-spacing:15.280000pt;}
.wsd6{word-spacing:15.520000pt;}
.wsd1{word-spacing:15.760000pt;}
.ws30{word-spacing:15.840000pt;}
.ws2d{word-spacing:15.880000pt;}
.ws80{word-spacing:15.960000pt;}
.ws61{word-spacing:16.080000pt;}
.ws17{word-spacing:16.120000pt;}
.wsa9{word-spacing:16.200000pt;}
.ws114{word-spacing:16.240000pt;}
.ws1b{word-spacing:16.280000pt;}
.ws120{word-spacing:16.360000pt;}
.wsff{word-spacing:16.400000pt;}
.wsdd{word-spacing:16.520000pt;}
.ws62{word-spacing:16.680000pt;}
.ws88{word-spacing:16.720000pt;}
.ws117{word-spacing:16.760000pt;}
.wsfb{word-spacing:16.840000pt;}
.ws9a{word-spacing:16.960000pt;}
.ws177{word-spacing:17.040000pt;}
.ws1f{word-spacing:17.240000pt;}
.ws143{word-spacing:17.360000pt;}
.wsc2{word-spacing:17.440000pt;}
.wsce{word-spacing:17.480000pt;}
.ws73{word-spacing:17.680000pt;}
.ws130{word-spacing:17.760000pt;}
.ws66{word-spacing:17.840000pt;}
.ws2a{word-spacing:17.960000pt;}
.wsf0{word-spacing:18.320000pt;}
.ws2b{word-spacing:18.480000pt;}
.ws6c{word-spacing:18.560000pt;}
.ws155{word-spacing:18.640000pt;}
.ws15c{word-spacing:18.680000pt;}
.ws81{word-spacing:18.800000pt;}
.ws24{word-spacing:18.960000pt;}
.ws84{word-spacing:19.120000pt;}
.ws18{word-spacing:19.160000pt;}
.wsa0{word-spacing:19.200000pt;}
.ws86{word-spacing:19.360000pt;}
.ws65{word-spacing:19.600000pt;}
.ws5c{word-spacing:19.720000pt;}
.ws172{word-spacing:19.840000pt;}
.ws6d{word-spacing:19.960000pt;}
.ws14b{word-spacing:20.080000pt;}
.ws126{word-spacing:20.320000pt;}
.ws15a{word-spacing:20.440000pt;}
.ws10f{word-spacing:20.480000pt;}
.ws95{word-spacing:20.760000pt;}
.wsbc{word-spacing:21.160000pt;}
.ws58{word-spacing:21.240000pt;}
.ws166{word-spacing:21.640000pt;}
.ws144{word-spacing:21.800000pt;}
.ws113{word-spacing:21.880000pt;}
.wsf3{word-spacing:22.160000pt;}
.wsa1{word-spacing:22.280000pt;}
.ws5e{word-spacing:22.440000pt;}
.ws1{word-spacing:22.462222pt;}
.ws176{word-spacing:23.520000pt;}
.ws104{word-spacing:23.600000pt;}
.ws153{word-spacing:23.680000pt;}
.ws39{word-spacing:24.280000pt;}
.ws5d{word-spacing:24.360000pt;}
.ws11a{word-spacing:24.760000pt;}
.ws157{word-spacing:24.840000pt;}
.ws76{word-spacing:24.880000pt;}
.ws171{word-spacing:25.000000pt;}
.ws49{word-spacing:26.600000pt;}
.ws59{word-spacing:27.720000pt;}
.ws16{word-spacing:27.840000pt;}
.wsde{word-spacing:28.360000pt;}
.wsd7{word-spacing:30.400000pt;}
.ws145{word-spacing:31.880000pt;}
.ws108{word-spacing:32.200000pt;}
.ws83{word-spacing:33.840000pt;}
.ws91{word-spacing:35.680000pt;}
._2{margin-left:-23.516000pt;}
._3{margin-left:-21.408444pt;}
._e{margin-left:-13.120000pt;}
._13{margin-left:-10.240000pt;}
._2a{margin-left:-8.120000pt;}
._7{margin-left:-5.881778pt;}
._5{margin-left:-4.142667pt;}
._0{margin-left:-2.964000pt;}
._4{margin-left:-1.617778pt;}
._8{width:1.360000pt;}
._6{width:2.803556pt;}
._12{width:4.501947pt;}
._11{width:6.408293pt;}
._f{width:7.520000pt;}
._b{width:10.200000pt;}
._10{width:12.144000pt;}
._a{width:21.311111pt;}
._9{width:24.353778pt;}
._29{width:62.275281pt;}
._17{width:72.159450pt;}
._16{width:80.175945pt;}
._1f{width:93.492509pt;}
._1b{width:99.944651pt;}
._d{width:110.698099pt;}
._14{width:113.279175pt;}
._21{width:119.714181pt;}
._28{width:143.572600pt;}
._27{width:218.894112pt;}
._25{width:421.475281pt;}
._1c{width:487.994653pt;}
._26{width:511.343505pt;}
._c{width:541.668270pt;}
._24{width:553.848156pt;}
._15{width:572.941764pt;}
._1e{width:595.306208pt;}
._18{width:601.279084pt;}
._1a{width:612.479725pt;}
._19{width:614.435097pt;}
._1d{width:618.038822pt;}
._22{width:621.013058pt;}
._20{width:631.572600pt;}
._23{width:635.483711pt;}
._1{width:701.848444pt;}
.fsa{font-size:18.137778pt;}
.fs6{font-size:23.320000pt;}
.fs2{font-size:31.111111pt;}
.fs5{font-size:33.333333pt;}
.fs8{font-size:35.555556pt;}
.fs0{font-size:40.000000pt;}
.fs3{font-size:44.444444pt;}
.fs9{font-size:48.888889pt;}
.fs1{font-size:53.333333pt;}
.fs4{font-size:88.888889pt;}
.fs7{font-size:114.696444pt;}
.y0{bottom:0.000000pt;}
.y3{bottom:43.066533pt;}
.y48{bottom:73.000000pt;}
.y1b{bottom:73.113333pt;}
.y273{bottom:73.333333pt;}
.y231{bottom:74.120000pt;}
.y8d{bottom:75.000000pt;}
.y189{bottom:75.026667pt;}
.y1e1{bottom:75.133333pt;}
.y1c3{bottom:75.293333pt;}
.yf7{bottom:75.320000pt;}
.y137{bottom:75.453333pt;}
.ybf{bottom:75.613333pt;}
.yff{bottom:78.996000pt;}
.y272{bottom:86.666667pt;}
.y230{bottom:87.586667pt;}
.y47{bottom:89.000000pt;}
.y1a{bottom:90.446667pt;}
.y8c{bottom:91.000000pt;}
.y188{bottom:91.026667pt;}
.y1df{bottom:91.133333pt;}
.y1c2{bottom:91.293333pt;}
.yf6{bottom:91.320000pt;}
.y136{bottom:91.453333pt;}
.ybe{bottom:91.613333pt;}
.y1e0{bottom:95.129333pt;}
.y271{bottom:100.000000pt;}
.y22f{bottom:101.053333pt;}
.y19{bottom:101.780000pt;}
.y46{bottom:105.000000pt;}
.y8b{bottom:107.000000pt;}
.y187{bottom:107.026667pt;}
.y1de{bottom:107.133333pt;}
.y1c1{bottom:107.293333pt;}
.yf4{bottom:107.320000pt;}
.y135{bottom:107.453333pt;}
.ybd{bottom:107.613333pt;}
.yf5{bottom:111.316000pt;}
.y18{bottom:113.113333pt;}
.y270{bottom:113.333333pt;}
.y22e{bottom:114.520000pt;}
.y45{bottom:121.000000pt;}
.y89{bottom:123.000000pt;}
.y186{bottom:123.026667pt;}
.y1dd{bottom:123.133333pt;}
.y1c0{bottom:123.293333pt;}
.yf3{bottom:123.320000pt;}
.y133{bottom:123.453333pt;}
.ybc{bottom:123.613333pt;}
.y26f{bottom:126.666667pt;}
.y8a{bottom:126.996000pt;}
.y134{bottom:127.449333pt;}
.y22d{bottom:127.986667pt;}
.y44{bottom:137.000000pt;}
.y88{bottom:139.000000pt;}
.y185{bottom:139.026667pt;}
.y1db{bottom:139.133333pt;}
.y1bf{bottom:139.293333pt;}
.yf2{bottom:139.320000pt;}
.y132{bottom:139.453333pt;}
.ybb{bottom:139.613333pt;}
.y26e{bottom:140.000000pt;}
.y22c{bottom:141.453333pt;}
.y1dc{bottom:143.129333pt;}
.y1fa{bottom:143.160000pt;}
.y17{bottom:147.113333pt;}
.yf1{bottom:151.324000pt;}
.y43{bottom:153.000000pt;}
.y26d{bottom:153.333333pt;}
.y22b{bottom:154.920000pt;}
.y87{bottom:155.000000pt;}
.y184{bottom:155.026667pt;}
.y1da{bottom:155.133333pt;}
.y1be{bottom:155.293333pt;}
.yf0{bottom:155.320000pt;}
.y131{bottom:155.453333pt;}
.yba{bottom:155.613333pt;}
.y4a{bottom:156.996000pt;}
.y16{bottom:158.446667pt;}
.y26c{bottom:166.666667pt;}
.y22a{bottom:168.386667pt;}
.y41{bottom:169.000000pt;}
.y86{bottom:171.000000pt;}
.y183{bottom:171.026667pt;}
.y1d9{bottom:171.133333pt;}
.y1f9{bottom:171.160000pt;}
.y1bd{bottom:171.293333pt;}
.yef{bottom:171.320000pt;}
.y130{bottom:171.453333pt;}
.yb9{bottom:171.613333pt;}
.y42{bottom:172.996000pt;}
.y26b{bottom:180.000000pt;}
.y229{bottom:181.853333pt;}
.y40{bottom:185.000000pt;}
.y85{bottom:187.000000pt;}
.y182{bottom:187.026667pt;}
.y1d8{bottom:187.133333pt;}
.y1f8{bottom:187.160000pt;}
.y1bc{bottom:187.293333pt;}
.yee{bottom:187.320000pt;}
.y12f{bottom:187.453333pt;}
.yb7{bottom:187.613333pt;}
.yb8{bottom:191.609333pt;}
.y26a{bottom:193.333333pt;}
.y228{bottom:195.320000pt;}
.yed{bottom:199.324000pt;}
.y3f{bottom:201.000000pt;}
.y84{bottom:203.000000pt;}
.y181{bottom:203.026667pt;}
.y1d7{bottom:203.133333pt;}
.y1f7{bottom:203.160000pt;}
.y1ba{bottom:203.293333pt;}
.yec{bottom:203.320000pt;}
.y12e{bottom:203.453333pt;}
.yb6{bottom:203.613333pt;}
.y269{bottom:206.666667pt;}
.y1bb{bottom:207.289333pt;}
.y14b{bottom:207.449333pt;}
.y227{bottom:208.786667pt;}
.y3e{bottom:217.000000pt;}
.y83{bottom:219.000000pt;}
.y180{bottom:219.026667pt;}
.y1d5{bottom:219.133333pt;}
.y1f6{bottom:219.160000pt;}
.y1b9{bottom:219.293333pt;}
.yeb{bottom:219.320000pt;}
.y12d{bottom:219.453333pt;}
.yb5{bottom:219.613333pt;}
.y268{bottom:220.000000pt;}
.y49{bottom:220.996000pt;}
.y226{bottom:222.253333pt;}
.y1d6{bottom:223.129333pt;}
.y3d{bottom:233.000000pt;}
.y267{bottom:233.333333pt;}
.y82{bottom:235.000000pt;}
.y17f{bottom:235.026667pt;}
.y1d4{bottom:235.133333pt;}
.y1f5{bottom:235.160000pt;}
.y1b8{bottom:235.293333pt;}
.yea{bottom:235.320000pt;}
.y12c{bottom:235.453333pt;}
.yb4{bottom:235.613333pt;}
.y225{bottom:235.720000pt;}
.y266{bottom:246.666667pt;}
.y3c{bottom:249.000000pt;}
.y224{bottom:249.186667pt;}
.y81{bottom:251.000000pt;}
.y17e{bottom:251.026667pt;}
.y1d3{bottom:251.133333pt;}
.y1f4{bottom:251.160000pt;}
.y1b7{bottom:251.293333pt;}
.ye9{bottom:251.320000pt;}
.y12b{bottom:251.453333pt;}
.yb3{bottom:251.613333pt;}
.yfe{bottom:254.996000pt;}
.y19a{bottom:255.022667pt;}
.y14a{bottom:255.293333pt;}
.y265{bottom:260.000000pt;}
.y223{bottom:262.653333pt;}
.y3b{bottom:265.000000pt;}
.y80{bottom:267.000000pt;}
.y17d{bottom:267.026667pt;}
.y1d2{bottom:267.133333pt;}
.y1f2{bottom:267.160000pt;}
.y1b6{bottom:267.293333pt;}
.ye7{bottom:267.320000pt;}
.y12a{bottom:267.453333pt;}
.yb2{bottom:267.613333pt;}
.y1f3{bottom:271.156000pt;}
.ye8{bottom:271.316000pt;}
.y264{bottom:273.333333pt;}
.y222{bottom:276.120000pt;}
.y39{bottom:281.000000pt;}
.y7e{bottom:283.000000pt;}
.y17c{bottom:283.026667pt;}
.y1d1{bottom:283.133333pt;}
.y1f1{bottom:283.160000pt;}
.y148{bottom:283.293333pt;}
.ye6{bottom:283.320000pt;}
.y129{bottom:283.453333pt;}
.yb1{bottom:283.613333pt;}
.y263{bottom:286.666667pt;}
.y7f{bottom:286.996000pt;}
.y149{bottom:287.289333pt;}
.y221{bottom:289.586667pt;}
.y3a{bottom:297.000000pt;}
.y7d{bottom:299.000000pt;}
.y17b{bottom:299.026667pt;}
.y1d0{bottom:299.133333pt;}
.y1f0{bottom:299.160000pt;}
.y147{bottom:299.293333pt;}
.ye5{bottom:299.320000pt;}
.y128{bottom:299.453333pt;}
.yb0{bottom:299.613333pt;}
.y262{bottom:300.000000pt;}
.y220{bottom:303.053333pt;}
.y261{bottom:313.333333pt;}
.y7b{bottom:315.000000pt;}
.y17a{bottom:315.026667pt;}
.y1cf{bottom:315.133333pt;}
.y1ef{bottom:315.160000pt;}
.y146{bottom:315.293333pt;}
.ye4{bottom:315.320000pt;}
.y127{bottom:315.453333pt;}
.yaf{bottom:315.613333pt;}
.y21f{bottom:316.520000pt;}
.y7c{bottom:318.996000pt;}
.y260{bottom:326.666667pt;}
.y21e{bottom:329.986667pt;}
.y7a{bottom:331.000000pt;}
.y179{bottom:331.026667pt;}
.y1ce{bottom:331.133333pt;}
.y1ee{bottom:331.160000pt;}
.y144{bottom:331.293333pt;}
.ye3{bottom:331.320000pt;}
.y126{bottom:331.453333pt;}
.yae{bottom:331.613333pt;}
.y199{bottom:335.022667pt;}
.y145{bottom:335.289333pt;}
.y25f{bottom:340.000000pt;}
.y21d{bottom:343.453333pt;}
.y79{bottom:347.000000pt;}
.y178{bottom:347.026667pt;}
.y1cd{bottom:347.133333pt;}
.y1ec{bottom:347.160000pt;}
.y143{bottom:347.293333pt;}
.ye2{bottom:347.320000pt;}
.y125{bottom:347.453333pt;}
.yac{bottom:347.613333pt;}
.y1ed{bottom:351.156000pt;}
.yad{bottom:351.609333pt;}
.y25e{bottom:353.333333pt;}
.y21c{bottom:356.920000pt;}
.y78{bottom:363.000000pt;}
.y177{bottom:363.026667pt;}
.y1cc{bottom:363.133333pt;}
.y1eb{bottom:363.160000pt;}
.y142{bottom:363.293333pt;}
.ye0{bottom:363.320000pt;}
.y124{bottom:363.453333pt;}
.yab{bottom:363.613333pt;}
.y25d{bottom:366.666667pt;}
.y1b5{bottom:367.289333pt;}
.ye1{bottom:367.316000pt;}
.y38{bottom:368.594667pt;}
.y21b{bottom:370.386667pt;}
.y77{bottom:379.000000pt;}
.y176{bottom:379.026667pt;}
.y1cb{bottom:379.133333pt;}
.y1ea{bottom:379.160000pt;}
.y140{bottom:379.293333pt;}
.ydf{bottom:379.320000pt;}
.y123{bottom:379.453333pt;}
.yaa{bottom:379.613333pt;}
.y25c{bottom:380.000000pt;}
.y141{bottom:383.289333pt;}
.y21a{bottom:383.853333pt;}
.y25b{bottom:393.333333pt;}
.y76{bottom:395.000000pt;}
.y175{bottom:395.026667pt;}
.y1ca{bottom:395.133333pt;}
.y1e9{bottom:395.160000pt;}
.y13f{bottom:395.293333pt;}
.yde{bottom:395.320000pt;}
.y121{bottom:395.453333pt;}
.ya9{bottom:395.613333pt;}
.y37{bottom:395.928000pt;}
.y219{bottom:397.320000pt;}
.y122{bottom:399.449333pt;}
.y25a{bottom:406.666667pt;}
.y36{bottom:407.265333pt;}
.y218{bottom:410.786667pt;}
.y74{bottom:411.000000pt;}
.y174{bottom:411.026667pt;}
.y1c9{bottom:411.133333pt;}
.y1e8{bottom:411.160000pt;}
.y35{bottom:411.261333pt;}
.y13e{bottom:411.293333pt;}
.ydd{bottom:411.320000pt;}
.y120{bottom:411.453333pt;}
.ya8{bottom:411.613333pt;}
.y75{bottom:414.996000pt;}
.y198{bottom:415.022667pt;}
.y259{bottom:420.000000pt;}
.y217{bottom:424.253333pt;}
.y73{bottom:427.000000pt;}
.y173{bottom:427.026667pt;}
.y1c8{bottom:427.133333pt;}
.y1e7{bottom:427.160000pt;}
.y13d{bottom:427.293333pt;}
.ydc{bottom:427.320000pt;}
.y11f{bottom:427.453333pt;}
.ya7{bottom:427.613333pt;}
.y150{bottom:430.996000pt;}
.y258{bottom:433.333333pt;}
.y216{bottom:437.720000pt;}
.y34{bottom:438.594667pt;}
.y72{bottom:443.000000pt;}
.y172{bottom:443.026667pt;}
.y1c7{bottom:443.133333pt;}
.y1e6{bottom:443.160000pt;}
.y13c{bottom:443.293333pt;}
.ydb{bottom:443.320000pt;}
.y11e{bottom:443.453333pt;}
.ya6{bottom:443.613333pt;}
.y257{bottom:446.666667pt;}
.y215{bottom:451.186667pt;}
.y33{bottom:453.928000pt;}
.y71{bottom:459.000000pt;}
.y171{bottom:459.026667pt;}
.y1c6{bottom:459.133333pt;}
.y1e5{bottom:459.160000pt;}
.y13a{bottom:459.293333pt;}
.yda{bottom:459.320000pt;}
.y11d{bottom:459.453333pt;}
.ya5{bottom:459.613333pt;}
.y256{bottom:460.000000pt;}
.y13b{bottom:463.289333pt;}
.y214{bottom:464.653333pt;}
.y32{bottom:469.261333pt;}
.y255{bottom:473.333333pt;}
.y70{bottom:475.000000pt;}
.y170{bottom:475.026667pt;}
.y1c5{bottom:475.133333pt;}
.y1e4{bottom:475.160000pt;}
.y139{bottom:475.293333pt;}
.yd9{bottom:475.320000pt;}
.y213{bottom:477.986667pt;}
.y1b4{bottom:479.133333pt;}
.y11c{bottom:479.293333pt;}
.y31{bottom:484.594667pt;}
.y254{bottom:486.666667pt;}
.y6f{bottom:491.000000pt;}
.y16f{bottom:491.026667pt;}
.y1c4{bottom:491.133333pt;}
.y138{bottom:491.293333pt;}
.yd8{bottom:491.320000pt;}
.yfd{bottom:494.996000pt;}
.y1e3{bottom:495.000000pt;}
.y30{bottom:499.928000pt;}
.y253{bottom:500.000000pt;}
.y212{bottom:504.653333pt;}
.y6e{bottom:507.000000pt;}
.y16e{bottom:507.026667pt;}
.y1b2{bottom:507.133333pt;}
.y11b{bottom:507.293333pt;}
.yd7{bottom:507.320000pt;}
.y14f{bottom:510.996000pt;}
.y1e2{bottom:511.000000pt;}
.y1b3{bottom:511.129333pt;}
.y252{bottom:513.333333pt;}
.y211{bottom:517.986667pt;}
.y6d{bottom:523.000000pt;}
.y16d{bottom:523.026667pt;}
.y1b1{bottom:523.133333pt;}
.y11a{bottom:523.293333pt;}
.y251{bottom:526.666667pt;}
.yd6{bottom:527.160000pt;}
.y2f{bottom:527.261333pt;}
.y210{bottom:531.320000pt;}
.y6c{bottom:539.000000pt;}
.y16c{bottom:539.026667pt;}
.y119{bottom:539.293333pt;}
.y250{bottom:540.000000pt;}
.y2e{bottom:542.594667pt;}
.y197{bottom:543.022667pt;}
.yd5{bottom:543.160000pt;}
.y20f{bottom:544.653333pt;}
.y24f{bottom:553.333333pt;}
.y6b{bottom:555.000000pt;}
.y16b{bottom:555.026667pt;}
.y118{bottom:555.293333pt;}
.ya4{bottom:556.685200pt;}
.y2d{bottom:557.928000pt;}
.y20e{bottom:557.986667pt;}
.y14e{bottom:558.996000pt;}
.y24e{bottom:566.666667pt;}
.y196{bottom:567.030533pt;}
.y6a{bottom:571.000000pt;}
.y16a{bottom:571.026667pt;}
.yd3{bottom:571.160000pt;}
.y117{bottom:571.293333pt;}
.y20d{bottom:571.320000pt;}
.ya3{bottom:572.685200pt;}
.y2c{bottom:573.261333pt;}
.yfc{bottom:574.996000pt;}
.yd4{bottom:575.156000pt;}
.y28f{bottom:579.386667pt;}
.y24d{bottom:580.000000pt;}
.y1b0{bottom:583.515333pt;}
.y20c{bottom:584.653333pt;}
.y1af{bottom:586.623333pt;}
.y69{bottom:587.000000pt;}
.y169{bottom:587.026667pt;}
.yd2{bottom:587.160000pt;}
.y116{bottom:587.293333pt;}
.y2b{bottom:588.594667pt;}
.ya2{bottom:588.685200pt;}
.y14d{bottom:590.996000pt;}
.y195{bottom:591.022667pt;}
.y28e{bottom:592.720000pt;}
.y24c{bottom:593.333333pt;}
.y20b{bottom:597.986667pt;}
.y1ae{bottom:601.517867pt;}
.y68{bottom:603.000000pt;}
.y168{bottom:603.026667pt;}
.yd1{bottom:603.160000pt;}
.y114{bottom:603.293333pt;}
.y2a{bottom:603.928000pt;}
.ya1{bottom:604.685200pt;}
.y28d{bottom:606.053333pt;}
.y24b{bottom:606.666667pt;}
.yfb{bottom:606.996000pt;}
.y115{bottom:607.289333pt;}
.y20a{bottom:611.320000pt;}
.y67{bottom:619.000000pt;}
.y167{bottom:619.026667pt;}
.yd0{bottom:619.160000pt;}
.y29{bottom:619.261333pt;}
.y113{bottom:619.293333pt;}
.y28c{bottom:619.386667pt;}
.y24a{bottom:620.000000pt;}
.y1ad{bottom:620.568533pt;}
.ya0{bottom:620.685200pt;}
.y209{bottom:624.653333pt;}
.y28b{bottom:632.720000pt;}
.y249{bottom:633.333333pt;}
.y28{bottom:634.594667pt;}
.y65{bottom:635.000000pt;}
.y166{bottom:635.026667pt;}
.ycf{bottom:635.160000pt;}
.y9f{bottom:636.685200pt;}
.y208{bottom:637.986667pt;}
.y66{bottom:638.996000pt;}
.y194{bottom:639.022667pt;}
.y1ac{bottom:639.619200pt;}
.y28a{bottom:646.053333pt;}
.y248{bottom:646.666667pt;}
.y27{bottom:649.928000pt;}
.y64{bottom:651.000000pt;}
.y165{bottom:651.026667pt;}
.yce{bottom:651.160000pt;}
.y207{bottom:651.320000pt;}
.y9e{bottom:652.685200pt;}
.yfa{bottom:654.996000pt;}
.y1ab{bottom:658.669733pt;}
.y289{bottom:659.386667pt;}
.y247{bottom:660.000000pt;}
.y15{bottom:660.659867pt;}
.y63{bottom:663.004000pt;}
.y206{bottom:664.653333pt;}
.y26{bottom:665.261333pt;}
.y62{bottom:667.000000pt;}
.y164{bottom:667.026667pt;}
.ycc{bottom:667.160000pt;}
.y193{bottom:671.022667pt;}
.ycd{bottom:671.156000pt;}
.y14{bottom:671.993200pt;}
.y288{bottom:672.720000pt;}
.y246{bottom:673.333333pt;}
.y9d{bottom:674.685200pt;}
.y1aa{bottom:677.720400pt;}
.y205{bottom:677.986667pt;}
.y25{bottom:680.594667pt;}
.y61{bottom:683.000000pt;}
.y163{bottom:683.026667pt;}
.ycb{bottom:683.160000pt;}
.y13{bottom:683.326533pt;}
.y287{bottom:686.053333pt;}
.y245{bottom:686.666667pt;}
.y9c{bottom:690.685200pt;}
.y204{bottom:691.320000pt;}
.y112{bottom:691.648267pt;}
.y12{bottom:694.659867pt;}
.y111{bottom:694.756267pt;}
.y24{bottom:695.928000pt;}
.y1a9{bottom:696.770933pt;}
.y60{bottom:699.000000pt;}
.y162{bottom:699.026667pt;}
.yca{bottom:699.160000pt;}
.y286{bottom:699.386667pt;}
.y244{bottom:700.000000pt;}
.y14c{bottom:702.996000pt;}
.y203{bottom:704.653333pt;}
.y11{bottom:705.993200pt;}
.y9b{bottom:706.685200pt;}
.y110{bottom:709.650933pt;}
.y5f{bottom:711.004000pt;}
.y23{bottom:711.261333pt;}
.y285{bottom:712.720000pt;}
.y243{bottom:713.333333pt;}
.y5e{bottom:715.000000pt;}
.y161{bottom:715.026667pt;}
.yc9{bottom:715.160000pt;}
.y1a8{bottom:715.821600pt;}
.y10{bottom:717.326533pt;}
.y202{bottom:717.986667pt;}
.y10f{bottom:721.650933pt;}
.y9a{bottom:722.685200pt;}
.y284{bottom:726.053333pt;}
.y22{bottom:726.594667pt;}
.y242{bottom:726.666667pt;}
.y5d{bottom:727.004000pt;}
.yc8{bottom:727.164000pt;}
.yf{bottom:728.659867pt;}
.y5c{bottom:731.000000pt;}
.y160{bottom:731.026667pt;}
.yc7{bottom:731.160000pt;}
.y201{bottom:731.320000pt;}
.y10e{bottom:733.650933pt;}
.y1a7{bottom:734.872267pt;}
.y99{bottom:738.685200pt;}
.y283{bottom:739.386667pt;}
.y241{bottom:740.000000pt;}
.y21{bottom:741.928000pt;}
.y200{bottom:744.653333pt;}
.y10d{bottom:745.650933pt;}
.ye{bottom:745.993200pt;}
.y5b{bottom:747.000000pt;}
.y15f{bottom:747.026667pt;}
.yc6{bottom:747.160000pt;}
.y282{bottom:752.720000pt;}
.y240{bottom:753.333333pt;}
.y1a6{bottom:753.922800pt;}
.y98{bottom:754.685200pt;}
.y20{bottom:757.261333pt;}
.yd{bottom:757.326533pt;}
.y1ff{bottom:757.986667pt;}
.y5a{bottom:763.000000pt;}
.y15e{bottom:763.026667pt;}
.yc5{bottom:763.160000pt;}
.y10c{bottom:764.701467pt;}
.y281{bottom:766.053333pt;}
.y23f{bottom:766.666667pt;}
.y152{bottom:766.996000pt;}
.yc{bottom:768.659867pt;}
.y97{bottom:770.685200pt;}
.y1fe{bottom:771.320000pt;}
.y1a5{bottom:772.973467pt;}
.y10b{bottom:776.701467pt;}
.y59{bottom:779.000000pt;}
.y15d{bottom:779.026667pt;}
.yc4{bottom:779.160000pt;}
.y280{bottom:779.386667pt;}
.yb{bottom:779.993200pt;}
.y23e{bottom:780.000000pt;}
.yf9{bottom:782.996000pt;}
.y1f{bottom:784.594667pt;}
.y96{bottom:786.685200pt;}
.y1fd{bottom:788.493333pt;}
.y10a{bottom:788.701467pt;}
.y151{bottom:791.004000pt;}
.ya{bottom:791.326533pt;}
.y1a4{bottom:792.024133pt;}
.y27f{bottom:792.720000pt;}
.y23d{bottom:793.333333pt;}
.y58{bottom:795.000000pt;}
.y15c{bottom:795.026667pt;}
.yc3{bottom:795.160000pt;}
.y1e{bottom:799.928000pt;}
.y95{bottom:802.685200pt;}
.y27e{bottom:806.053333pt;}
.y23c{bottom:806.666667pt;}
.y109{bottom:807.752133pt;}
.y9{bottom:808.659867pt;}
.y56{bottom:811.000000pt;}
.y15b{bottom:811.026667pt;}
.y1a3{bottom:811.074667pt;}
.yc2{bottom:811.160000pt;}
.y192{bottom:814.866667pt;}
.y57{bottom:814.996000pt;}
.y1d{bottom:815.261333pt;}
.y1fc{bottom:816.493333pt;}
.y27d{bottom:819.386667pt;}
.y108{bottom:819.752133pt;}
.y8{bottom:819.993200pt;}
.y23b{bottom:820.000000pt;}
.y94{bottom:824.685200pt;}
.y55{bottom:827.000000pt;}
.y15a{bottom:827.026667pt;}
.yc1{bottom:827.160000pt;}
.y1fb{bottom:829.826667pt;}
.y1a2{bottom:830.125333pt;}
.y1c{bottom:830.594667pt;}
.y7{bottom:831.326533pt;}
.y107{bottom:831.752133pt;}
.y27c{bottom:832.720000pt;}
.y23a{bottom:833.333333pt;}
.y93{bottom:840.685200pt;}
.y6{bottom:842.659867pt;}
.y190{bottom:842.866667pt;}
.y54{bottom:843.000000pt;}
.y159{bottom:843.026667pt;}
.y27b{bottom:846.053333pt;}
.y239{bottom:846.666667pt;}
.y191{bottom:846.862667pt;}
.yc0{bottom:847.000000pt;}
.y1a1{bottom:849.176000pt;}
.y106{bottom:850.802800pt;}
.y92{bottom:856.685200pt;}
.y18f{bottom:858.866667pt;}
.y53{bottom:859.000000pt;}
.y158{bottom:859.026667pt;}
.y27a{bottom:859.386667pt;}
.y238{bottom:860.000000pt;}
.y105{bottom:862.802800pt;}
.y19e{bottom:868.226533pt;}
.y91{bottom:872.685200pt;}
.y279{bottom:872.720000pt;}
.y237{bottom:873.333333pt;}
.y104{bottom:874.802800pt;}
.y18e{bottom:874.866667pt;}
.y52{bottom:875.000000pt;}
.y157{bottom:875.026667pt;}
.y1a0{bottom:880.226533pt;}
.y278{bottom:886.053333pt;}
.y236{bottom:886.666667pt;}
.y90{bottom:888.685200pt;}
.y18d{bottom:890.866667pt;}
.y50{bottom:891.000000pt;}
.y156{bottom:891.026667pt;}
.y19f{bottom:892.226533pt;}
.y103{bottom:893.853333pt;}
.y51{bottom:894.996000pt;}
.y5{bottom:897.706800pt;}
.y277{bottom:899.386667pt;}
.y235{bottom:900.000000pt;}
.y8f{bottom:904.685200pt;}
.y18c{bottom:906.866667pt;}
.y4f{bottom:907.000000pt;}
.y155{bottom:907.026667pt;}
.y19d{bottom:911.064000pt;}
.y276{bottom:912.720000pt;}
.y101{bottom:912.781467pt;}
.y234{bottom:913.333333pt;}
.y102{bottom:916.777467pt;}
.y18b{bottom:922.866667pt;}
.y4e{bottom:923.000000pt;}
.y154{bottom:923.026667pt;}
.y8e{bottom:923.565200pt;}
.y275{bottom:926.053333pt;}
.y233{bottom:926.666667pt;}
.yf8{bottom:926.996000pt;}
.y4{bottom:927.040133pt;}
.y100{bottom:927.448133pt;}
.y19b{bottom:929.901333pt;}
.y19c{bottom:933.897333pt;}
.y18a{bottom:938.866667pt;}
.y4d{bottom:939.000000pt;}
.y153{bottom:939.026667pt;}
.y274{bottom:939.386667pt;}
.y232{bottom:940.000000pt;}
.y2{bottom:982.666667pt;}
.y4b{bottom:983.333333pt;}
.y1{bottom:984.000000pt;}
.y4c{bottom:984.666667pt;}
.h10{height:14.256293pt;}
.hb{height:17.443360pt;}
.h8{height:18.329520pt;}
.h5{height:24.300000pt;}
.h11{height:24.453333pt;}
.hd{height:25.800000pt;}
.he{height:25.920000pt;}
.h6{height:26.200000pt;}
.h12{height:26.595556pt;}
.hf{height:27.946667pt;}
.h1{height:29.240000pt;}
.ha{height:29.920000pt;}
.h7{height:31.440000pt;}
.h3{height:32.400000pt;}
.hc{height:35.640000pt;}
.h2{height:38.880000pt;}
.h4{height:69.866667pt;}
.h9{height:81.893261pt;}
.h0{height:1044.000000pt;}
.w0{width:780.000000pt;}
.x0{left:0.000000pt;}
.x3{left:72.480000pt;}
.x1{left:78.293333pt;}
.x41{left:82.860000pt;}
.x42{left:86.524400pt;}
.x19{left:90.000000pt;}
.x3d{left:93.008400pt;}
.x3e{left:99.824267pt;}
.x39{left:103.101467pt;}
.x72{left:104.676267pt;}
.x1b{left:106.458800pt;}
.x1c{left:110.089333pt;}
.x73{left:111.300267pt;}
.x6e{left:112.659467pt;}
.x82{left:119.451600pt;}
.x21{left:122.353600pt;}
.x3f{left:125.240267pt;}
.x6b{left:127.651333pt;}
.x7f{left:130.025867pt;}
.x22{left:131.141600pt;}
.x40{left:132.569200pt;}
.x6c{left:134.275333pt;}
.x80{left:136.649733pt;}
.x85{left:143.142000pt;}
.x3b{left:149.266400pt;}
.x7b{left:153.111333pt;}
.x3c{left:156.459600pt;}
.x7c{left:159.735333pt;}
.x6f{left:163.468533pt;}
.x95{left:168.834133pt;}
.x78{left:170.812400pt;}
.x96{left:176.027333pt;}
.x79{left:177.436267pt;}
.x84{left:178.806667pt;}
.x87{left:182.473600pt;}
.x13{left:185.263200pt;}
.x14{left:188.859867pt;}
.x15{left:191.229067pt;}
.x81{left:195.125333pt;}
.x67{left:196.924400pt;}
.x16{left:198.849067pt;}
.x74{left:202.772267pt;}
.x68{left:204.158400pt;}
.x7a{left:205.462933pt;}
.x75{left:209.802667pt;}
.x7d{left:213.953467pt;}
.x7e{left:220.577467pt;}
.x97{left:224.882400pt;}
.x65{left:227.094133pt;}
.x1d{left:228.342133pt;}
.x6d{left:229.828000pt;}
.x1e{left:231.972667pt;}
.x66{left:234.042000pt;}
.x3a{left:237.342933pt;}
.x76{left:239.382133pt;}
.x69{left:241.028133pt;}
.x77{left:246.006133pt;}
.x6a{left:247.652133pt;}
.x86{left:248.893867pt;}
.x70{left:251.381733pt;}
.x1f{left:253.139867pt;}
.x20{left:256.770533pt;}
.x71{left:258.412133pt;}
.x23{left:262.282267pt;}
.x1a{left:265.284933pt;}
.x17{left:268.403333pt;}
.x18{left:272.000000pt;}
.x8{left:287.594800pt;}
.xa{left:290.000000pt;}
.x98{left:295.712000pt;}
.x24{left:302.226667pt;}
.x4{left:303.840000pt;}
.x9{left:308.621733pt;}
.x54{left:313.070267pt;}
.x25{left:314.226667pt;}
.xb{left:315.980133pt;}
.x46{left:318.867733pt;}
.x55{left:319.982133pt;}
.x45{left:321.547333pt;}
.x47{left:322.780933pt;}
.x43{left:324.227067pt;}
.xc{left:325.833467pt;}
.x8f{left:341.633867pt;}
.x89{left:366.583067pt;}
.x44{left:371.120000pt;}
.x56{left:385.633867pt;}
.x50{left:390.321333pt;}
.x57{left:392.545733pt;}
.x51{left:397.233200pt;}
.x58{left:399.861067pt;}
.x59{left:408.998267pt;}
.x5a{left:425.183067pt;}
.x4d{left:427.559733pt;}
.x83{left:428.757867pt;}
.x4b{left:432.392533pt;}
.x4e{left:434.471600pt;}
.x4c{left:435.989200pt;}
.x52{left:449.290133pt;}
.x4f{left:452.895733pt;}
.x7{left:455.078000pt;}
.x53{left:456.202000pt;}
.x26{left:459.361200pt;}
.x27{left:462.957867pt;}
.x90{left:466.754133pt;}
.x48{left:471.683200pt;}
.x49{left:475.347600pt;}
.x4a{left:482.738933pt;}
.x28{left:487.043467pt;}
.x29{left:490.640000pt;}
.xd{left:508.000000pt;}
.x8c{left:520.497867pt;}
.x8a{left:522.168800pt;}
.x2a{left:526.000000pt;}
.x8b{left:527.145200pt;}
.x5f{left:532.068667pt;}
.x10{left:535.016000pt;}
.x5c{left:539.020133pt;}
.x11{left:544.007600pt;}
.x5d{left:546.213333pt;}
.x35{left:548.072267pt;}
.xe{left:549.402800pt;}
.xf{left:552.999333pt;}
.x32{left:558.691467pt;}
.x2{left:562.583467pt;}
.x33{left:574.876133pt;}
.x2f{left:585.893200pt;}
.x8d{left:588.899467pt;}
.x37{left:591.853067pt;}
.x8e{left:598.185333pt;}
.x2b{left:601.228000pt;}
.x2c{left:604.186667pt;}
.x88{left:605.397200pt;}
.x60{left:609.384400pt;}
.x61{left:612.981067pt;}
.x38{left:617.029467pt;}
.x94{left:623.294800pt;}
.x91{left:628.890800pt;}
.x12{left:638.990667pt;}
.x5b{left:642.637600pt;}
.x63{left:648.782667pt;}
.x62{left:658.754400pt;}
.x5{left:662.622267pt;}
.x30{left:665.365867pt;}
.x6{left:666.512000pt;}
.x5e{left:671.362667pt;}
.x34{left:676.716533pt;}
.x92{left:686.362933pt;}
.x31{left:690.542133pt;}
.x64{left:691.733867pt;}
.x93{left:693.556133pt;}
.x36{left:694.889333pt;}
.x2d{left:700.806800pt;}
.x2e{left:708.000000pt;}
}
</style>
<script>
/*
 Copyright 2012 Mozilla Foundation 
 Copyright 2013 Lu Wang <coolwanglu@gmail.com>
 Apachine License Version 2.0 
*/
(function(){function b(a,b,e,f){var c=(a.className||"").split(/\s+/g);""===c[0]&&c.shift();var d=c.indexOf(b);0>d&&e&&c.push(b);0<=d&&f&&c.splice(d,1);a.className=c.join(" ");return 0<=d}if(!("classList"in document.createElement("div"))){var e={add:function(a){b(this.element,a,!0,!1)},contains:function(a){return b(this.element,a,!1,!1)},remove:function(a){b(this.element,a,!1,!0)},toggle:function(a){b(this.element,a,!0,!0)}};Object.defineProperty(HTMLElement.prototype,"classList",{get:function(){if(this._classList)return this._classList;
var a=Object.create(e,{element:{value:this,writable:!1,enumerable:!0}});Object.defineProperty(this,"_classList",{value:a,writable:!1,enumerable:!1});return a},enumerable:!0})}})();
</script>
<script>
(function(){/*
 pdf2htmlEX.js: Core UI functions for pdf2htmlEX 
 Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> and other contributors 
 https://github.com/pdf2htmlEX/pdf2htmlEX/blob/master/share/LICENSE 
*/
var pdf2htmlEX=window.pdf2htmlEX=window.pdf2htmlEX||{},CSS_CLASS_NAMES={page_frame:"pf",page_content_box:"pc",page_data:"pi",background_image:"bi",link:"l",input_radio:"ir",__dummy__:"no comma"},DEFAULT_CONFIG={container_id:"page-container",sidebar_id:"sidebar",outline_id:"outline",loading_indicator_cls:"loading-indicator",preload_pages:3,render_timeout:100,scale_step:0.9,key_handler:!0,hashchange_handler:!0,view_history_handler:!0,__dummy__:"no comma"},EPS=1E-6;
function invert(a){var b=a[0]*a[3]-a[1]*a[2];return[a[3]/b,-a[1]/b,-a[2]/b,a[0]/b,(a[2]*a[5]-a[3]*a[4])/b,(a[1]*a[4]-a[0]*a[5])/b]}function transform(a,b){return[a[0]*b[0]+a[2]*b[1]+a[4],a[1]*b[0]+a[3]*b[1]+a[5]]}function get_page_number(a){return parseInt(a.getAttribute("data-page-no"),16)}function disable_dragstart(a){for(var b=0,c=a.length;b<c;++b)a[b].addEventListener("dragstart",function(){return!1},!1)}
function clone_and_extend_objs(a){for(var b={},c=0,e=arguments.length;c<e;++c){var h=arguments[c],d;for(d in h)h.hasOwnProperty(d)&&(b[d]=h[d])}return b}
function Page(a){if(a){this.shown=this.loaded=!1;this.page=a;this.num=get_page_number(a);this.original_height=a.clientHeight;this.original_width=a.clientWidth;var b=a.getElementsByClassName(CSS_CLASS_NAMES.page_content_box)[0];b&&(this.content_box=b,this.original_scale=this.cur_scale=this.original_height/b.clientHeight,this.page_data=JSON.parse(a.getElementsByClassName(CSS_CLASS_NAMES.page_data)[0].getAttribute("data-data")),this.ctm=this.page_data.ctm,this.ictm=invert(this.ctm),this.loaded=!0)}}
Page.prototype={hide:function(){this.loaded&&this.shown&&(this.content_box.classList.remove("opened"),this.shown=!1)},show:function(){this.loaded&&!this.shown&&(this.content_box.classList.add("opened"),this.shown=!0)},rescale:function(a){this.cur_scale=0===a?this.original_scale:a;this.loaded&&(a=this.content_box.style,a.msTransform=a.webkitTransform=a.transform="scale("+this.cur_scale.toFixed(3)+")");a=this.page.style;a.height=this.original_height*this.cur_scale+"px";a.width=this.original_width*this.cur_scale+
"px"},view_position:function(){var a=this.page,b=a.parentNode;return[b.scrollLeft-a.offsetLeft-a.clientLeft,b.scrollTop-a.offsetTop-a.clientTop]},height:function(){return this.page.clientHeight},width:function(){return this.page.clientWidth}};function Viewer(a){this.config=clone_and_extend_objs(DEFAULT_CONFIG,0<arguments.length?a:{});this.pages_loading=[];this.init_before_loading_content();var b=this;document.addEventListener("DOMContentLoaded",function(){b.init_after_loading_content()},!1)}
Viewer.prototype={scale:1,cur_page_idx:0,first_page_idx:0,init_before_loading_content:function(){this.pre_hide_pages()},initialize_radio_button:function(){for(var a=document.getElementsByClassName(CSS_CLASS_NAMES.input_radio),b=0;b<a.length;b++)a[b].addEventListener("click",function(){this.classList.toggle("checked")})},init_after_loading_content:function(){this.sidebar=document.getElementById(this.config.sidebar_id);this.outline=document.getElementById(this.config.outline_id);this.container=document.getElementById(this.config.container_id);
this.loading_indicator=document.getElementsByClassName(this.config.loading_indicator_cls)[0];for(var a=!0,b=this.outline.childNodes,c=0,e=b.length;c<e;++c)if("ul"===b[c].nodeName.toLowerCase()){a=!1;break}a||this.sidebar.classList.add("opened");this.find_pages();if(0!=this.pages.length){disable_dragstart(document.getElementsByClassName(CSS_CLASS_NAMES.background_image));this.config.key_handler&&this.register_key_handler();var h=this;this.config.hashchange_handler&&window.addEventListener("hashchange",
function(a){h.navigate_to_dest(document.location.hash.substring(1))},!1);this.config.view_history_handler&&window.addEventListener("popstate",function(a){a.state&&h.navigate_to_dest(a.state)},!1);this.container.addEventListener("scroll",function(){h.update_page_idx();h.schedule_render(!0)},!1);[this.outline].concat(Array.from(this.container.querySelectorAll("a.l"))).forEach(function(a){a.addEventListener("click",h.link_handler.bind(h),!1)});this.initialize_radio_button();this.render()}},find_pages:function(){for(var a=
[],b={},c=this.container.childNodes,e=0,h=c.length;e<h;++e){var d=c[e];d.nodeType===Node.ELEMENT_NODE&&d.classList.contains(CSS_CLASS_NAMES.page_frame)&&(d=new Page(d),a.push(d),b[d.num]=a.length-1)}this.pages=a;this.page_map=b},load_page:function(a,b,c){var e=this.pages;if(!(a>=e.length||(e=e[a],e.loaded||this.pages_loading[a]))){var e=e.page,h=e.getAttribute("data-page-url");if(h){this.pages_loading[a]=!0;var d=e.getElementsByClassName(this.config.loading_indicator_cls)[0];"undefined"===typeof d&&
(d=this.loading_indicator.cloneNode(!0),d.classList.add("active"),e.appendChild(d));var f=this,g=new XMLHttpRequest;g.open("GET",h,!0);g.onload=function(){if(200===g.status||0===g.status){var b=document.createElement("div");b.innerHTML=g.responseText;for(var d=null,b=b.childNodes,e=0,h=b.length;e<h;++e){var p=b[e];if(p.nodeType===Node.ELEMENT_NODE&&p.classList.contains(CSS_CLASS_NAMES.page_frame)){d=p;break}}b=f.pages[a];f.container.replaceChild(d,b.page);b=new Page(d);f.pages[a]=b;b.hide();b.rescale(f.scale);
disable_dragstart(d.getElementsByClassName(CSS_CLASS_NAMES.background_image));f.schedule_render(!1);c&&c(b)}delete f.pages_loading[a]};g.send(null)}void 0===b&&(b=this.config.preload_pages);0<--b&&(f=this,setTimeout(function(){f.load_page(a+1,b)},0))}},pre_hide_pages:function(){var a="@media screen{."+CSS_CLASS_NAMES.page_content_box+"{display:none;}}",b=document.createElement("style");b.styleSheet?b.styleSheet.cssText=a:b.appendChild(document.createTextNode(a));document.head.appendChild(b)},render:function(){for(var a=
this.container,b=a.scrollTop,c=a.clientHeight,a=b-c,b=b+c+c,c=this.pages,e=0,h=c.length;e<h;++e){var d=c[e],f=d.page,g=f.offsetTop+f.clientTop,f=g+f.clientHeight;g<=b&&f>=a?d.loaded?d.show():this.load_page(e):d.hide()}},update_page_idx:function(){var a=this.pages,b=a.length;if(!(2>b)){for(var c=this.container,e=c.scrollTop,c=e+c.clientHeight,h=-1,d=b,f=d-h;1<f;){var g=h+Math.floor(f/2),f=a[g].page;f.offsetTop+f.clientTop+f.clientHeight>=e?d=g:h=g;f=d-h}this.first_page_idx=d;for(var g=h=this.cur_page_idx,
k=0;d<b;++d){var f=a[d].page,l=f.offsetTop+f.clientTop,f=f.clientHeight;if(l>c)break;f=(Math.min(c,l+f)-Math.max(e,l))/f;if(d===h&&Math.abs(f-1)<=EPS){g=h;break}f>k&&(k=f,g=d)}this.cur_page_idx=g}},schedule_render:function(a){if(void 0!==this.render_timer){if(!a)return;clearTimeout(this.render_timer)}var b=this;this.render_timer=setTimeout(function(){delete b.render_timer;b.render()},this.config.render_timeout)},register_key_handler:function(){var a=this;window.addEventListener("DOMMouseScroll",function(b){if(b.ctrlKey){b.preventDefault();
var c=a.container,e=c.getBoundingClientRect(),c=[b.clientX-e.left-c.clientLeft,b.clientY-e.top-c.clientTop];a.rescale(Math.pow(a.config.scale_step,b.detail),!0,c)}},!1);window.addEventListener("keydown",function(b){var c=!1,e=b.ctrlKey||b.metaKey,h=b.altKey;switch(b.keyCode){case 61:case 107:case 187:e&&(a.rescale(1/a.config.scale_step,!0),c=!0);break;case 173:case 109:case 189:e&&(a.rescale(a.config.scale_step,!0),c=!0);break;case 48:e&&(a.rescale(0,!1),c=!0);break;case 33:h?a.scroll_to(a.cur_page_idx-
1):a.container.scrollTop-=a.container.clientHeight;c=!0;break;case 34:h?a.scroll_to(a.cur_page_idx+1):a.container.scrollTop+=a.container.clientHeight;c=!0;break;case 35:a.container.scrollTop=a.container.scrollHeight;c=!0;break;case 36:a.container.scrollTop=0,c=!0}c&&b.preventDefault()},!1)},rescale:function(a,b,c){var e=this.scale;this.scale=a=0===a?1:b?e*a:a;c||(c=[0,0]);b=this.container;c[0]+=b.scrollLeft;c[1]+=b.scrollTop;for(var h=this.pages,d=h.length,f=this.first_page_idx;f<d;++f){var g=h[f].page;
if(g.offsetTop+g.clientTop>=c[1])break}g=f-1;0>g&&(g=0);var g=h[g].page,k=g.clientWidth,f=g.clientHeight,l=g.offsetLeft+g.clientLeft,m=c[0]-l;0>m?m=0:m>k&&(m=k);k=g.offsetTop+g.clientTop;c=c[1]-k;0>c?c=0:c>f&&(c=f);for(f=0;f<d;++f)h[f].rescale(a);b.scrollLeft+=m/e*a+g.offsetLeft+g.clientLeft-m-l;b.scrollTop+=c/e*a+g.offsetTop+g.clientTop-c-k;this.schedule_render(!0)},fit_width:function(){var a=this.cur_page_idx;this.rescale(this.container.clientWidth/this.pages[a].width(),!0);this.scroll_to(a)},fit_height:function(){var a=
this.cur_page_idx;this.rescale(this.container.clientHeight/this.pages[a].height(),!0);this.scroll_to(a)},get_containing_page:function(a){for(;a;){if(a.nodeType===Node.ELEMENT_NODE&&a.classList.contains(CSS_CLASS_NAMES.page_frame)){a=get_page_number(a);var b=this.page_map;return a in b?this.pages[b[a]]:null}a=a.parentNode}return null},link_handler:function(a){var b=a.target,c=b.getAttribute("data-dest-detail");c||(b=a.currentTarget,c=b.getAttribute("data-dest-detail"));if(c){if(this.config.view_history_handler)try{var e=
this.get_current_view_hash();window.history.replaceState(e,"","#"+e);window.history.pushState(c,"","#"+c)}catch(h){}this.navigate_to_dest(c,this.get_containing_page(b));a.preventDefault()}},navigate_to_dest:function(a,b){try{var c=JSON.parse(a)}catch(e){return}if(c instanceof Array){var h=c[0],d=this.page_map;if(h in d){for(var f=d[h],h=this.pages[f],d=2,g=c.length;d<g;++d){var k=c[d];if(null!==k&&"number"!==typeof k)return}for(;6>c.length;)c.push(null);var g=b||this.pages[this.cur_page_idx],d=g.view_position(),
d=transform(g.ictm,[d[0],g.height()-d[1]]),g=this.scale,l=[0,0],m=!0,k=!1,n=this.scale;switch(c[1]){case "XYZ":l=[null===c[2]?d[0]:c[2]*n,null===c[3]?d[1]:c[3]*n];g=c[4];if(null===g||0===g)g=this.scale;k=!0;break;case "Fit":case "FitB":l=[0,0];k=!0;break;case "FitH":case "FitBH":l=[0,null===c[2]?d[1]:c[2]*n];k=!0;break;case "FitV":case "FitBV":l=[null===c[2]?d[0]:c[2]*n,0];k=!0;break;case "FitR":l=[c[2]*n,c[5]*n],m=!1,k=!0}if(k){this.rescale(g,!1);var p=this,c=function(a){l=transform(a.ctm,l);m&&
(l[1]=a.height()-l[1]);p.scroll_to(f,l)};h.loaded?c(h):(this.load_page(f,void 0,c),this.scroll_to(f))}}}},scroll_to:function(a,b){var c=this.pages;if(!(0>a||a>=c.length)){c=c[a].view_position();void 0===b&&(b=[0,0]);var e=this.container;e.scrollLeft+=b[0]-c[0];e.scrollTop+=b[1]-c[1]}},get_current_view_hash:function(){var a=[],b=this.pages[this.cur_page_idx];a.push(b.num);a.push("XYZ");var c=b.view_position(),c=transform(b.ictm,[c[0],b.height()-c[1]]);a.push(c[0]/this.scale);a.push(c[1]/this.scale);
a.push(this.scale);return JSON.stringify(a)}};pdf2htmlEX.Viewer=Viewer;})();
</script>
<script>
try{
pdf2htmlEX.defaultViewer = new pdf2htmlEX.Viewer({});
}catch(e){}
</script>
<title></title>
</head>
<body>
<div id="sidebar">
<div id="outline">
<ul><li><a class="l" href="#pf1" data-dest-detail='[1,"XYZ",53,715,null]'>_GoBack</a></li><li><a class="l" href="#pf3" data-dest-detail='[3,"XYZ",286,656,null]'>_GoBack</a></li><li><a class="l" href="#pf5" data-dest-detail='[5,"XYZ",447,645,null]'>_GoBack</a></li></ul></div>
</div>
<div id="page-container">
<div id="pf1" class="pf w0 h0" data-page-no="1"><div class="pc pc1 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x1 h1 y1 ff1 fs0 fc0 sc0 ls0 ws0"><span class="fc3 sc0">SELEXIP</span><span class="_ _0"></span><span class="fc3 sc0">AG </span></div><div class="t m0 x2 h2 y2 ff2 fs1 fc0 sc0 ls0 ws0"><span class="fc3 sc0">CLINICAL REVIEW</span></div><div class="t m1 x3 h3 y3 ff3 fs2 fc1 sc0 ls0 ws0"> <span class="_ _1"> </span><span class="ff4">AM J HEAL<span class="_ _0"></span>TH-SYST PHARM<span class="ff3 ws1"> | VOLUME <span class="_ _2"></span>74 | NUMBER <span class="_ _2"></span>15 | AUGUST <span class="_ _3"></span>1, <span class="_ _2"></span>2017  <span class="ff4 fs3 ws0">1135</span></span></span></div><div class="t m2 x3 h4 y4 ff3 fs4 fc2 sc0 ls0 ws0">Selexipag for the tr<span class="_ _4"></span>eatment of pulmonary arterial </div><div class="t m2 x3 h4 y5 ff3 fs4 fc2 sc0 ls0 ws0">hypertension</div><div class="t m1 x3 h5 y6 ff4 fs5 fc1 sc0 ls0 ws0">Zachary R. Noel, Pharm.D., BCPS, </div><div class="t m1 x3 h6 y7 ff3 fs5 fc1 sc0 ls0 ws0">Department of Pharmacy Practice and </div><div class="t m1 x3 h6 y8 ff3 fs5 fc1 sc0 ls0 ws0">Science, University of Maryland School of </div><div class="t m1 x3 h6 y9 ff3 fs5 fc1 sc0 ls0 ws0">Pharmacy<span class="_ _0"></span>, Baltimore, MD.</div><div class="t m1 x3 h5 ya ff4 fs5 fc1 sc0 ls0 ws0">Kazuhiko Kido, Pharm.D., M.S., </div><div class="t m1 x3 h6 yb ff3 fs5 fc1 sc0 ls0 ws0">Department of Pharmacy Practice, South </div><div class="t m1 x3 h6 yc ff3 fs5 fc1 sc0 ls0 ws0">Dakota State University<span class="_ _0"></span>, Sioux Falls, SD, </div><div class="t m1 x3 h6 yd ff3 fs5 fc1 sc0 ls0 ws0">and Department of Pharmacy<span class="_ _0"></span>, Avera </div><div class="t m1 x3 h6 ye ff3 fs5 fc1 sc0 ls0 ws0">McKennan Hospital, Sioux Falls, SD.</div><div class="t m1 x3 h5 yf ff4 fs5 fc1 sc0 ls0 ws0">T<span class="_ _0"></span>racy E. Macaulay<span class="_ _0"></span>, Pharm.D., </div><div class="t m1 x3 h6 y10 ff4 fs5 fc1 sc0 ls0 ws0">AACC,<span class="ff3"> </span>BCPS-AQ Cardiology<span class="_ _0"></span>,<span class="ff3"> </span></div><div class="t m1 x3 h6 y11 ff3 fs5 fc1 sc0 ls0 ws0">Department of Pharmacy Practice </div><div class="t m1 x3 h6 y12 ff3 fs5 fc1 sc0 ls0 ws0">and Science, University of Kentucky </div><div class="t m1 x3 h6 y13 ff3 fs5 fc1 sc0 ls0 ws0">College of Pharmacy<span class="_ _0"></span>, Lexington, KY<span class="_ _5"></span>, and </div><div class="t m1 x3 h6 y14 ff3 fs5 fc1 sc0 ls0 ws0">UKHealthCare Jack and Linda Gill Heart </div><div class="t m1 x3 h6 y15 ff3 fs5 fc1 sc0 ls0 ws0">Institute, Lexington, KY<span class="_ _5"></span>.</div><div class="t m1 x3 h6 y16 ff3 fs5 fc1 sc0 ls0 ws0">Address corr<span class="_ _4"></span>espondence to Dr<span class="_ _0"></span>. Noel </div><div class="t m1 x3 h6 y17 ff3 fs5 fc1 sc0 ls0 ws0">(znoel@rx.umaryland.edu). </div><div class="t m1 x3 h6 y18 ff3 fs5 fc1 sc0 ls0 ws0">Copyright  2017, American Society of </div><div class="t m1 x3 h6 y19 ff3 fs5 fc1 sc0 ls0 ws0">Health-System Pharmacists, Inc. All rights </div><div class="t m1 x3 h6 y1a ff3 fs5 fc1 sc0 ls0 ws0">reserved. 1079-2082/17/0801-1135.</div><div class="t m1 x3 h6 y1b ff3 fs5 fc1 sc0 ls0 ws0">DOI 10.2146/ajhp160798</div><div class="t m1 x4 h7 y1c ff4 fs0 fc2 sc0 ls0 ws0">Purpose.<span class="ff3 fc1 ws2"> The pharmacology<span class="_ _0"></span>, pharmacokinetics, clinical efcacy<span class="_ _0"></span>, safety </span></div><div class="t m1 x4 h7 y1d ff3 fs0 fc1 sc0 ls0 ws3">and tolerability<span class="_ _0"></span>, dosing and administration, and place in therapy of selexi<span class="ws0">-</span></div><div class="t m1 x4 h7 y1e ff3 fs0 fc1 sc0 ls0 ws4">pag, an orally administered selective pr<span class="_ _4"></span>ostacyclin receptor agonist for the </div><div class="t m1 x4 h7 y1f ff3 fs0 fc1 sc0 ls0 ws0">treatment of pulmonary arterial hypertension (P<span class="_ _5"></span>AH), are reviewed.</div><div class="t m1 x4 h7 y20 ff4 fs0 fc2 sc0 ls0 ws0">Summary<span class="_ _5"></span>. <span class="_ _6"></span><span class="ff3 fc1 ws5">The rst-in-class oral prostacyclin IP r<span class="_ _4"></span>eceptor agonist selexi<span class="ws0">-</span></span></div><div class="t m1 x4 h7 y21 ff3 fs0 fc1 sc0 ls0 ws6">pag (Uptravi, Actelion Pharmaceuticals) was approved by the Food and </div><div class="t m1 x4 h7 y22 ff3 fs0 fc1 sc0 ls0 ws7">Drug Administration in December 2015. Selexipag is rapidly hydrolyzed </div><div class="t m1 x4 h7 y23 ff3 fs0 fc1 sc0 ls0 ws8">to a long-acting metabolite that binds with high selectivity to IP recep<span class="ws0">-</span></div><div class="t m1 x4 h7 y24 ff3 fs0 fc1 sc0 ls0 ws2">tors, resulting in vasodilation, inhibition of platelet aggr<span class="_ _4"></span>egation, and an<span class="ws0">-</span></div><div class="t m1 x4 h7 y25 ff3 fs0 fc1 sc0 ls0 ws9">tiinammatory effects. Results of a long-term, placebo-contr<span class="_ _4"></span>olled, clini<span class="ws0">-</span></div><div class="t m1 x4 h7 y26 ff3 fs0 fc1 sc0 ls0 ws3">cal outcomesdriven trial showed that selexipag signicantly reduced the </div><div class="t m1 x4 h7 y27 ff3 fs0 fc1 sc0 ls0 wsa">occurrence of the composite primary outcome (all-cause mortality and </div><div class="t m1 x4 h7 y28 ff3 fs0 fc1 sc0 ls0 wsb">development of P<span class="_ _0"></span>AH-related complications). Selexipag is indicated for use </div><div class="t m1 x4 h7 y29 ff3 fs0 fc1 sc0 ls0 wsc">in patients with W<span class="_ _0"></span>orld Health Organization functional class (FC) II or III </div><div class="t m1 x4 h7 y2a ff3 fs0 fc1 sc0 ls0 wsd">disease. The recommended initial selexipag dosage is 200 <span class="ff5 ws0">m</span>g twice daily<span class="_ _5"></span>. </div><div class="t m1 x4 h7 y2b ff3 fs0 fc1 sc0 ls0 wse">Like prostanoid analogs, selexipag has a dose-dependent adverse-ef<span class="_ _4"></span>fect </div><div class="t m1 x4 h7 y2c ff3 fs0 fc1 sc0 ls0 wsf">prole that includes nausea, vomiting, diarrhea, headache, and muscu<span class="ws0">-</span></div><div class="t m1 x4 h7 y2d ff3 fs0 fc1 sc0 ls0 ws10">loskeletal pain. Although selexipag offers distinct pharmacologic advan<span class="ws0">-</span></div><div class="t m1 x4 h7 y2e ff3 fs0 fc1 sc0 ls0 ws11">tages over other agents for the treatment of P<span class="_ _5"></span>AH, important issues of cost </div><div class="t m1 x4 h7 y2f ff3 fs0 fc1 sc0 ls0 ws0">and access must be considered.</div><div class="t m1 x4 h7 y30 ff4 fs0 fc2 sc0 ls0 ws0">Conclusion.<span class="ff3 fc1 ws12"> Selexipag is an oral prostacyclin IP r<span class="_ _4"></span>eceptor agonist ap<span class="ws0">-</span></span></div><div class="t m1 x4 h7 y31 ff3 fs0 fc1 sc0 ls0 ws13">proved for use as monotherapy or in combination with other therapies to </div><div class="t m1 x4 h7 y32 ff3 fs0 fc1 sc0 ls0 ws8">slow P<span class="_ _0"></span>AH progr<span class="_ _4"></span>ession and reduce the risk of hospitalization in patients </div><div class="t m1 x4 h7 y33 ff3 fs0 fc1 sc0 ls0 ws14">with FC II or III symptoms. Its stability and relatively long half-life of<span class="_ _4"></span>fer </div><div class="t m1 x4 h7 y34 ff3 fs0 fc1 sc0 ls0 ws0">conveniences over conventional prostanoid therapies.</div><div class="t m1 x4 h7 y35 ff4 fs0 fc2 sc0 ls0 ws0">Keywords:<span class="ff3 fc1 ws15"> ACT<span class="_ _7"></span>-293987, MRE-269, prostacyclin, pr<span class="_ _4"></span>ostaglandin I</span></div><div class="t m1 x5 h8 y36 ff3 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m1 x6 h7 y35 ff3 fs0 fc1 sc0 ls0 ws15">, pul<span class="ws0">-</span></div><div class="t m1 x4 h7 y37 ff3 fs0 fc1 sc0 ls0 ws0">monary arterial hypertension, selexipag</div><div class="t m1 x7 h7 y38 ff6 fs0 fc1 sc0 ls0 ws0">Am J Health-Syst Pharm.<span class="ff3"> 2017; 74:1135-41</span></div><div class="t m3 x8 h9 y39 ff7 fs7 fc2 sc0 ls0 ws0">P</div><div class="t m3 x9 ha y3a ff8 fs0 fc1 sc0 ls0 ws16">ulmonary arter<span class="_ _8"></span>ial hypertension </div><div class="t m3 x9 ha y39 ff8 fs0 fc1 sc0 ls0 ws17">(P<span class="_ _0"></span>AH) is a rare disease charac<span class="ws0">-</span></div><div class="t m3 xa ha y3b ff8 fs0 fc1 sc0 ls0 ws18">terized by incr<span class="_ _4"></span>eases in pulmonary </div><div class="t m3 xa ha y3c ff8 fs0 fc1 sc0 ls0 ws19">vascular resistance<span class="_ _4"></span>. P<span class="_ _0"></span>AH most com<span class="ws0">-</span></div><div class="t m3 xa ha y3d ff8 fs0 fc1 sc0 ls0 ws1a">monly refers to elevated pulmonary </div><div class="t m3 xa ha y3e ff8 fs0 fc1 sc0 ls0 ws1b">pressur<span class="_ _4"></span>es secondary to precapillary </div><div class="t m3 xa ha y3f ff8 fs0 fc1 sc0 ls0 ws4">causes and not attributable to chronic </div><div class="t m3 xa ha y40 ff8 fs0 fc1 sc0 ls0 ws1c">lung, heart, or thromboembolic dis<span class="ws0">-</span></div><div class="t m3 xa ha y41 ff8 fs0 fc1 sc0 ls0 ws0">ease.</div><div class="t m3 xb hb y42 ff8 fs6 fc1 sc0 ls0 ws0">1-3</div><div class="t m3 xc ha y41 ff8 fs0 fc1 sc0 ls0 ws1d"> In the 5-group pulmonary hy<span class="_ _4"></span><span class="ws0">-</span></div><div class="t m3 xa ha y43 ff8 fs0 fc1 sc0 ls0 ws1e">pertension classication system of the </div><div class="t m3 xa ha y44 ff8 fs0 fc1 sc0 ls0 ws1f">W<span class="_ _0"></span>orld Health Organization (<span class="_ _8"></span>WHO), </div><div class="t m3 xa ha y45 ff8 fs0 fc1 sc0 ls0 ws20">group 1 comprises P<span class="_ _0"></span>AH of various eti<span class="ws0">-</span></div><div class="t m3 xa ha y46 ff8 fs0 fc1 sc0 ls0 wsf">ologies, which include heritable con<span class="ws0">-</span></div><div class="t m3 xa ha y47 ff8 fs0 fc1 sc0 ls0 ws21">ditions (e.g., mutation of <span class="ff9 ws0">BMPR2<span class="ff8">,</span> <span class="_ _6"></span><span class="ff8">the </span></span></div><div class="t m3 xa ha y48 ff8 fs0 fc1 sc0 ls0 ws21">gene coding for bone morphogenetic </div><div class="t m3 xd ha y3a ff8 fs0 fc1 sc0 ls0 ws22">protein receptor type 2), <span class="_ _4"></span>exposure to </div><div class="t m3 xd ha y39 ff8 fs0 fc1 sc0 ls0 ws23">toxins or drugs (e<span class="_ _4"></span>.g., stimulants such </div><div class="t m3 xd ha y3b ff8 fs0 fc1 sc0 ls0 ws24">as fenuramine), connective tissue </div><div class="t m3 xd ha y3c ff8 fs0 fc1 sc0 ls0 ws25">disorders<span class="_ _4"></span>, human immunodeciency </div><div class="t m3 xd ha y3d ff8 fs0 fc1 sc0 ls0 ws26">virus infection, and congenital heart </div><div class="t m3 xd ha y3e ff8 fs0 fc1 sc0 ls0 ws0">disease.</div><div class="t m3 xe hb y49 ff8 fs6 fc1 sc0 ls0 ws0">4</div><div class="t m3 xf ha y3e ff8 fs0 fc1 sc0 ls0 ws27"> <span class="_ _4"></span>The incidence of P<span class="_ _0"></span>AH is ap<span class="ws0">-</span></div><div class="t m3 xd ha y3f ff8 fs0 fc1 sc0 ls0 ws28">proximately 2.4 cases per million an<span class="ws0">-</span></div><div class="t m3 xd ha y40 ff8 fs0 fc1 sc0 ls0 ws29">nually<span class="_ _5"></span>, and the disease is 24 times </div><div class="t m3 xd ha y41 ff8 fs0 fc1 sc0 ls0 ws2a">more common in women than in </div><div class="t m3 xd ha y43 ff8 fs0 fc1 sc0 ls0 ws0">men.</div><div class="t m3 x10 hb y4a ff8 fs6 fc1 sc0 ls0 ws0">1,2</div><div class="t m3 x11 ha y43 ff8 fs0 fc1 sc0 ls0 ws2b"> M<span class="_ _4"></span>orbidity from P<span class="_ _0"></span>AH stems </div><div class="t m3 xd ha y44 ff8 fs0 fc1 sc0 ls0 ws2c">from elevated right heart pressur<span class="_ _4"></span>es </div><div class="t m3 xd ha y45 ff8 fs0 fc1 sc0 ls0 ws2d">that, ultimately<span class="_ _5"></span>, lead to right-sided </div><div class="t m3 xd ha y46 ff8 fs0 fc1 sc0 ls0 ws29">heart failure<span class="_ _4"></span>, a need for lung trans<span class="ws0">-</span></div><div class="t m3 xd ha y47 ff8 fs0 fc1 sc0 ls0 ws2e">plantation, and death. P<span class="_ _4"></span>atients with </div><div class="t m3 xd ha y48 ff8 fs0 fc1 sc0 ls0 ws2f">P<span class="_ _0"></span>AH are categorized into 4 <span class="_ _0"></span>WHO func<span class="ws0">-</span></div><div class="t m0 x1 h1 y1 ffa fs0 fc0 sc0 ls0 ws0"> </div><div class="t m0 x2 h2 y2 ff4 fs1 fc0 sc0 ls0 ws0">CLINICAL REVIEW</div><a class="l" href="mailto:znoel@rx.umaryland.edu"><div class="d m4" style="border-style:none;position:absolute;left:67.130880px;bottom:130.476000px;width:82.116600px;height:8.745000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf2" class="pf w0 h0" data-page-no="2"><div class="pc pc2 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x1 h2 y4b ffb fs1 fc0 sc0 ls0 ws0">CLINICAL REVIEW </div><div class="t m0 x12 h1 y4c ffc fs0 fc0 sc0 ls0 ws0">SELEXIP<span class="_ _0"></span>AG</div><div class="t m1 x3 h3 y3 ff4 fs3 fc1 sc0 ls0 ws0">1136<span class="fs8"> <span class="_ _9"> </span><span class="fs2"> <span class="_ _a"> </span>AM J HEAL<span class="_ _5"></span>TH-SYST PHARM<span class="ff3 ws1"> | VOLUME <span class="_ _3"></span>74 | NUMBER <span class="_ _2"></span>15 | AUGUST <span class="_ _3"></span>1, <span class="_ _2"></span>2017</span></span></span></div><div class="t m3 x3 ha y4d ff8 fs0 fc1 sc0 ls0 ws30">tional class (FCs) according to the </div><div class="t m3 x3 ha y4e ff8 fs0 fc1 sc0 ls0 wsc">frequency and severity of symptoms, </div><div class="t m3 x3 ha y4f ff8 fs0 fc1 sc0 ls0 ws31">with <span class="_ _0"></span>WHO FC IV disease being the </div><div class="t m3 x3 ha y50 ff8 fs0 fc1 sc0 ls0 ws11">most severe (<span class="_ _8"></span>T<span class="_ _5"></span>able 1).</div><div class="t m3 x13 hb y51 ff8 fs6 fc1 sc0 ls0 ws0">5</div><div class="t m3 x14 ha y50 ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m1 x15 ha y50 ff8 fs0 fc1 sc0 ls0 ws0">A</div><div class="t m3 x16 ha y50 ff8 fs0 fc1 sc0 ls0 ws11">nnual mortal<span class="ws0">-</span></div><div class="t m3 x3 ha y52 ff8 fs0 fc1 sc0 ls0 ws32">ity in patients with P<span class="_ _0"></span>AH overall is 15%, </div><div class="t m3 x3 ha y53 ff8 fs0 fc1 sc0 ls0 ws33">and 3-year mortality ranges from 35% </div><div class="t m3 x3 ha y54 ff8 fs0 fc1 sc0 ls0 ws34">to 77%, depending on the underlying </div><div class="t m3 x3 ha y55 ff8 fs0 fc1 sc0 ls0 ws35">cause, the tr<span class="_ _4"></span>eatments pursued (i.e., </div><div class="t m3 x3 ha y56 ff8 fs0 fc1 sc0 ls0 ws36">lung transplantation), and FC status<span class="_ _4"></span>.</div><div class="t m3 x17 hb y57 ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x18 ha y56 ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 x3 ha y58 ff8 fs0 fc1 sc0 ls0 ws37">There is no cur<span class="_ _4"></span>e for P<span class="_ _0"></span>AH, and available </div><div class="t m3 x3 ha y59 ff8 fs0 fc1 sc0 ls0 ws38">therapies only slo<span class="_ _4"></span>w disease progres<span class="ws0">-</span></div><div class="t m3 x3 ha y5a ff8 fs0 fc1 sc0 ls0 ws0">sion or pro<span class="_ _4"></span>vide symptomatic relief.</div><div class="t m3 x19 ha y5b ff8 fs0 fc1 sc0 ls1 ws39">In P<span class="_ _0"></span>AH, levels of prostacyclin </div><div class="t m3 x3 ha y5c ff8 fs0 fc1 sc0 ls1 ws3a">(also referr<span class="_ _4"></span>ed to as prostaglandin I</div><div class="t m3 x1a hb y5d ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x17 ha y5c ff8 fs0 fc1 sc0 ls0 ws0">, </div><div class="t m3 x3 ha y5e ff8 fs0 fc1 sc0 ls1 ws3b">or PGI</div><div class="t m3 x1b hb y5f ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x1c ha y5e ff8 fs0 fc1 sc0 ls1 ws3b">) and nitric oxide<span class="_ _4"></span>, both potent </div><div class="t m3 x3 ha y60 ff8 fs0 fc1 sc0 ls1 ws3c">vasodilators and inhibitors of plate<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y61 ff8 fs0 fc1 sc0 ls1 ws3d">let aggregation, ar<span class="_ _4"></span>e decreased, while </div><div class="t m3 x3 ha y62 ff8 fs0 fc1 sc0 ls1 ws3e">the level of thrombo<span class="_ _4"></span>xane A</div><div class="t m3 x1d hb y63 ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x1e ha y62 ff8 fs0 fc1 sc0 ls1 ws3e">, a po<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y64 ff8 fs0 fc1 sc0 ls1 ws3f">tent vasoconstrictor and promotor of </div><div class="t m3 x3 ha y65 ff8 fs0 fc1 sc0 ls1 ws40">platelet aggregation, is incr<span class="_ _4"></span>eased.</div><div class="t m3 x1f hb y66 ff8 fs6 fc1 sc0 ls0 ws0">3</div><div class="t m3 x20 ha y65 ff8 fs0 fc1 sc0 ls2 ws41"> In </div><div class="t m3 x3 ha y67 ff8 fs0 fc1 sc0 ls1 ws42">addition, endothelin-1 activity is in<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y68 ff8 fs0 fc1 sc0 ls1 ws43">creased, enhancing vasoconstriction </div><div class="t m3 x3 ha y69 ff8 fs0 fc1 sc0 ls1 ws44">and smooth muscle cell proliferation </div><div class="t m3 x3 ha y6a ff8 fs0 fc1 sc0 ls1 ws45">within the pulmonary arter<span class="_ _8"></span>ies. C<span class="_ _4"></span>ur<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y6b ff8 fs0 fc1 sc0 ls1 ws46">rent F<span class="_ _0"></span>ood and Drug Administration </div><div class="t m3 x3 ha y6c ff8 fs0 fc1 sc0 ls1 ws47">(FDA)appro<span class="_ _4"></span>ved therapies for P<span class="_ _0"></span>AH in<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y6d ff8 fs0 fc1 sc0 ls1 ws48">clude endothelin receptor antagonists </div><div class="t m3 x3 ha y6e ff8 fs0 fc1 sc0 ls1 ws49">(ERAs), phosphodiesterase type 5 </div><div class="t m3 x3 ha y6f ff8 fs0 fc1 sc0 ls1 ws4a">(PDE5) inhibitors, a soluble guanylate </div><div class="t m3 x3 ha y70 ff8 fs0 fc1 sc0 ls1 ws4b">cyclase stimulator<span class="_ _0"></span>, prostacyclin ana<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y71 ff8 fs0 fc1 sc0 ls1 ws4c">logs, and the most r<span class="_ _4"></span>ecently approv<span class="_ _4"></span>ed </div><div class="t m3 x3 ha y72 ff8 fs0 fc1 sc0 ls1 ws4d">therap<span class="_ _4"></span>y<span class="_ _5"></span>, an agonist of the pros<span class="_ _4"></span>ta<span class="_ _4"></span>cyc<span class="_ _4"></span>li<span class="_ _4"></span>n </div><div class="t m3 x3 ha y73 ff8 fs0 fc1 sc0 ls3 ws4e">IP receptor (1 of 9 types of pr<span class="_ _4"></span>ostanoid </div><div class="t m3 x3 ha y74 ff8 fs0 fc1 sc0 ls3 ws4f">receptor).</div><div class="t m3 x21 hb y75 ff8 fs6 fc1 sc0 ls4 ws50">5,6</div><div class="t m3 x22 ha y74 ff8 fs0 fc1 sc0 ls3 ws37"> IP receptor agonists ar<span class="_ _4"></span>e de<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y76 ff8 fs0 fc1 sc0 ls3 ws51">signed to modulate pulmonary vaso<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y77 ff8 fs0 fc1 sc0 ls3 ws52">constriction, platelet aggregation, and </div><div class="t m3 x3 ha y78 ff8 fs0 fc1 sc0 ls3 ws53">smooth muscle cell proliferation that </div><div class="t m3 x3 ha y79 ff8 fs0 fc1 sc0 ls3 ws54">result from alter<span class="_ _4"></span>ations in the balance </div><div class="t m3 x3 ha y7a ff8 fs0 fc1 sc0 ls3 ws55">of endothelin, nitric oxide<span class="_ _4"></span>, and prosta<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y7b ff8 fs0 fc1 sc0 ls3 ws4f">cyclin.</div><div class="t m3 x1b hb y7c ff8 fs6 fc1 sc0 ls0 ws0">3</div><div class="t m3 x1c ha y7b ff8 fs0 fc1 sc0 ls3 ws56"> <span class="_ _4"></span>The choice of therap<span class="_ _4"></span>y is based </div><div class="t m3 x3 ha y7d ff8 fs0 fc1 sc0 ls3 ws27">on a variety of patient-specic factors </div><div class="t m3 x3 ha y7e ff8 fs0 fc1 sc0 ls3 ws57">and largely guided b<span class="_ _4"></span>y the <span class="_ _0"></span>WHO FC.</div><div class="t m3 x23 hb y7f ff8 fs6 fc1 sc0 ls4 ws50">5-7</div><div class="t m3 x18 ha y7e ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 x3 ha y80 ff8 fs0 fc1 sc0 ls3 ws58">In addition to the afor<span class="_ _4"></span>ementioned </div><div class="t m3 x3 ha y81 ff8 fs0 fc1 sc0 ls3 ws59">medications, supportive treatments </div><div class="t m3 x3 ha y82 ff8 fs0 fc1 sc0 ls3 ws5a">include diuretics for symptomatic r<span class="_ _4"></span>e<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y83 ff8 fs0 fc1 sc0 ls3 ws5b">lief and anticoagulation for prevention </div><div class="t m3 x3 ha y84 ff8 fs0 fc1 sc0 ls3 ws0">of thromboembolic events<span class="_ _4"></span>. </div><div class="t m3 x19 ha y85 ff8 fs0 fc1 sc0 ls0 ws5c">Although patients often requir<span class="_ _4"></span>e </div><div class="t m3 x3 ha y86 ff8 fs0 fc1 sc0 ls0 ws5d">combinations of therapies, target<span class="ws0">-</span></div><div class="t m3 x3 ha y87 ff8 fs0 fc1 sc0 ls0 ws5e">ing prostacyclin has been consis<span class="ws0">-</span></div><div class="t m3 x3 ha y88 ff8 fs0 fc1 sc0 ls0 ws5f">tently pro<span class="_ _4"></span>ven to be an effective strat<span class="ws0">-</span></div><div class="t m3 x3 ha y89 ff8 fs0 fc1 sc0 ls0 ws60">egy for reducing morbidity in P<span class="_ _0"></span>AH.</div><div class="t m3 x23 hb y8a ff8 fs6 fc1 sc0 ls0 ws0">5,6</div><div class="t m3 x18 ha y89 ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 x3 ha y8b ff8 fs0 fc1 sc0 ls0 ws61">Epoprostenol is the synthetic form </div><div class="t m3 x3 ha y8c ff8 fs0 fc1 sc0 ls0 ws62">of prostacyclin, and other analogs, </div><div class="t m3 x3 ha y8d ff8 fs0 fc1 sc0 ls0 ws63">such as treprostinil and <span class="_ _4"></span>iloprost, are </div><div class="t m2 x24 hc y8e ff4 fs9 fc2 sc0 ls0 ws0">KEY POINTS</div><div class="t m2 x24 h7 y8f ff3 fs0 fc2 sc0 ls0 ws0"><span class="fc1 ls5"> <span class="_ _b"> </span>Selexipag is the only Food and </span></div><div class="t m2 x25 h7 y90 ff3 fs0 fc1 sc0 ls5 ws0">Drug Administrationapproved<span class="_ _4"></span> </div><div class="t m2 x25 h7 y91 ff3 fs0 fc1 sc0 ls5 ws0">oral prostacyclin IP r<span class="_ _4"></span>eceptor </div><div class="t m2 x25 h7 y92 ff3 fs0 fc1 sc0 ls5 ws0">agonist for the treatment of<span class="_ _4"></span> </div><div class="t m2 x25 h7 y93 ff3 fs0 fc1 sc0 ls5 ws0">pulmonary arterial hyperten<span class="ls0">-</span></div><div class="t m2 x25 h7 y94 ff3 fs0 fc1 sc0 ls5 ws0">sion (P<span class="_ _0"></span>AH). </div><div class="t m2 x24 h7 y95 ff3 fs0 fc2 sc0 ls0 ws0"><span class="fc1 ls5"> <span class="_ _b"> </span>Selexipag reduces the risks<span class="_ _4"></span> </span></div><div class="t m2 x25 h7 y96 ff3 fs0 fc1 sc0 ls5 ws0">of hospitalization and disease </div><div class="t m2 x25 h7 y97 ff3 fs0 fc1 sc0 ls5 ws0">progr<span class="_ _4"></span>ession in patients with </div><div class="t m2 x25 h7 y98 ff3 fs0 fc1 sc0 ls5 ws0">P<span class="_ _0"></span>AH and W<span class="_ _0"></span>orld Health Organ<span class="ls0">-</span></div><div class="t m2 x25 h7 y99 ff3 fs0 fc1 sc0 ls5 ws0">ization functional class II or III </div><div class="t m2 x25 h7 y9a ff3 fs0 fc1 sc0 ls5 ws0">symptoms, as compared with<span class="_ _4"></span> </div><div class="t m2 x25 h7 y9b ff3 fs0 fc1 sc0 ls5 ws0">patients not receiving selexi<span class="ls0">-</span></div><div class="t m2 x25 h7 y9c ff3 fs0 fc1 sc0 ls5 ws0">pag, but has not been shown </div><div class="t m2 x25 h7 y9d ff3 fs0 fc1 sc0 ls5 ws0">to reduce mortality<span class="_ _5"></span>.</div><div class="t m2 x24 h7 y9e ff3 fs0 fc2 sc0 ls0 ws0"><span class="fc1 ls5"> <span class="_ _b"> </span>Selexipag has predictable,<span class="_ _4"></span> </span></div><div class="t m2 x25 h7 y9f ff3 fs0 fc1 sc0 ls5 ws0">dose-dependent adverse ef<span class="ls0">-</span></div><div class="t m2 x25 h7 ya0 ff3 fs0 fc1 sc0 ls5 ws0">fects consistent with those of </div><div class="t m2 x25 h7 ya1 ff3 fs0 fc1 sc0 ls5 ws0">other prostanoid therapies, in<span class="ls0">-</span></div><div class="t m2 x25 h7 ya2 ff3 fs0 fc1 sc0 ls5 ws0">cluding musculoskeletal pain, </div><div class="t m2 x25 h7 ya3 ff3 fs0 fc1 sc0 ls5 ws0">ushing, nausea, vomiting, </div><div class="t m2 x25 h7 ya4 ff3 fs0 fc1 sc0 ls5 ws0">and headache.</div><div class="t m3 xa ha ya5 ff8 fs0 fc1 sc0 ls0 ws64">also available. H<span class="_ _0"></span>owever<span class="_ _5"></span>, these agents </div><div class="t m3 xa ha ya6 ff8 fs0 fc1 sc0 ls0 ws65">have signicant drawbacks due to </div><div class="t m3 xa ha ya7 ff8 fs0 fc1 sc0 ls0 ws66">their pharmacologic instability and </div><div class="t m3 xa ha ya8 ff8 fs0 fc1 sc0 ls0 ws67">short biological half-life, which cr<span class="_ _4"></span>eate </div><div class="t m3 xa ha ya9 ff8 fs0 fc1 sc0 ls0 ws68">challenges with drug administration, </div><div class="t m3 xa ha yaa ff8 fs0 fc1 sc0 ls0 ws69">including a need for continuous in<span class="ws0">-</span></div><div class="t m3 xa ha yab ff8 fs0 fc1 sc0 ls0 ws4c">fusion or administration as often as 9 </div><div class="t m3 xa ha yac ff8 fs0 fc1 sc0 ls0 ws11">times per day in some instances.</div><div class="t m3 x26 hb yad ff8 fs6 fc1 sc0 ls0 ws0">8</div><div class="t m3 x27 ha yac ff8 fs0 fc1 sc0 ls0 ws11"> Lim<span class="ws0">-</span></div><div class="t m3 xa ha yae ff8 fs0 fc1 sc0 ls0 ws6a">itations of available drug entities have </div><div class="t m3 xa ha yaf ff8 fs0 fc1 sc0 ls0 ws6b">led to the ongoing development of </div><div class="t m3 xa ha yb0 ff8 fs0 fc1 sc0 ls0 ws6c">pharmaceuticals targeting prostacy<span class="_ _4"></span><span class="ws0">-</span></div><div class="t m3 xa ha yb1 ff8 fs0 fc1 sc0 ls0 ws0">clin and the prostacyclin IP r<span class="_ _4"></span>eceptor<span class="_ _0"></span>. </div><div class="t m3 x9 ha yb2 ff8 fs0 fc1 sc0 ls0 ws6d">In late 2015, selexipag (U<span class="_ _0"></span>ptiva, </div><div class="t m3 xa ha yb3 ff8 fs0 fc1 sc0 ls0 ws6e">Actelion Pharmaceuticals, S<span class="_ _4"></span>outh San </div><div class="t m3 xa ha yb4 ff8 fs0 fc1 sc0 ls0 ws6f">Fr<span class="_ _4"></span>ancisco<span class="_ _4"></span>, CA) was approv<span class="_ _4"></span>ed by FDA </div><div class="t m3 xa ha yb5 ff8 fs0 fc1 sc0 ls0 ws1c">and granted the orphan drug desig<span class="ws0">-</span></div><div class="t m3 xa ha yb6 ff8 fs0 fc1 sc0 ls0 ws9">nation as the rst-in-class oral selec<span class="ws0">-</span></div><div class="t m3 xa ha yb7 ff8 fs0 fc1 sc0 ls0 ws40">tive prostacyclin IP r<span class="_ _4"></span>eceptor agonist.</div><div class="t m3 x28 hb yb8 ff8 fs6 fc1 sc0 ls0 ws0">9</div><div class="t m3 x29 ha yb7 ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 xa ha yb9 ff8 fs0 fc1 sc0 ls0 ws70">Selexipag is appro<span class="_ _0"></span>ved for treatment </div><div class="t m3 xa ha yba ff8 fs0 fc1 sc0 ls0 ws71">of P<span class="_ _0"></span>AH to delay disease progression </div><div class="t m3 xa ha ybb ff8 fs0 fc1 sc0 ls0 ws4e">and reduce the risk of hospitalization </div><div class="t m3 xa ha ybc ff8 fs0 fc1 sc0 ls0 ws72">and offers therapeutic conveniences </div><div class="t m3 xa ha ybd ff8 fs0 fc1 sc0 ls0 ws37">o<span class="_ _4"></span>ver the aforementioned prostacyclin-</div><div class="t m3 xa ha ybe ff8 fs0 fc1 sc0 ls0 ws32">targeted therapies<span class="_ _4"></span>. <span class="_ _4"></span>This article focuses </div><div class="t m3 xa ha ybf ff8 fs0 fc1 sc0 ls0 ws73">on the pharmacology<span class="_ _5"></span>, phar<span class="_ _8"></span>macoki<span class="ws0">-</span></div><div class="t m3 xd ha y4d ff8 fs0 fc1 sc0 ls0 ws29">netics and pharmacodynamics, dos<span class="ws0">-</span></div><div class="t m3 xd ha y4e ff8 fs0 fc1 sc0 ls0 ws74">age and administration, and clinical </div><div class="t m3 xd ha y4f ff8 fs0 fc1 sc0 ls0 ws75">efcacy and safety of selexipag; cost </div><div class="t m3 xd ha y50 ff8 fs0 fc1 sc0 ls0 ws2e">considerations and place in therap<span class="_ _4"></span>y </div><div class="t m3 xd ha y52 ff8 fs0 fc1 sc0 ls0 ws0">are also discussed.</div><div class="t m2 xd h3 yc0 ff4 fs3 fc2 sc0 ls0 ws0">Pharmacology</div><div class="t m3 x2a ha yc1 ff8 fs0 fc1 sc0 ls5 ws76">Selexipag (formerly kno<span class="_ _4"></span>wn as </div><div class="t m3 xd ha yc2 ff8 fs0 fc1 sc0 ls0 ws77">NS<span class="_ _8"></span>-304) is an orally administered pro<span class="ws0">-</span></div><div class="t m3 xd ha yc3 ff8 fs0 fc1 sc0 ls0 ws78">drug that is rapidly hydrolyzed to a </div><div class="t m3 xd ha yc4 ff8 fs0 fc1 sc0 ls0 ws79">long-acting metabolite that is a high<span class="ws0">-</span></div><div class="t m3 xd ha yc5 ff8 fs0 fc1 sc0 ls0 ws7a">ly selective prostacyclin IP r<span class="_ _4"></span>eceptor </div><div class="t m3 xd ha yc6 ff8 fs0 fc1 sc0 ls0 ws3d">agonist. <span class="_ _4"></span>The prostacyclin IP receptor </div><div class="t m3 xd ha yc7 ff8 fs0 fc1 sc0 ls0 ws7b">is coupled to a G</div><div class="t m3 x2b hb yc8 ff8 fs6 fc1 sc0 ls0 ws0">s</div><div class="t m3 x2c ha yc7 ff8 fs0 fc1 sc0 ls0 ws7b"> protein and, when </div><div class="t m3 xd ha yc9 ff8 fs0 fc1 sc0 ls0 ws7c">activated b<span class="_ _4"></span>y a prostacyclin modulator </div><div class="t m3 xd ha yca ff8 fs0 fc1 sc0 ls0 ws7d">such as selexipag, causes stimulation </div><div class="t m3 xd ha ycb ff8 fs0 fc1 sc0 ls0 ws7e">of adenylate cyclase and an increase </div><div class="t m3 xd ha ycc ff8 fs0 fc1 sc0 ls0 ws4e">in cytosolic calcium concentrations<span class="_ _4"></span>.</div><div class="t m3 x2d hb ycd ff8 fs6 fc1 sc0 ls0 ws0">10</div><div class="t m3 x2e ha ycc ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 xd ha yce ff8 fs0 fc1 sc0 ls0 ws7f">Ultimately<span class="_ _5"></span>, activity on this receptor </div><div class="t m3 xd ha ycf ff8 fs0 fc1 sc0 ls0 ws3a">results in vasodilation, an antipr<span class="_ _4"></span>olif<span class="ws0">-</span></div><div class="t m3 xd ha yd0 ff8 fs0 fc1 sc0 ls0 ws80">eration effect on pulmonary arter<span class="_ _8"></span>y </div><div class="t m3 xd ha yd1 ff8 fs0 fc1 sc0 ls0 ws81">smooth muscle cells, inhibition of </div><div class="t m3 xd ha yd2 ff8 fs0 fc1 sc0 ls0 ws82">platelet aggregation, and antiinam<span class="ws0">-</span></div><div class="t m3 xd ha yd3 ff8 fs0 fc1 sc0 ls0 ws0">matory effects.</div><div class="t m3 x2f hb yd4 ff8 fs6 fc1 sc0 ls0 ws0">11 </div><div class="t m2 xd h3 yd5 ff4 fs3 fc2 sc0 ls0 ws0">Pharmacokinetics and </div><div class="t m2 xd h3 yd6 ff4 fs3 fc2 sc0 ls0 ws0">pharmacodynamics</div><div class="t m3 x2a ha yd7 ff8 fs0 fc1 sc0 ls6 ws83">F<span class="_ _4"></span>ollowing or<span class="_ _4"></span>al administration, </div><div class="t m3 xd ha yd8 ff8 fs0 fc1 sc0 ls6 ws84">selexipag is rapidly hydrolyz<span class="_ _4"></span>ed to </div><div class="t m3 xd ha yd9 ff8 fs0 fc1 sc0 ls6 ws85">the primary active metabolite ACT<span class="_ _5"></span>-</div><div class="t m3 xd ha yda ff8 fs0 fc1 sc0 ls6 ws86">333679 (formerly known as MRE-</div><div class="t m3 xd ha ydb ff8 fs0 fc1 sc0 ls6 ws75">269). <span class="_ _4"></span>The afnity of ACT<span class="_ _7"></span>-333679 for </div><div class="t m3 xd ha ydc ff8 fs0 fc1 sc0 ls6 ws87">the prostacyclin IP r<span class="_ _4"></span>eceptor is 10-fold </div><div class="t m3 xd ha ydd ff8 fs0 fc1 sc0 ls6 ws88">higher than that of selexipag and </div><div class="t m3 xd ha yde ff8 fs0 fc1 sc0 ls6 ws89">more than 130 times mor<span class="_ _4"></span>e specic for </div><div class="t m3 xd ha ydf ff8 fs0 fc1 sc0 ls6 ws8a">the IP receptor than for other pros<span class="ls0 ws0">-</span></div><div class="t m3 xd ha ye0 ff8 fs0 fc1 sc0 ls0 ws7a">taglandin receptor subtypes<span class="_ _4"></span>.</div><div class="t m3 x30 hb ye1 ff8 fs6 fc1 sc0 ls0 ws0">10,12,13</div><div class="t m3 x31 ha ye0 ff8 fs0 fc1 sc0 ls7 ws8b"> In </div><div class="t m3 xd ha ye2 ff8 fs0 fc1 sc0 ls0 ws69">addition to being more potent than </div><div class="t m3 xd ha ye3 ff8 fs0 fc1 sc0 ls0 ws8c">selexipag, ACT<span class="_ _7"></span>-333679 produces over<span class="_ _4"></span><span class="ws0">-</span></div><div class="t m3 xd ha ye4 ff8 fs0 fc1 sc0 ls0 ws8d">all exposure<span class="_ _4"></span>, as measured b<span class="_ _4"></span>y the area </div><div class="t m3 xd ha ye5 ff8 fs0 fc1 sc0 ls0 ws19">under the concentrationtime curve </div><div class="t m3 xd ha ye6 ff8 fs0 fc1 sc0 ls0 ws8e">(A<span class="_ _0"></span>UC), 3 times higher than selexipag </div><div class="t m3 xd ha ye7 ff8 fs0 fc1 sc0 ls0 ws0">exposure<span class="_ _4"></span>.</div><div class="t m3 x32 hb ye8 ff8 fs6 fc1 sc0 ls0 ws0">14,15</div><div class="t m3 x33 ha ye7 ff8 fs0 fc1 sc0 ls0 ws8f"> <span class="_ _4"></span>The mean half-lives of </div><div class="t m3 xd ha ye9 ff8 fs0 fc1 sc0 ls0 ws90">selexipag and ACT<span class="_ _7"></span>-333679 are 0.72.3 </div><div class="t m3 xd ha yea ff8 fs0 fc1 sc0 ls0 ws91">and 9.414.2 hours, r<span class="_ _4"></span>espectively<span class="_ _5"></span>. </div><div class="t m3 xd ha yeb ff8 fs0 fc1 sc0 ls0 ws92">When taken on an empty stomach, </div><div class="t m3 xd ha yec ff8 fs0 fc1 sc0 ls0 ws93">the maximum concentration (<span class="ff9 ws0">C</span></div><div class="t m3 x34 hb yed ff8 fs6 fc1 sc0 ls0 ws0">max</div><div class="t m3 x31 ha yec ff8 fs0 fc1 sc0 ls0 ws93">) of </div><div class="t m3 xd ha yee ff8 fs0 fc1 sc0 ls0 ws94">ACT<span class="_ _7"></span>-333679 occurs at approximately 4 </div><div class="t m3 xd ha yef ff8 fs0 fc1 sc0 ls0 ws5">hours. <span class="_ _5"></span>With administration with food, </div><div class="t m3 xd ha yf0 ff8 fs0 fc1 sc0 ls0 ws0">the <span class="_ _4"></span><span class="ff9">C</span></div><div class="t m3 x10 hb yf1 ff8 fs6 fc1 sc0 ls0 ws0">max</div><div class="t m3 x35 ha yf0 ff8 fs0 fc1 sc0 ls0 ws89"> is reduced and the time to <span class="ff9 ws0">C</span></div><div class="t m3 x36 hb yf1 ff8 fs6 fc1 sc0 ls0 ws0">max</div><div class="t m3 x2e ha yf0 ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 xd ha yf2 ff8 fs0 fc1 sc0 ls0 ws71">is delayed considerably<span class="_ _5"></span>, with ov<span class="_ _4"></span>erall </div><div class="t m3 xd ha yf3 ff8 fs0 fc1 sc0 ls0 ws95">ACT<span class="_ _7"></span>-333679 exposure modestly re<span class="ws0">-</span></div><div class="t m3 xd ha yf4 ff8 fs0 fc1 sc0 ls0 ws0">duced (by 25%).</div><div class="t m3 x37 hb yf5 ff8 fs6 fc1 sc0 ls0 ws0">10,12,16</div><div class="t m3 x38 ha yf4 ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 x2a ha yf6 ff8 fs0 fc1 sc0 ls0 ws96">After selexipag metabolism, elimi<span class="ws0">-</span></div><div class="t m3 xd ha yf7 ff8 fs0 fc1 sc0 ls0 ws26">nation is predominately through the </div></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf3" class="pf w0 h0" data-page-no="3"><div class="pc pc3 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x1 h1 y1 ff1 fs0 fc0 sc0 ls0 ws0">SELEXIP<span class="_ _0"></span>AG </div><div class="t m0 x2 h2 y2 ff2 fs1 fc0 sc0 ls0 ws0">CLINICAL REVIEW</div><div class="t m1 x3 h3 y3 ff3 fs2 fc1 sc0 ls0 ws0"> <span class="_ _1"> </span><span class="ff4">AM J HEAL<span class="_ _5"></span>TH-SYST PHARM<span class="ff3 ws1"> | VOLUME <span class="_ _3"></span>74 | NUMBER <span class="_ _2"></span>15 | AUGUST <span class="_ _3"></span>1, <span class="_ _2"></span>2017  <span class="ff4 fs3 ws0">1137</span></span></span></div><div class="t m3 x3 ha y4d ff8 fs0 fc1 sc0 ls0 ws97">feces, with negligible excr<span class="_ _4"></span>etion in the </div><div class="t m3 x3 ha y4e ff8 fs0 fc1 sc0 ls0 ws0">urine.</div><div class="t m3 x39 hb yf8 ff8 fs6 fc1 sc0 ls0 ws0">16</div><div class="t m3 x1c ha y4e ff8 fs0 fc1 sc0 ls0 ws98"> Selexipag and A<span class="_ _4"></span>CT<span class="_ _5"></span>-333679 are </div><div class="t m3 x3 ha y4f ff8 fs0 fc1 sc0 ls0 ws99">greater than 99% protein bound and </div><div class="t m3 x3 ha y50 ff8 fs0 fc1 sc0 ls0 ws9a">are extensively metaboliz<span class="_ _4"></span>ed by the </div><div class="t m3 x3 ha y52 ff8 fs0 fc1 sc0 ls0 ws9b">liver<span class="_ _0"></span>. Both selexipag and ACT<span class="_ _7"></span>-333679 </div><div class="t m3 x3 ha y53 ff8 fs0 fc1 sc0 ls0 ws9c">undergo metabolism b<span class="_ _4"></span>y cytochrome </div><div class="t m3 x3 ha y54 ff8 fs0 fc1 sc0 ls0 ws9d">P<span class="_ _4"></span>-450 (CYP) isozymes 3A4 and 2C8 </div><div class="t m3 x3 ha y55 ff8 fs0 fc1 sc0 ls0 ws42">and are substr<span class="_ _4"></span>ates for organic anion </div><div class="t m3 x3 ha y56 ff8 fs0 fc1 sc0 ls0 ws9e">transporting polypeptide (OA<span class="_ _5"></span>TP) 1B1 </div><div class="t m3 x3 ha y58 ff8 fs0 fc1 sc0 ls0 ws55">and OA<span class="_ _5"></span>TP1B3. Selexipag is also a sub<span class="ws0">-</span></div><div class="t m3 x3 ha y59 ff8 fs0 fc1 sc0 ls0 ws0">strate for P<span class="_ _0"></span>-glycoprotein (P<span class="_ _4"></span>-gp).</div><div class="t m3 x3a hb yf9 ff8 fs6 fc1 sc0 ls0 ws0">9</div><div class="t m3 x19 ha y5a ff8 fs0 fc1 sc0 ls0 ws9f">A pharmacokinetic study involv<span class="ws0">-</span></div><div class="t m3 x3 ha y5b ff8 fs0 fc1 sc0 ls0 wsa0">ing 20 healthy men taking selexi<span class="ws0">-</span></div><div class="t m3 x3 ha y5c ff8 fs0 fc1 sc0 ls0 wsa1">pag concomitantly with lopinavir</div><div class="t m3 x3 ha y5e ff8 fs0 fc1 sc0 ls8 wsa2">rito<span class="_ _8"></span>navir<span class="_ _4"></span>, an inhibitor of CYP3A4, P<span class="_ _4"></span>-gp<span class="_ _4"></span>, </div><div class="t m3 x3 ha y60 ff8 fs0 fc1 sc0 ls0 wsa3">OA<span class="_ _5"></span>TP1B1, <span class="_ _4"></span>and OA<span class="_ _5"></span>TP1B3, resulted in a </div><div class="t m3 x3 ha y61 ff8 fs0 fc1 sc0 ls0 wsa4">more than 2-fold incr<span class="_ _4"></span>ease in the A<span class="_ _0"></span>UC </div><div class="t m3 x3 ha y62 ff8 fs0 fc1 sc0 ls0 wsa5">of selexipag but only an 8% increase in </div><div class="t m3 x3 ha y64 ff8 fs0 fc1 sc0 ls0 ws6a">the ACT<span class="_ _7"></span>-333679 AUC.</div><div class="t m3 x13 hb yfa ff8 fs6 fc1 sc0 ls0 ws0">15</div><div class="t m3 x15 ha y64 ff8 fs0 fc1 sc0 ls0 wsa6"> These <span class="_ _8"></span>changes </div><div class="t m3 x3 ha y65 ff8 fs0 fc1 sc0 ls0 wsa7">in ACT<span class="_ _7"></span>-333679 phar<span class="_ _8"></span>macokinetic val<span class="ws0">-</span></div><div class="t m3 x3 ha y67 ff8 fs0 fc1 sc0 ls0 wsa8">ues were not consider<span class="_ _4"></span>ed to be clini<span class="ws0">-</span></div><div class="t m3 x3 ha y68 ff8 fs0 fc1 sc0 ls0 wsa9">cally relevant,</div><div class="t m3 x3b hb yfb ff8 fs6 fc1 sc0 ls0 ws0">15</div><div class="t m3 x3c ha y68 ff8 fs0 fc1 sc0 ls0 wsa9"> and selexipag dose </div><div class="t m3 x3 ha y69 ff8 fs0 fc1 sc0 ls0 ws7b">adjustment is not requir<span class="_ _4"></span>ed with con<span class="ws0">-</span></div><div class="t m3 x3 ha y6a ff8 fs0 fc1 sc0 ls0 ws31">comitant use of lopinavirritonavir<span class="_ _0"></span>.</div><div class="t m3 x17 hb yfc ff8 fs6 fc1 sc0 ls0 ws0">9</div><div class="t m3 x18 ha y6a ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 x3 ha y6b ff8 fs0 fc1 sc0 ls0 wsaa">Another pharmacokinetic study<span class="_ _5"></span>, in<span class="ws0">-</span></div><div class="t m3 x3 ha y6c ff8 fs0 fc1 sc0 ls0 ws10">volving 19 healthy men and designed </div><div class="t m3 x3 ha y6d ff8 fs0 fc1 sc0 ls0 wsab">to measure the effects of selexipag </div><div class="t m3 x3 ha y6e ff8 fs0 fc1 sc0 ls9 ws7a">admi<span class="_ _8"></span>nistration on warfarin pharma<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y6f ff8 fs0 fc1 sc0 ls9 ws77">codynamics, was r<span class="_ _4"></span>ecently conducted.</div><div class="t m3 x1a hb yfd ff8 fs6 fc1 sc0 lsa wsac">17</div><div class="t m3 x18 ha y6f ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 x3 ha y70 ff8 fs0 fc1 sc0 ls9 wsad">After multiple oral doses of selexipag </div><div class="t m3 x3 ha y71 ff8 fs0 fc1 sc0 ls9 wsae">400 </div><div class="t m1 x3d hd y71 ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x3e ha y71 ff8 fs0 fc1 sc0 ls9 wsaf">g, a single dose of warfarin 20 mg </div><div class="t m3 x3 ha y72 ff8 fs0 fc1 sc0 ls9 wsb0">was administered. C<span class="_ _4"></span>oncentrations of </div><div class="t m3 x3 ha y73 ff8 fs0 fc1 sc0 ls3 wsb1">selexipag and ACT<span class="_ _7"></span>-333679 were unaf<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y74 ff8 fs0 fc1 sc0 ls3 wsb2">fected by concurr<span class="_ _4"></span>ent warfarin adminis<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y76 ff8 fs0 fc1 sc0 ls3 wsb3">tration. Likewise<span class="_ _4"></span>, relative to values ob<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y77 ff8 fs0 fc1 sc0 ls3 ws96">served with placebo use, International </div><div class="t m3 x3 ha y78 ff8 fs0 fc1 sc0 ls3 wsb4">N<span class="_ _4"></span>ormalized Ratio values and <span class="ff9 ls0 ws0">R</span>- and </div><div class="t m3 x3 ha y79 ff9 fs0 fc1 sc0 ls0 ws0">S<span class="ff8 ls3 wsb5">-warfarin concentrations wer<span class="_ _4"></span>e unaf<span class="ls0 ws0">-</span></span></div><div class="t m3 x3 ha y7a ff8 fs0 fc1 sc0 ls3 ws0">fected by selexipag administr<span class="_ _4"></span>ation. </div><div class="t m3 x19 ha y7b ff8 fs0 fc1 sc0 ls6 wsb6">In a prospectiv<span class="_ _4"></span>e Phase I study<span class="_ _5"></span>, </div><div class="t m3 x3 ha y7d ff8 fs0 fc1 sc0 ls6 wsb7">selexipag and ACT<span class="_ _7"></span>-333679 concentra<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y7e ff8 fs0 fc1 sc0 ls6 ws96">tions were assessed in <span class="_ _4"></span>18 individuals </div><div class="t m3 x3 ha y80 ff8 fs0 fc1 sc0 ls6 ws63">with varying degrees of hepatic im<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y81 ff8 fs0 fc1 sc0 ls6 ws87">pairment.</div><div class="t m3 x3f hb yfe ff8 fs6 fc1 sc0 lsb wsb8">18</div><div class="t m3 x40 ha y81 ff8 fs0 fc1 sc0 ls6 ws4e"> Selexipag concentrations<span class="_ _4"></span> </div><div class="t m3 x3 ha y82 ff8 fs0 fc1 sc0 ls6 ws9c">increased 2.1- and 4.5-fold in indi<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y83 ff8 fs0 fc1 sc0 ls6 ws8">viduals with ChildPugh class A and </div><div class="t m3 x3 ha y84 ff8 fs0 fc1 sc0 ls6 wsb9">class B liver impairment, respectively<span class="_ _5"></span>. </div><div class="t m3 x3 ha y85 ff8 fs0 fc1 sc0 ls6 wsba">In addition, A<span class="_ _4"></span>CT<span class="_ _5"></span>-333679 concentra<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y86 ff8 fs0 fc1 sc0 ls6 wsb9">tions increased 1.2-, 2.2-, and 2.9-fold<span class="_ _4"></span> </div><div class="t m3 x3 ha y87 ff8 fs0 fc1 sc0 ls6 ws5b">in those with classes A, B, and C liver<span class="_ _4"></span> </div><div class="t m3 x3 ha y88 ff8 fs0 fc1 sc0 ls6 wsb6">impairment, respectively<span class="_ _5"></span>. A second </div><div class="t m3 x3 ha y89 ff8 fs0 fc1 sc0 ls6 wsbb">Phase I trial enrolled patients with </div><div class="t m3 x3 ha y8b ff8 fs0 fc1 sc0 ls6 wsbc">an estimated glomerular ltration </div><div class="t m3 x3 ha y8c ff8 fs0 fc1 sc0 ls6 ws1e">rate (eGFR) of 1530 mL/min per 1.73 </div><div class="t m3 x3 ha y8d ff8 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x41 hb yff ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x42 ha y8d ff8 fs0 fc1 sc0 ls6 wsbd"> of body surface area and a con<span class="ls0 ws0">-</span></div><div class="t m3 x24 h7 y100 ff4 fs0 fc2 sc0 ls0 ws0">T<span class="_ _5"></span>able 1.<span class="ff3 fc1"> W<span class="_ _0"></span>orld Health Organization Functional Class Descriptions for </span></div><div class="t m3 x24 h7 y101 ff3 fs0 fc1 sc0 lsc wsbe">PA<span class="_ _6"></span>H</div><div class="t m3 xc h8 y102 ff3 fs6 fc1 sc0 ls0 ws0">5,a</div><div class="t m3 x9 he y103 ff4 fs8 fc1 sc0 ls0 ws0">Class<span class="_ _c"> </span>Description</div><div class="t m3 x43 hf y104 ff3 fs8 fc1 sc0 ls0 ws0">I<span class="_ _d"> </span>Patients with P<span class="_ _0"></span>AH but without resulting limitation of physical activity<span class="_ _0"></span>. </div><div class="t m3 x44 hf y105 ff3 fs8 fc1 sc0 ls0 ws0">Ordinary physical activity does not cause undue dyspnea or fatigue, </div><div class="t m3 x44 hf y106 ff3 fs8 fc1 sc0 ls0 ws0">chest pain, or near syncope.</div><div class="t m3 x45 hf y107 ff3 fs8 fc1 sc0 ls0 ws0">II<span class="_ _d"> </span>Patients with P<span class="_ _0"></span>AH resulting in slight limitation of physical activity<span class="_ _0"></span>. They </div><div class="t m3 x44 hf y108 ff3 fs8 fc1 sc0 ls0 ws0">are comfortable at r<span class="_ _4"></span>est. Ordinary physical activity causes undue </div><div class="t m3 x44 hf y109 ff3 fs8 fc1 sc0 ls0 ws0">dyspnea or fatigue, chest pain, or near syncope.</div><div class="t m3 x46 hf y10a ff3 fs8 fc1 sc0 ls0 ws0">III<span class="_ _d"> </span>Patients with P<span class="_ _0"></span>AH resulting in marked limitation of physical activity<span class="_ _0"></span>. </div><div class="t m3 x44 hf y10b ff3 fs8 fc1 sc0 ls0 ws0">They are comfortable at r<span class="_ _4"></span>est. Less than ordinary activity causes </div><div class="t m3 x44 hf y10c ff3 fs8 fc1 sc0 ls0 ws0">undue dyspnea or fatigue, chest pain, or near syncope.</div><div class="t m3 x46 hf y10d ff3 fs8 fc1 sc0 ls0 ws0">IV<span class="_ _d"> </span>Patients with P<span class="_ _0"></span>AH with inability to carry out any physical activity </div><div class="t m3 x44 hf y10e ff3 fs8 fc1 sc0 ls0 ws0">without symptoms. These patients manifest signs of right-sided </div><div class="t m3 x44 hf y10f ff3 fs8 fc1 sc0 ls0 ws0">heart failure. Dyspnea and/or fatigue may even be pr<span class="_ _4"></span>esent at rest. </div><div class="t m3 x44 hf y110 ff3 fs8 fc1 sc0 ls0 ws0">Discomfort is increased by any physical activity<span class="_ _5"></span>.</div><div class="t m5 x46 h10 y111 ff3 fsa fc1 sc0 ls0 ws0">a</div><div class="t m1 x47 h11 y112 ff3 fs2 fc1 sc0 ls0 ws0">P<span class="_ _0"></span>AH = pulmonary arterial hypertension.</div><div class="t m3 xa ha y113 ff8 fs0 fc1 sc0 ls6 wsbf">trol group of individuals with normal </div><div class="t m3 xa ha y114 ff8 fs0 fc1 sc0 ls6 wsc0">eGFR values (&gt;90 mL/min/1.73 m</div><div class="t m3 x48 hb y115 ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x49 ha y114 ff8 fs0 fc1 sc0 ls6 ws87">).</div><div class="t m3 x4a hb y115 ff8 fs6 fc1 sc0 lsb wsb8">18</div><div class="t m3 x29 ha y114 ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 xa ha y116 ff8 fs0 fc1 sc0 ls6 wsae">M<span class="_ _4"></span>ean selexipag and ACT<span class="_ _5"></span>-333679 A<span class="_ _0"></span>UC </div><div class="t m3 xa ha y117 ff8 fs0 fc1 sc0 ls6 wsc1">values wer<span class="_ _4"></span>e increased 1.7- and 1.6-</div><div class="t m3 xa ha y118 ff8 fs0 fc1 sc0 ls6 wsc2">fold, respectively<span class="_ _5"></span>, in patients with </div><div class="t m3 xa ha y119 ff8 fs0 fc1 sc0 ls6 wsa0">renal impairment r<span class="_ _4"></span>elative to A<span class="_ _0"></span>UC </div><div class="t m3 xa ha y11a ff8 fs0 fc1 sc0 ls6 wsc3">values in subjects with normal renal<span class="_ _4"></span> </div><div class="t m3 xa ha y11b ff8 fs0 fc1 sc0 ls6 ws87">function.</div><div class="t m2 xa h3 y11c ff4 fs3 fc2 sc0 ls0 ws0">Dosage and administration</div><div class="t m3 x9 ha y11d ff8 fs0 fc1 sc0 ls0 wsc4">As with other prostanoid therapies, </div><div class="t m3 xa ha y11e ff8 fs0 fc1 sc0 ls0 wsc5">the target dose of selexipag is the high<span class="ws0">-</span></div><div class="t m3 xa ha y11f ff8 fs0 fc1 sc0 ls0 wsc6">est dose tolerated befor<span class="_ _4"></span>e dose-limiting </div><div class="t m3 xa ha y120 ff8 fs0 fc1 sc0 ls0 ws3f">adverse effects such as headache, jaw </div><div class="t m3 xa ha y121 ff8 fs0 fc1 sc0 ls0 wsc7">pain, ushing, and nausea.</div><div class="t m3 x4b hb y122 ff8 fs6 fc1 sc0 ls0 ws0">9</div><div class="t m3 x4c ha y121 ff8 fs0 fc1 sc0 ls0 ws94"> The <span class="_ _8"></span>start<span class="ws0">-</span></div><div class="t m3 xa ha y123 ff8 fs0 fc1 sc0 ls0 wsc8">ing dose of selexipag is 200 </div><div class="t m1 x4d hd y123 ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x4e ha y123 ff8 fs0 fc1 sc0 ls0 wsc8">g, to be ad<span class="ws0">-</span></div><div class="t m3 xa ha y124 ff8 fs0 fc1 sc0 ls0 ws21">ministered or<span class="_ _4"></span>ally twice daily<span class="_ _5"></span>. As soon </div><div class="t m3 xa ha y125 ff8 fs0 fc1 sc0 ls0 wsc9">as 1 week after initiation of selexipag </div><div class="t m3 xa ha y126 ff8 fs0 fc1 sc0 ls0 ws22">therap<span class="_ _4"></span>y<span class="_ _5"></span>, the twice-daily dose may be </div><div class="t m3 xa ha y127 ff8 fs0 fc1 sc0 ls0 ws93">adjusted in increments of 200 </div><div class="t m1 x4f hd y127 ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x26 ha y127 ff8 fs0 fc1 sc0 ls0 ws93">g to a </div><div class="t m3 xa ha y128 ff8 fs0 fc1 sc0 ls0 wsca">maximum of 1,600 </div><div class="t m1 x50 hd y128 ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x51 ha y128 ff8 fs0 fc1 sc0 ls0 wsca">g or until unman<span class="ws0">-</span></div><div class="t m3 xa ha y129 ff8 fs0 fc1 sc0 ls0 wsf">ageable or intolerable adverse effects </div><div class="t m3 xa ha y12a ff8 fs0 fc1 sc0 ls0 wscb">occur<span class="_ _0"></span>. If the threshold for intolerable </div><div class="t m3 xa ha y12b ff8 fs0 fc1 sc0 ls0 wsbf">adverse effects is breached, the twice-</div><div class="t m3 xa ha y12c ff8 fs0 fc1 sc0 ls0 wscc">daily dose is reduced b<span class="_ _4"></span>y 200 </div><div class="t m1 x52 hd y12c ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x53 ha y12c ff8 fs0 fc1 sc0 ls0 wscc">g, and </div><div class="t m3 xa ha y12d ff8 fs0 fc1 sc0 ls0 wsd">this is considered the maximum toler<span class="_ _4"></span><span class="ws0">-</span></div><div class="t m3 xa ha y12e ff8 fs0 fc1 sc0 ls0 ws3">ated dose. <span class="_ _0"></span>T<span class="_ _5"></span>o help with dosage adjust<span class="ws0">-</span></div><div class="t m3 xa ha y12f ff8 fs0 fc1 sc0 ls0 ws37">ment, selexipag tablets are available in </div><div class="t m3 xa ha y130 ff8 fs0 fc1 sc0 ls0 ws0">200-</div><div class="t m1 x54 hd y130 ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x55 ha y130 ff8 fs0 fc1 sc0 ls0 ws4a">g increments of str<span class="_ _4"></span>ength ranging </div><div class="t m3 xa ha y131 ff8 fs0 fc1 sc0 ls0 wscd">from 200 to 1,600 </div><div class="t m1 x56 hd y131 ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x57 ha y131 ff8 fs0 fc1 sc0 ls0 wscd">g. In clinical trials, </div><div class="t m3 xa ha y132 ff8 fs0 fc1 sc0 ls0 wsce">the median twice-daily dose toler<span class="ws0">-</span></div><div class="t m3 xa ha y133 ff8 fs0 fc1 sc0 ls0 wsca">ated was 8001,000 </div><div class="t m1 x57 hd y133 ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x58 ha y133 ff8 fs0 fc1 sc0 ls0 ws0">g.</div><div class="t m3 x59 hb y134 ff8 fs6 fc1 sc0 ls0 ws0">19,20</div><div class="t m3 x5a ha y133 ff8 fs0 fc1 sc0 ls0 wsca"> In the event </div><div class="t m3 xa ha y135 ff8 fs0 fc1 sc0 ls0 ws23">doses are missed for 3 days or mor<span class="_ _4"></span>e, </div><div class="t m3 xa ha y136 ff8 fs0 fc1 sc0 ls0 ws7d">it is recommended that tr<span class="_ _4"></span>eatment be </div><div class="t m3 xa ha y137 ff8 fs0 fc1 sc0 ls0 wsa6">resumed at a nonspecied lo<span class="_ _0"></span>wer dose, </div><div class="t m3 xd ha y113 ff8 fs0 fc1 sc0 ls0 wscf">with subsequent adjustment to the </div><div class="t m3 xd ha y114 ff8 fs0 fc1 sc0 ls0 ws0">maximum tolerated dose<span class="_ _4"></span>.</div><div class="t m3 x5b hb y115 ff8 fs6 fc1 sc0 ls0 ws0">9</div><div class="t m3 x2a ha y116 ff8 fs0 fc1 sc0 ls0 wsd0">F<span class="_ _4"></span>ormal recommendations on se-</div><div class="t m3 xd ha y117 ff8 fs0 fc1 sc0 ls0 ws97">lex <span class="_ _e"></span>ipag dosing in the context of renal </div><div class="t m3 xd ha y118 ff8 fs0 fc1 sc0 ls0 wsd1">or hepatic impairment are lacking. </div><div class="t m3 xd ha y119 ff8 fs0 fc1 sc0 ls0 wsd2">Based on the afor<span class="_ _4"></span>ementioned phar<span class="ws0">-</span></div><div class="t m3 xd ha y11a ff8 fs0 fc1 sc0 ls0 wsd3">macokinetic studies, no adjustment </div><div class="t m3 xd ha y11b ff8 fs0 fc1 sc0 ls0 wsd4">is necessary for patients with mild he<span class="ws0">-</span></div><div class="t m3 xd ha y138 ff8 fs0 fc1 sc0 ls0 wsd5">patic impairment (ChildPugh class </div><div class="t m3 xd ha y139 ff8 fs0 fc1 sc0 ls0 ws27">A) or mild-to-moderate r<span class="_ _4"></span>enal impair<span class="ws0">-</span></div><div class="t m3 xd ha y13a ff8 fs0 fc1 sc0 ls0 ws0">ment.</div><div class="t m3 x5c hb y13b ff8 fs6 fc1 sc0 ls0 ws0">18</div><div class="t m3 x5d ha y13a ff8 fs0 fc1 sc0 ls0 ws97"> By contr<span class="_ _4"></span>ast, the initial dosing </div><div class="t m3 xd ha y13c ff8 fs0 fc1 sc0 ls0 wsd6">for patients with moderate hepatic </div><div class="t m3 xd ha y13d ff8 fs0 fc1 sc0 ls0 wsd7">impairment (ChildPugh class B) </div><div class="t m3 xd ha y13e ff8 fs0 fc1 sc0 ls0 wsd8">should be decreased to 200 </div><div class="t m1 x30 hd y13e ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x5e ha y13e ff8 fs0 fc1 sc0 ls0 wsd8">g daily </div><div class="t m3 xd ha y13f ff8 fs0 fc1 sc0 ls0 wsd9">and adjusted in weekly increments of </div><div class="t m3 xd ha y140 ff8 fs0 fc1 sc0 ls0 ws0">200 </div><div class="t m1 x5f hd y140 ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x5c ha y140 ff8 fs0 fc1 sc0 ls0 wsda">g once daily<span class="_ _5"></span>.</div><div class="t m3 x60 hb y141 ff8 fs6 fc1 sc0 ls0 ws0">9</div><div class="t m3 x61 ha y140 ff8 fs0 fc1 sc0 ls0 wsda"> Selexipag use in </div><div class="t m3 xd ha y142 ff8 fs0 fc1 sc0 ls0 wsdb">patients with severe hepatic impair<span class="_ _4"></span><span class="ws0">-</span></div><div class="t m3 xd ha y143 ff8 fs0 fc1 sc0 ls0 ws40">ment or severe r<span class="_ _4"></span>enal impairment (an </div><div class="t m3 xd ha y144 ff8 fs0 fc1 sc0 ls0 wsae">eGFR of &lt;15 mL/min/1.73 m</div><div class="t m3 x62 hb y145 ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x5 ha y144 ff8 fs0 fc1 sc0 ls0 wsae">) has not </div><div class="t m3 xd ha y146 ff8 fs0 fc1 sc0 ls0 wsdc">been studied adequately<span class="_ _5"></span>, and current </div><div class="t m3 xd ha y147 ff8 fs0 fc1 sc0 ls0 ws44">recommendations ar<span class="_ _4"></span>e to avoid use of </div><div class="t m3 xd ha y148 ff8 fs0 fc1 sc0 ls0 ws0">selexipag in these patients.</div><div class="t m3 x63 hb y149 ff8 fs6 fc1 sc0 ls0 ws0">9</div><div class="t m2 xd h3 y14a ff4 fs3 fc2 sc0 ls0 ws0">Clinical efcacy</div><div class="t m3 x2a ha y12c ff8 fs0 fc1 sc0 lsd ws8f">Selexipag has been studied in 2 </div><div class="t m3 xd ha y12d ff8 fs0 fc1 sc0 lsd wsdd">randomized, multinational, double-</div><div class="t m3 xd ha y12e ff8 fs0 fc1 sc0 lsd wsde">blind, placebo-controlled trials.</div><div class="t m3 x64 hb y14b ff8 fs6 fc1 sc0 lse wsdf">19,20</div><div class="t m3 x2e ha y12e ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 xd ha y12f ff8 fs0 fc1 sc0 lsd ws8c">In both trials the use of selexipag was </div><div class="t m3 xd ha y130 ff8 fs0 fc1 sc0 lsd wse0">evaluated in patients with symptom<span class="ls0 ws0">-</span></div><div class="t m3 xd ha y131 ff8 fs0 fc1 sc0 lsd ws7">atic P<span class="_ _0"></span>AH, including P<span class="_ _4"></span>AH due to idio<span class="ls0 ws0">-</span></div><div class="t m3 xd ha y132 ff8 fs0 fc1 sc0 lsd wse1">pathic or hereditary causes, connec<span class="ls0 ws0">-</span></div><div class="t m3 xd ha y133 ff8 fs0 fc1 sc0 lsd wse2">tive tissue disease, congenital heart </div><div class="t m3 xd ha y135 ff8 fs0 fc1 sc0 lsd ws1d">disease, or drug or to<span class="_ _4"></span>xin exposure<span class="_ _4"></span>. In </div><div class="t m3 xd ha y136 ff8 fs0 fc1 sc0 lsd wse3">addition to patients who wer<span class="_ _4"></span>e receiv<span class="ls0 ws0">-</span></div><div class="t m3 xd ha y137 ff8 fs0 fc1 sc0 lsd ws15">ing no background therap<span class="_ _4"></span>y for P<span class="_ _0"></span>AH, </div></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf4" class="pf w0 h0" data-page-no="4"><div class="pc pc4 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x1 h2 y4b ffb fs1 fc0 sc0 ls0 ws0">CLINICAL REVIEW </div><div class="t m0 x12 h1 y4c ffc fs0 fc0 sc0 ls0 ws0">SELEXIP<span class="_ _0"></span>AG</div><div class="t m1 x3 h3 y3 ff4 fs3 fc1 sc0 ls0 ws0">1138<span class="fs8"> <span class="_ _9"> </span><span class="fs2"> <span class="_ _a"> </span>AM J HEAL<span class="_ _5"></span>TH-SYST PHARM<span class="ff3 ws1"> | VOLUME <span class="_ _3"></span>74 | NUMBER <span class="_ _2"></span>15 | AUGUST <span class="_ _3"></span>1, <span class="_ _2"></span>2017</span></span></span></div><div class="t m3 x3 ha y4d ff8 fs0 fc1 sc0 lsd ws9b">the trials included patients receiving </div><div class="t m3 x3 ha y4e ff8 fs0 fc1 sc0 lsd wse4">an ERA or a PDE5 inhibitor (or both) </div><div class="t m3 x3 ha y4f ff8 fs0 fc1 sc0 lsd wse4">pro<span class="_ _4"></span>vided that they had been taking a </div><div class="t m3 x3 ha y50 ff8 fs0 fc1 sc0 lsd wsad">stable dose of these medications for </div><div class="t m3 x3 ha y52 ff8 fs0 fc1 sc0 lsd ws38">at least 12 weeks. P<span class="_ _0"></span>atients receiving </div><div class="t m3 x3 ha y53 ff8 fs0 fc1 sc0 lsd wse5">prostacyclin analogs wer<span class="_ _4"></span>e excluded; </div><div class="t m3 x3 ha y54 ff8 fs0 fc1 sc0 lsd wsf">thus, FC IV patients wer<span class="_ _4"></span>e largely un<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y55 ff8 fs0 fc1 sc0 lsd wsbf">repr<span class="_ _4"></span>esented. One of the 2 trials evalu<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y56 ff8 fs0 fc1 sc0 lsd wse6">ated the effects of selexipag on pul<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y58 ff8 fs0 fc1 sc0 lsd wse7">monary hemodynamics in 43 patients </div><div class="t m3 x3 ha y59 ff8 fs0 fc1 sc0 lsd wscd">randomly assigned in a 3:1 fashion to </div><div class="t m3 x3 ha y5a ff8 fs0 fc1 sc0 lsd ws38">treatment with selexipag or placebo </div><div class="t m3 x3 ha y5b ff8 fs0 fc1 sc0 lsd ws2c">use, with the selexipag dosage ad<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y5c ff8 fs0 fc1 sc0 lsd ws1d">justed to a maximum of 800 </div><div class="t m1 x65 hd y5c ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x66 ha y5c ff8 fs0 fc1 sc0 lsd ws1d">g twice </div><div class="t m3 x3 ha y5e ff8 fs0 fc1 sc0 lsd wsd8">daily or until intolerable adverse ef<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y60 ff8 fs0 fc1 sc0 lsd wse8">fects were experienced.</div><div class="t m3 x67 hb y14c ff8 fs6 fc1 sc0 lse wsdf">19</div><div class="t m3 x68 ha y60 ff8 fs0 fc1 sc0 lsd wse8"> M<span class="_ _4"></span>ean </div><div class="t m1 x69 hd y60 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x6a ha y60 ff8 fs0 fc1 sc0 lsd wse8"> S.D<span class="_ _0"></span>. </div><div class="t m3 x3 ha y61 ff8 fs0 fc1 sc0 lsd wse9">pulmonary vascular resistance (PVR) </div><div class="t m3 x3 ha y62 ff8 fs0 fc1 sc0 lsd ws28">values at baseline wer<span class="_ _4"></span>e 948.6 </div><div class="t m1 x66 hd y62 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x69 ha y62 ff8 fs0 fc1 sc0 lsd ws28"> 428.0 </div><div class="t m3 x3 ha y64 ff8 fs0 fc1 sc0 lsd wsea">and 867.2 </div><div class="t m1 x6b hd y64 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x6c ha y64 ff8 fs0 fc1 sc0 lsd wseb"> <span class="_ _f"> </span>379.38 <span class="_ _f"> </span>dyn  s  cm</div><div class="t m3 x6d hb yfa ff8 fs6 fc1 sc0 lse wsdf">5</div><div class="t m3 x3a ha y64 ff8 fs0 fc1 sc0 lsd wsea"> in the </div><div class="t m3 x3 ha y65 ff8 fs0 fc1 sc0 lsd wsec">selexipag (<span class="ff9 ls0 ws0">n</span> = 32) and placebo (<span class="ff9 ws32">n </span>= 10) </div><div class="t m3 x3 ha y67 ff8 fs0 fc1 sc0 lsd wsed">groups, r<span class="_ _4"></span>espectively<span class="_ _5"></span>. At 17 weeks, the </div><div class="t m3 x3 ha y68 ff8 fs0 fc1 sc0 lsd ws32">mean </div><div class="t m1 x1b hd y68 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x6e ha y68 ff8 fs0 fc1 sc0 lsd wsed"> S.D<span class="_ _0"></span>. change from baseline in </div><div class="t m3 x3 ha y69 ff8 fs0 fc1 sc0 lsd wsee">PVR was 129.8 </div><div class="t m1 x3c hd y69 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x6f ha y69 ff8 fs0 fc1 sc0 lsd wseb"> <span class="_"> </span>309.7 <span class="_"> </span>dyn  s  cm</div><div class="t m3 x70 hb y14d ff8 fs6 fc1 sc0 lse wsdf">5</div><div class="t m3 x71 ha y69 ff8 fs0 fc1 sc0 ls0 ws6a"> in </div><div class="t m3 x3 ha y6a ff8 fs0 fc1 sc0 lsd ws3b">patients treated with selexipag versus<span class="_ _4"></span> </div><div class="t m3 x3 ha y6b ff8 fs0 fc1 sc0 lsd ws32">223.6 </div><div class="t m1 x72 hd y6b ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x73 ha y6b ff8 fs0 fc1 sc0 lsd wseb"> <span class="_ _b"> </span>355.4 <span class="_ _10"> </span>dyn  s  cm</div><div class="t m3 x74 hb y14e ff8 fs6 fc1 sc0 lse wsdf">5</div><div class="t m3 x75 ha y6b ff8 fs0 fc1 sc0 lsd wsef"> in placebo </div><div class="t m3 x3 ha y6c ff8 fs0 fc1 sc0 lsd wsd8">users (<span class="ff9 ls0 ws0">p</span> = 0.0022). <span class="_ _4"></span>The mean </div><div class="t m1 x76 hd y6c ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x77 ha y6c ff8 fs0 fc1 sc0 lsd wsd8"> S.D<span class="_ _0"></span>. </div><div class="t m3 x3 ha y6d ff8 fs0 fc1 sc0 lsd ws34">cardiac index values at baseline w<span class="_ _4"></span>ere </div><div class="t m3 x3 ha y6e ff8 fs0 fc1 sc0 lsd ws32">2.5 </div><div class="t m1 x3d hd y6e ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x3e ha y6e ff8 fs0 fc1 sc0 lsd wsd8"> 0.5 and 2.4 </div><div class="t m1 x78 hd y6e ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x79 ha y6e ff8 fs0 fc1 sc0 lsd wsd8"> 0.6 L/min/m</div><div class="t m3 x1f hb y14f ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x20 ha y6e ff8 fs0 fc1 sc0 ls0 ws53"> in </div><div class="t m3 x3 ha y6f ff8 fs0 fc1 sc0 lsd wsf0">the selexipag and placebo groups, </div><div class="t m3 x3 ha y70 ff8 fs0 fc1 sc0 lsd wsba">respectively<span class="_ _7"></span>. The tr<span class="_ _4"></span>eatment effect of </div><div class="t m3 x3 ha y71 ff8 fs0 fc1 sc0 lsd wsbb">selexipag resulted in an incr<span class="_ _4"></span>ease in </div><div class="t m3 x3 ha y72 ff8 fs0 fc1 sc0 lsd ws68">the mean cardiac index value of 0.5<span class="_ _4"></span> </div><div class="t m3 x3 ha y73 ff8 fs0 fc1 sc0 lsd ws32">L/min/m</div><div class="t m3 x21 hb y150 ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x3f ha y73 ff8 fs0 fc1 sc0 lsd ws2c"> (95% condence interval </div><div class="t m3 x3 ha y74 ff8 fs0 fc1 sc0 lsd wsf1">[CI], 0.130.83 L/min/m</div><div class="t m3 x7a hb y75 ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x75 ha y74 ff8 fs0 fc1 sc0 lsd ws32">; <span class="_ _b"> </span><span class="ff9 ls0 ws0">p</span><span class="wsf1"> = 0.01). </span></div><div class="t m3 x3 ha y76 ff8 fs0 fc1 sc0 lsd wsf2">Baseline mean </div><div class="t m1 x7b hd y76 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x7c ha y76 ff8 fs0 fc1 sc0 lsd wsf2"> S.D<span class="_ _0"></span>. values for mean </div><div class="t m3 x3 ha y77 ff8 fs0 fc1 sc0 lsd wsd2">pulmonary arter<span class="_ _8"></span>ial pressur<span class="_ _4"></span>e (mP<span class="_ _0"></span>AP) </div><div class="t m3 x3 ha y78 ff8 fs0 fc1 sc0 lsd ws40">were 54.5 </div><div class="t m1 x6b hd y78 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x6c ha y78 ff8 fs0 fc1 sc0 lsd ws40"> 15.3 and 54.6 </div><div class="t m1 x7d hd y78 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x7e ha y78 ff8 fs0 fc1 sc0 lsd ws40"> 13.8 mm </div><div class="t m3 x3 ha y79 ff8 fs0 fc1 sc0 lsd wsf3">Hg in the selexipag and placebo </div><div class="t m3 x3 ha y7a ff8 fs0 fc1 sc0 lsd ws45">groups, r<span class="_ _4"></span>espectively<span class="_ _5"></span>. After 17 weeks, </div><div class="t m3 x3 ha y7b ff8 fs0 fc1 sc0 lsd wsf4">the mean </div><div class="t m1 x7f hd y7b ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x80 ha y7b ff8 fs0 fc1 sc0 lsd wsf4"> S.D<span class="_ _0"></span>. change from base<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y7d ff8 fs0 fc1 sc0 lsd wsf5">line in mP<span class="_ _0"></span>AP was 1.7 </div><div class="t m1 x81 hd y7d ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x74 ha y7d ff8 fs0 fc1 sc0 lsd wsf5"> 11.0 mm Hg </div><div class="t m3 x3 ha y7e ff8 fs0 fc1 sc0 lsd ws33">in patients treated with selexipag ver<span class="_ _0"></span><span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y80 ff8 fs0 fc1 sc0 lsd wsf6">sus 5.7 </div><div class="t m1 x6e hd y80 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x82 ha y80 ff8 fs0 fc1 sc0 lsd wsf6"> 13.3 mm Hg in the placebo </div><div class="t m3 x3 ha y81 ff8 fs0 fc1 sc0 lsd ws7b">group (treatment effect, 7.4 <span class="_ _4"></span>mm Hg </div><div class="t m3 x3 ha y82 ff8 fs0 fc1 sc0 lsd ws4d">[95% CI, 15.9 to 1.1 mm Hg]; <span class="ff9 ls0 ws0">p</span> = 0.1). </div><div class="t m3 x3 ha y83 ff8 fs0 fc1 sc0 lsd wsf7">The mean </div><div class="t m1 x7f hd y83 ff5 fs0 fc1 sc0 ls0 ws0"></div><div class="t m3 x80 ha y83 ff8 fs0 fc1 sc0 lsd wsf7"> S.D<span class="_ _0"></span>. changes from base<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y84 ff8 fs0 fc1 sc0 lsd wsf8">line in 6-minute walk distance were<span class="_ _4"></span> </div><div class="t m3 x3 ha y85 ff8 fs0 fc1 sc0 lsd wsf9">24.7 m (95% CI, 1.6 to 50.9 m) in the </div><div class="t m3 x3 ha y86 ff8 fs0 fc1 sc0 lsd wsfa">selexipag group and 0.4 m (95% CI, </div><div class="t m3 x3 ha y87 ff8 fs0 fc1 sc0 lsd ws67">19.7 to 20.5 m) in the placebo group </div><div class="t m3 x3 ha y88 ff8 fs0 fc1 sc0 lsd wsfb">(treatment effect, 24.2 m; 95% CI, </div><div class="t m3 x3 ha y89 ff8 fs0 fc1 sc0 lsd wsfc">23.7 to 72.2 m). Adverse effects wer<span class="_ _4"></span>e </div><div class="t m3 x3 ha y8b ff8 fs0 fc1 sc0 lsd wsfd">reported in almost all patients in both </div><div class="t m3 x3 ha y8c ff8 fs0 fc1 sc0 lsd wsfe">the treatment and placebo groups<span class="_ _4"></span>. </div><div class="t m3 x3 ha y8d ff8 fs0 fc1 sc0 lsd wsff">The most common adverse effects </div><div class="t m3 xa ha y4d ff8 fs0 fc1 sc0 lsd ws100">that emerged as a result of tr<span class="_ _4"></span>eatment </div><div class="t m3 xa ha y4e ff8 fs0 fc1 sc0 lsd ws101">with selexipag were headache (67%),<span class="_ _4"></span> </div><div class="t m3 xa ha y4f ff8 fs0 fc1 sc0 lsd ws102">jaw pain (36%), pain in an extremity </div><div class="t m3 xa ha y50 ff8 fs0 fc1 sc0 lsd ws103">(30%), nausea (27%), and nasophar<span class="ls0 ws0">-</span></div><div class="t m3 xa ha y52 ff8 fs0 fc1 sc0 lsd ws7c">yngitis (24%). Although the study was </div><div class="t m3 xa ha y53 ff8 fs0 fc1 sc0 lsd ws92">limited by a small sample siz<span class="_ _4"></span>e, the </div><div class="t m3 xa ha y54 ff8 fs0 fc1 sc0 lsd ws104">positive hemodynamic effects ob<span class="ls0 ws0">-</span></div><div class="t m3 xa ha y55 ff8 fs0 fc1 sc0 lsd ws105">served supported fur<span class="_ _8"></span>ther investiga<span class="ls0 ws0">-</span></div><div class="t m3 xa ha y56 ff8 fs0 fc1 sc0 lsd wse4">tion of selexipag in the then-ongoing </div><div class="t m3 xa ha y58 ff8 fs0 fc1 sc0 lsd ws106">Phase III Prostacy<span class="_ _4"></span>clin (PGI</div><div class="t m3 x4b hb y151 ff8 fs6 fc1 sc0 ls0 ws0">2</div><div class="t m3 x4e ha y58 ff8 fs0 fc1 sc0 lsd ws106">) Receptor </div><div class="t m3 xa ha y59 ff8 fs0 fc1 sc0 lsd ws107">Agonist in Pulmonary Arterial Hyper<span class="ls0 ws0">-</span></div><div class="t m3 xa ha y5a ff8 fs0 fc1 sc0 lsd ws0">tension (GRIPHON) study<span class="_ _5"></span>.</div><div class="t m3 x83 hb y152 ff8 fs6 fc1 sc0 lse wsdf">20</div><div class="t m3 x4c ha y5a ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 x9 ha y5b ff8 fs0 fc1 sc0 ls0 ws108">The no<span class="_ _4"></span>w-completed GRIPHON </div><div class="t m3 xa ha y5c ff8 fs0 fc1 sc0 ls0 wsf3">study is considered the landmark </div><div class="t m3 xa ha y5e ff8 fs0 fc1 sc0 ls0 ws109">trial of selexipag use in P<span class="_ _0"></span>AH. Enroll<span class="ws0">-</span></div><div class="t m3 xa ha y60 ff8 fs0 fc1 sc0 ls0 ws7b">ment in this event-driven trial began </div><div class="t m3 xa ha y61 ff8 fs0 fc1 sc0 ls0 wse6">in 2009 and was completed in 2014. </div><div class="t m3 xa ha y62 ff8 fs0 fc1 sc0 ls0 ws10a">A total of 1,156 patients were r<span class="_ _4"></span>an<span class="ws0">-</span></div><div class="t m3 xa ha y64 ff8 fs0 fc1 sc0 ls0 wsa4">domly assigned in a 1:1 fashion to ei<span class="ws0">-</span></div><div class="t m3 xa ha y65 ff8 fs0 fc1 sc0 ls0 ws10b">ther selexipag or placebo use; about </div><div class="t m3 xa ha y67 ff8 fs0 fc1 sc0 ls0 ws10c">80% of all study participants (<span class="ff9 ws0">n</span> = 920) </div><div class="t m3 xa ha y68 ff8 fs0 fc1 sc0 ls0 ws7">were r<span class="_ _4"></span>eceiving standard ther<span class="_ _4"></span>apies for </div><div class="t m3 xa ha y69 ff8 fs0 fc1 sc0 ls0 ws10d">P<span class="_ _0"></span>AH at baseline, with most continuing </div><div class="t m3 xa ha y6a ff8 fs0 fc1 sc0 ls0 ws10e">those therapies during the study<span class="_ _5"></span>. P<span class="_ _0"></span>AH </div><div class="t m3 xa ha y6b ff8 fs0 fc1 sc0 ls0 ws8">among study enrollees was predomi<span class="ws0">-</span></div><div class="t m3 xa ha y6c ff8 fs0 fc1 sc0 ls0 ws10f">nately idiopathic (56% of patients </div><div class="t m3 xa ha y6d ff8 fs0 fc1 sc0 ls0 ws110">o<span class="_ _4"></span>verall) or associated with connective </div><div class="t m3 xa ha y6e ff8 fs0 fc1 sc0 ls0 ws42">tissue disease (29% of patients). <span class="_ _4"></span>The </div><div class="t m3 xa ha y6f ff8 fs0 fc1 sc0 ls0 ws111">primary outcome was a composite of </div><div class="t m3 xa ha y70 ff8 fs0 fc1 sc0 ls0 ws109">all-cause mortality and development </div><div class="t m3 xa ha y71 ff8 fs0 fc1 sc0 ls0 ws2f">of a complication due to P<span class="_ _0"></span>AH (dened </div><div class="t m3 xa ha y72 ff8 fs0 fc1 sc0 ls0 ws45">as disease progression or worsening </div><div class="t m3 xa ha y73 ff8 fs0 fc1 sc0 ls0 ws109">of P<span class="_ _0"></span>AH resulting in initiation of par<span class="ws0">-</span></div><div class="t m3 xa ha y74 ff8 fs0 fc1 sc0 ls0 ws7b">enteral prostanoid therap<span class="_ _0"></span>y or oxygen </div><div class="t m3 xa ha y76 ff8 fs0 fc1 sc0 ls0 wse2">supplementation, hospitalization for </div><div class="t m3 xa ha y77 ff8 fs0 fc1 sc0 ls0 ws112">worsening P<span class="_ _0"></span>AH, or a need for lung </div><div class="t m3 xa ha y78 ff8 fs0 fc1 sc0 ls0 ws7b">transplantation or balloon atrial sep<span class="ws0">-</span></div><div class="t m3 xa ha y79 ff8 fs0 fc1 sc0 ls0 ws113">tostomy). Disease progr<span class="_ _4"></span>ession was </div><div class="t m3 xa ha y7a ff8 fs0 fc1 sc0 ls0 ws114">dened as a decrease in 6-minute </div><div class="t m3 xa ha y7b ff8 fs0 fc1 sc0 ls0 ws111">walk distance of at least 15% in com<span class="ws0">-</span></div><div class="t m3 xa ha y7d ff8 fs0 fc1 sc0 ls0 wsc7">bination with worsening in functional </div><div class="t m3 xa ha y7e ff8 fs0 fc1 sc0 ls0 ws93">class or (in FC III or IV patients only) </div><div class="t m3 xa ha y80 ff8 fs0 fc1 sc0 ls0 ws4a">a need for additional therap<span class="_ _4"></span>y<span class="_ _5"></span>. Baseline </div><div class="t m3 xa ha y81 ff8 fs0 fc1 sc0 ls0 ws9c">characteristics wer<span class="_ _4"></span>e similar between </div><div class="t m3 xa ha y82 ff8 fs0 fc1 sc0 ls0 ws115">the study groups. Ov<span class="_ _4"></span>erall (both groups </div><div class="t m3 xa ha y83 ff8 fs0 fc1 sc0 ls0 ws116">combined), approximately 45% and </div><div class="t m3 xa ha y84 ff8 fs0 fc1 sc0 ls0 ws7b">52% of patients were classied as FC </div><div class="t m3 xa ha y85 ff8 fs0 fc1 sc0 ls0 ws4b">II and FC III, respectively; 20% wer<span class="_ _4"></span>e </div><div class="t m3 xa ha y86 ff8 fs0 fc1 sc0 ls0 ws117">receiving no background tr<span class="_ _0"></span>eatment </div><div class="t m3 xa ha y87 ff8 fs0 fc1 sc0 ls0 wsea">for P<span class="_ _0"></span>AH, 32% were on PDE5 inhibitor </div><div class="t m3 xa ha y88 ff8 fs0 fc1 sc0 ls0 ws118">monotherap<span class="_ _4"></span>y<span class="_ _5"></span>, 14% were on endothe<span class="ws0">-</span></div><div class="t m3 xa ha y89 ff8 fs0 fc1 sc0 ls0 wscb">lin receptor antagonist monother<span class="_ _4"></span>apy<span class="_ _5"></span>, </div><div class="t m3 xa ha y8b ff8 fs0 fc1 sc0 ls0 ws46">and 32% were r<span class="_ _4"></span>eceiving both forms </div><div class="t m3 xa ha y8c ff8 fs0 fc1 sc0 ls0 wsf9">of therap<span class="_ _4"></span>y<span class="_ _5"></span>. A total of 397 patients, 155 </div><div class="t m3 xa ha y8d ff8 fs0 fc1 sc0 ls0 ws119">(27.0%) in the selexipag group and </div><div class="t m3 xd ha y153 ff8 fs0 fc1 sc0 ls0 ws33">242 (41.6%) in the placebo group<span class="_ _4"></span>, had </div><div class="t m3 xd ha y154 ff8 fs0 fc1 sc0 ls0 ws11a">a primary-endpoint event (hazar<span class="_ _4"></span>d </div><div class="t m3 xd ha y155 ff8 fs0 fc1 sc0 ls0 ws11b">ratio [HR], 0.60; 99% CI, 0.460.78; </div><div class="t m3 xd ha y156 ff9 fs0 fc1 sc0 ls0 ws0">p<span class="ff8 ws8c"> &lt; 0.001). <span class="_ _4"></span>The treatment effect favor<span class="_ _4"></span><span class="ws0">-</span></span></div><div class="t m3 xd ha y157 ff8 fs0 fc1 sc0 ls0 ws11b">ing selexipag was consistent across </div><div class="t m3 xd ha y158 ff8 fs0 fc1 sc0 ls0 ws4b">all prespecied selexipag dosing lev<span class="ws0">-</span></div><div class="t m3 xd ha y159 ff8 fs0 fc1 sc0 ls0 ws11c">els and primarily driven by relativ<span class="_ _4"></span>e </div><div class="t m3 xd ha y15a ff8 fs0 fc1 sc0 ls0 ws9b">reductions in r<span class="_ _4"></span>ates of hospitalization </div><div class="t m3 xd ha y15b ff8 fs0 fc1 sc0 ls0 ws11d">(13.6% with selexipag versus 18.7% </div><div class="t m3 xd ha y15c ff8 fs0 fc1 sc0 ls0 ws11e">with placebo use) and disease pro<span class="ws0">-</span></div><div class="t m3 xd ha y15d ff8 fs0 fc1 sc0 ls0 ws1d">gression (6.6% versus 17.3%). <span class="_ _0"></span>The oc<span class="ws0">-</span></div><div class="t m3 xd ha y15e ff8 fs0 fc1 sc0 ls0 ws2">currence of the composite secondary </div><div class="t m3 xd ha y15f ff8 fs0 fc1 sc0 ls0 ws2c">endpoint, comprising death due to </div><div class="t m3 xd ha y160 ff8 fs0 fc1 sc0 ls0 ws63">P<span class="_ _0"></span>AH and hospitalization for worsen<span class="ws0">-</span></div><div class="t m3 xd ha y161 ff8 fs0 fc1 sc0 ls0 ws99">ing P<span class="_ _0"></span>AH, was also signicantly lower </div><div class="t m3 xd ha y162 ff8 fs0 fc1 sc0 ls0 ws11f">in patients treated with selexipag than </div><div class="t m3 xd ha y163 ff8 fs0 fc1 sc0 ls0 ws116">in placebo recipients: 17.8% versus </div><div class="t m3 xd ha y164 ff8 fs0 fc1 sc0 ls0 ws120">23.5% (HR, 0.7; 99% CI, 0.540.91; </div><div class="t m3 xd ha y165 ff9 fs0 fc1 sc0 ls0 ws0">p<span class="ff8 ws121"> = 0.003). <span class="_ _4"></span>There was no signicant </span></div><div class="t m3 xd ha y166 ff8 fs0 fc1 sc0 ls0 ws28">difference between the selexipag and </div><div class="t m3 xd ha y167 ff8 fs0 fc1 sc0 ls0 wse8">placebo groups in the all-cause death </div><div class="t m3 xd ha y168 ff8 fs0 fc1 sc0 ls0 ws111">rate (17.4% versus 18.0%, <span class="ff9 ws0">p</span> = 0.42) or </div><div class="t m3 xd ha y169 ff8 fs0 fc1 sc0 ls0 ws122">in the rate of death due to P<span class="_ _0"></span>AH during </div><div class="t m3 xd ha y16a ff8 fs0 fc1 sc0 ls0 ws123">the treatment period (12.2% versus </div><div class="t m3 xd ha y16b ff8 fs0 fc1 sc0 ls0 ws0">14.3%, <span class="_ _11"> </span><span class="ff9">p</span><span class="ws9b"> = 0.18). Relative to baseline </span></div><div class="t m3 xd ha y16c ff8 fs0 fc1 sc0 ls0 ws32">values, the median 6-minute walk dis<span class="ws0">-</span></div><div class="t m3 xd ha y16d ff8 fs0 fc1 sc0 ls0 wsbf">tance at 26 weeks was reduced b<span class="_ _0"></span>y 9 m </div><div class="t m3 xd ha y16e ff8 fs0 fc1 sc0 ls0 ws11f">in the placebo group and increased b<span class="_ _0"></span>y </div><div class="t m3 xd ha y16f ff8 fs0 fc1 sc0 ls0 wsaf">4 m in the selexipag group (<span class="ff9 ws0">p</span> = 0.003). </div><div class="t m3 xd ha y170 ff8 fs0 fc1 sc0 ls0 ws124">The percentages of patients with no </div><div class="t m3 xd ha y171 ff8 fs0 fc1 sc0 ls0 ws125">worsening of <span class="_ _0"></span>WHO FC status were </div><div class="t m3 xd ha y172 ff8 fs0 fc1 sc0 ls0 ws53">similar in the placebo and selexipag </div><div class="t m3 xd ha y173 ff8 fs0 fc1 sc0 ls0 ws5f">groups (74.9% and 77.8%, respectiv<span class="_ _4"></span>e<span class="ws0">-</span></div><div class="t m3 xd ha y174 ff8 fs0 fc1 sc0 ls0 ws0">ly; <span class="_ _12"></span><span class="ff9">p</span><span class="ws97"> = 0.28). A prespecied subgroup </span></div><div class="t m3 xd ha y175 ff8 fs0 fc1 sc0 ls8 ws126">analysis indicated that background </div><div class="t m3 xd ha y176 ff8 fs0 fc1 sc0 ls8 ws127">P<span class="_ _0"></span>AH regimens, including monother<span class="_ _4"></span><span class="ls0 ws0">-</span></div><div class="t m3 xd ha y177 ff8 fs0 fc1 sc0 ls8 ws9b">apy with an ERA or a PDE5 inhibitor </div><div class="t m3 xd ha y178 ff8 fs0 fc1 sc0 ls8 ws128">and combination therap<span class="_ _4"></span>y with both an </div><div class="t m3 xd ha y179 ff8 fs0 fc1 sc0 ls8 ws129">ERA and a PDE5 inhibitor<span class="_ _0"></span>, did not sig<span class="ls0 ws0">-</span></div><div class="t m3 xd ha y17a ff8 fs0 fc1 sc0 ls8 ws0">nicantly affect outcomes (<span class="ff9 ls0">p</span> = 0.95). </div><div class="t m3 x2a ha y17b ff8 fs0 fc1 sc0 ls1 ws3a">The rates of discontinuation due </div><div class="t m3 xd ha y17c ff8 fs0 fc1 sc0 ls1 wsc5">to adverse effects wer<span class="_ _4"></span>e 7.1% (<span class="ff9 ls0 ws0">n</span> = 41) in </div><div class="t m3 xd ha y17d ff8 fs0 fc1 sc0 ls1 ws12a">the placebo group and 14.3% (<span class="ff9 ls0 ws0">n</span> = 82) </div><div class="t m3 xd ha y17e ff8 fs0 fc1 sc0 ls1 ws12b">in the treatment group (<span class="ff9 ls0 ws0">p</span> &lt; 0.001). <span class="_ _0"></span>The </div><div class="t m3 xd ha y17f ff8 fs0 fc1 sc0 ls1 ws12c">most common adverse effects lead<span class="ls0 ws0">-</span></div><div class="t m3 xd ha y180 ff8 fs0 fc1 sc0 ls1 ws2c">ing to discontinuation of selexipag </div><div class="t m3 xd ha y181 ff8 fs0 fc1 sc0 ls1 ws12d">use were headache (3.3% <span class="_ _4"></span>of patients), </div><div class="t m3 xd ha y182 ff8 fs0 fc1 sc0 ls1 ws2e">diarrhea (2.3%), and nausea (1.7%). </div><div class="t m3 xd ha y183 ff8 fs0 fc1 sc0 ls1 ws12e">There was no signicant differ<span class="_ _4"></span>ence </div><div class="t m3 xd ha y184 ff8 fs0 fc1 sc0 ls1 ws12f">in rates of serious adverse effects in </div><div class="t m3 xd ha y185 ff8 fs0 fc1 sc0 ls1 ws130">the selexipag and placebo groups.<span class="_ _4"></span> </div><div class="t m3 xd ha y186 ff8 fs0 fc1 sc0 ls1 ws86">Although the high discontinuation </div><div class="t m3 xd ha y187 ff8 fs0 fc1 sc0 ls1 ws131">rate (18.9% for the study population </div><div class="t m3 xd ha y188 ff8 fs0 fc1 sc0 ls1 ws132">o<span class="_ _4"></span>verall) was the most signicant limi<span class="ls0 ws0">-</span></div><div class="t m3 xd ha y189 ff8 fs0 fc1 sc0 ls1 ws133">tation of this study<span class="_ _5"></span>, the investigators </div></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf5" class="pf w0 h0" data-page-no="5"><div class="pc pc5 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAABJIAAAYeCAIAAACbYpbCAAAACXBIWXMAABYlAAAWJQFJUiTwAAAfN0lEQVR42uzbwY3VSBSGURqVJU9F0QhWoApllk6lgmDjYCodLIiisOSFJ4EeEN1X5rl0Tgj/pvpr3/d0nuc7AAAAHtV7EwAAAMg2AAAAZBsAAIBsAwAAQLYBAAAg2wAAAGQbAAAAsg0AAEC2AQAAINsAAACQbQAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAyDYAAADZBgAAgGwDAACQbQAAAMg2AAAAZBsAAIBsAwAAQLYBAADINgAAAGQbAAAAsg0AAEC2AQAAINsAAABkGwAAAI8lmeDtPv771QgAAPCirVUjvJGvbQAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALLNBAAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABe9HSepxUAAAAelq9tAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAss0EAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZBsAAACyDQAAgD+QTADwok/PH4wAAFG+/fhuBNkG4IEBgAfln6Fv5EgSAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAsg0AAADZBgAAgGwDAACQbQAAAMg2AAAA2QYAAIBsAwAAQLYBAADINgAAAGQbAACAbAMAAEC2AQAAINsAAABkGwAAALINAABAtpkAAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAg0smAIjys/fy+YsdABjYtx/fjXA9X9sAwvyTsxEAANkGAAAg2wAAAHgYftsGEMnFPwAQztc2AAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAsg0AAADZBgAAgGwDAACQbQAAAMg2AAAA2WYCAAAA2QYAAMArJRMAAEPq+1GW1Q78LVurRkC2AQD8Sp4nfzcDY3AkCQAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAANkGAACAbAMAAEC2AQAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAINtMAAAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAANkGAACAbAMAAEC2AQAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAQLYBAADINgAAAGQbAACAbAMAAEC2AQAAINsAAABkGwAAALINAABAtgEAACDbAAAA+I1kAoAofT/KstoBgIFtrRrher62AYTJ82QEAEC2AQAAyDYAAAAeht+2AURy8Q8AhPO1DQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAANkGAACAbAMAAEC2AQAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLaZAAAAQLYBAADwSskEAFH6fpRltQMAA9taNYJsA7ixPE8eMwAgnCNJAAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAsg0AAADZBgAAgGwDAACQbQAAAMg2AAAA2WYCAAAA2QYAAIBsAwAAGFEyAUCUvh9lWe0AwMC2Vo0g2wBuLM+TxwwACOdIEgAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAANkGAACAbAMAAEC2AQAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLaZAAAAQLYBAAAg2wAAAGQbAAAAF0smAIjS96Msqx0AGNjWqhFkG8CN5XnymAEA4RxJAgAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYTAAAAyDYAAABkGwAAwIiSCQCi9P0oy2oHAAa2tWoE2QZwY3mePGYAQDhHkgAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALLNBAAAALINAAAA2QYAACDbAAAAuFgyAUCUvh9lWe0AwMC2Vo0g2wBuLM+TxwwACOdIEgAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAANkGAACAbAMAAEC2AQAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLaZAAAAQLYBAAAg2wAAAGQbAAAAF0smAIjS96Msqx0AGNjWqhFkG8CN5XnymAEA4RxJAgAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYTAAAAyDYAAABkGwAAwIiSCQCi9P0oy2oHAAa2tWoE2QZwY3mePGYAQDhHkgAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALLNBAAAALINAAAA2QYAACDbAAAAuFgyAUCUvh9lWe0AwMC2Vo0g2wBuLM+TxwwACOdIEgAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAANkGAACAbAMAAEC2AQAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLaZAAAAQLYBAAAg2wAAAEaUTAAQpe9HWVY7ADCwrVUjyDaAG8vz5DEDAMI5kgQAAJBtAAAAyDYAAADZBgAAgGwDAABAtgEAAMg2AAAAZBsAAIBsAwAAQLYBAAAg2wAAAGQbAAAAsg0AAEC2AQAAINsAAACQbQAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtJgAAAJBtAAAAyDYAAADZBgAAwMWSCQCi9P0oy2oHAAa2tWoE2QZwY3mePGYAQDhHkgAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALLNBAAAALINAAAA2QYAADCiZAKAKH0/yrLaAYCBba0aQbYB3FieJ48ZABDOkSQAAIBsAwAAQLYBAADINgAAAGQbAAAAsg0AAEC2AQAAINsAAABkGwAAALINAAAA2QYAACDbAAAAkG0AAACyDQAAANkGAACAbAMAAJBtAAAAyDYAAADZBgAAgGwDAABAtgEAAMg2AAAAZBsAAIBsMwEAAIBsAwAAQLYBAADINgAAAC6WTAAQpe9HWVY7ADCwrVUjyDaAG8vz5DEDAMI5kgQAAJBtAAAAyDYAAADZBgAAgGwDAABAtgEAAMg2AAAAZBsAAIBsAwAAQLYBAAAg2wAAAGQbAAAAsg0AAEC2AQAAINsAAACQbQAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtJgAAAJBtAAAAyDYAAADZBgAAwMWSCQCi9P0oy2oHAAa2tWoE2QZwY3mePGYAQDhHkgAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALLNBAAAALINAACAV0omAIjS96Msqx0AGNjWqhGu52sbQJg8T0YAAGQbAACAbAMAAOBh+G0bQCQX/wBAOF/bAAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZJsJAAAAZBsAAACyDQAAQLYBAABwsWQCgP/z6fmDEQCAv+7pPE8rAAAAPCxHkgAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALLNBAAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAsg0AAADZBgAAgGwDAACQbQAAAMg2AAAA2QYAAIBsAwAAQLYBAADINgAAAGQbAAAAsg0AAEC2AQAAINsAAABkGwAAALINAAAA2QYAACDbAAAAkG0AAACyDQAAANkGAACAbAMAAJBtAAAAyDYAAADZBgAAgGwDAABAtgEAAMg2AAAAZBsAAIBsAwAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAANkGAACAbAMAAEC2AQAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAgGwDAACQbQAAAMg2AAAA2QYAAIBsAwAAQLYBAADINgAAAGQbAACAbAMAAEC2AQAAINsAAABkGwAAALINAABAtgEAACDbAAAAkG0AAACyDQAAANkGAAAg2wAAAJBtAAAAyDYAAADZBgAAgGwDAABAtgEAAMg2AAAAZBsAAIBsAwAAQLYBAAAg2wAAAGQbAAAAsg0AAEC2AQAAINsAAACQbQAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAkG0AAACyDQAAANkGAAAg2wAAAJBtAAAAyDYAAADZBgAAgGwDAACQbQAAAMg2AAAAZBsAAIBsAwAAQLYBAADINgAAAGQbAAAAsg0AAEC2AQAAINsAAABkGwAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAsg0AAADZBgAAgGwDAACQbQAAAMg2AAAA2QYAAIBsAwAAQLYBAADINgAAAGQbAAAAsg0AAEC2AQAAINsAAABkGwAAALINAAAA2QYAACDbAAAAkG0AAACyDQAAANkGAACAbAMAAJBtAAAAyDYAAADZBgAAgGwDAABAtgEAAMg2AAAAZBsAAIBsAwAAQLYBAAAg2wAAAGQbAAAAsg0AAEC2mQAAAEC2AQAAINsAAABkGwAAALINAAAA2QYAACDbAAAAkG0AAACyDQAAANkGAACAbAMAAJBtAAAAyDYAAADZBgAAgGwDAABAtgEAAMg2AAAAZBsAAIBsAwAAQLYBAAAg2wAAAGQbAAAAsg0AAEC2AQAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAANkGAACAbAMAAEC2AQAAyDYAAABkGwAAgGwDAABAtgEAACDbAAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAQLYBAADINgAAAGQbAACAbAMAAEC2AQAAINsAAABkGwAAALINAABAtgEAACDbAAAAkG0AAACyDQAAANkGAAAg2wAAAJBtAAAAyDYAAADZBgAAgGwDAACQbQAAAMg2AAAAZBsAAIBsAwAAQLYBAAAg2wAAAGQbAAAAsg0AAEC2AQAAINsAAACQbQAAALINAAAA2QYAACDbAAAAkG0AAADINgAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAJBtAAAAsg0AAADZBgAAINsAAACQbQAAAMg2AAAA2QYAAIBsAwAAkG0AAADINgAAAGQbAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAyDYAAADZBgAAgGwDAACQbQAAAMg2AAAAZBsAAIBsAwAAQLYBAADINgAAAGQbAAAAsg0AAEC2AQAAINsAAABkGwAAALINAAAA2QYAACDbAAAAkG0AAACyDQAAANkGAACAbAMAAJBtAAAAyDYAAABkGwAAgGwDAABAtgEAAMg2AAAAZBsAAACyDQAAQLYBAAAg2wAAAGQbAAAAsg0AAADZBgAAINsAAACQbQAAALINAAAA2QYAAIBsAwAAkG0AAADINgAAANkGAACAbAMAAEC2AQAAyDYAAABkGwAAALINAABAtgEAACDbAAAAZBsAAACyDQAAANkGAAAg2wAAAJBtAAAAsg0AAADZBgAAgGwDAACQbQAAAMg2AAAA2QYAAIBsAwAAQLYBAADINgAAAGQbAACAbAMAAEC2AQAAINsAAABkGwAAALINAAAA2QYAACDbAAAAkG0AAACyDQAAANkGAACAbAMAAJBtAAAAyDb4r/06JAAAAAAQ9P+1NwwwwSYAANg2AAAAbBsAAAC2DQAAwLYBAABg2wAAAGwbAAAAtg0AAADbBgAAYNsAAACwbQAAALYNAAAA2wYAAIBtAwAAsG0AAADYNgAAAGwbAACAbQMAAMC2AQAA2DYAAABsGwAAALYNAADAtgEAAGDbAAAAbBsAAAC2DQAAANsGAABg2wAAALBtAAAAtg0AAADbBgAAgG0DAACwbQAAANg2AAAA2wYAAIBtAwAAwLYBAADYNgAAAGwbAAAAtg0AAMC2AQAAYNsAAABsGwAAALYNAAAA2wYAAGDbAAAAsG0AAAC2DQAAANsGAACAbQMAALBtAAAA2DYAAADbBgAAgG0DAADAtgEAANg2AAAAbBsAAIBtAwAAwLYBAABg2wAAAGwbAAAAtg0AAMC2SQAAAGDbAAAAsG0AAAC2DQAAANsGAACAbQMAALBtAAAA2DYAAADbBgAAgG0DAADAtgEAANg2AAAAbBsAAIBtAwAAwLYBAABg2wAAAGwbAAAAtg0AAMC2AQAAYNsAAACwbQAAALYNAAAA2wYAAGDbAAAAsG0AAADYNgAAANsGAACAbQMAAMC2AQAA2DYAAABsGwAAgG0DAADAtgEAAGDbAAAAbBsAAAC2DQAAwLYBAABg2wAAALBtAAAAtg0AAADbBgAAYNsAAACwbQAAANg2AAAA2wYAAIBtAwAAsG0AAADYNgAAAGwbAACAbQMAAMC2AQAAYNsAAABsGwAAALYNAADAtgEAAGDbAAAAsG0AAAC2DQAAANsGAABg2wAAALBtAAAA2DYAAADbBgAAgG0DAACwbQAAANg2AAAAbBsAAIBtAwAAwLYBAADYNgAAAGwbAAAAtg0AAMC2AQAAYNsAAACwbQAAALYNAAAA2wYAAGDbAAAAsG0AAADYNgAAANsGAACAbQMAALBtAAAA2DYAAABsGwAAgG0DAADAtgEAANg2AAAAbBsAAAC2DQAAwLYBAABg2wAAAGwbAAAAtg0AAADbBgAAYNsAAACwbQAAANg2AAAA2wYAAIBtAwAAsG0AAADYNgAAAGwbAACAbQMAAMC2AQAA2DYAAABsGwAAALYNAADAtgEAAGDbAAAAbBsAAAC2DQAAANsGAABg2wAAALBtAAAAtg0AAADbBgAAgG0DAACwbQAAANg2AAAAbBsAAIBtAwAAwLYBAADYNgAAAGwbAAAAtg0AAMC2AQAAYNsAAABsGwAAALYNAAAA2wYAAGDbAAAAsG0AAAC2DQAAANsGAACAbQMAALBtAAAA2DYAAADbBgAAgG0DAADAtgEAANg2AAAAbBsAAAC2DQAAwLYBAABg2wAAAGwbAAAAtg0AAADbBgAAYNsAAACwbQAAALYNAAAA2wYAAIBtAwAAsG0AAADYNgAAANsGAACAbQMAAMC2AQAA2DYAAABsGwAAgG0DAADAtgEAAGDbAAAAbBsAAAC2DQAAANsGAABg2wAAALBtAAAAtg0AAADbBgAAgG0DAACwbQAAANg2AAAA2wYAAIBtAwAAwLYBAADYNgAAAGwbAACAbQMAAMC2AQAAYNsAAABsGwAAALYNAADAtgEAAGDbAAAAsG0AAAC2DQAAANsGAACAbQMAALBtAAAA2DYAAADbBgAAgG0DAADAtgEAANg2AAAAbBsAAIBtAwAAwLYBAABg2wAAAGwbAAAAtg0AAMC2AQAAYNsAAACwbQAAALYNAAAA2wYAAGDbAAAAsG0AAADYNgAAANsGAACAbQMAAMC2AQAA2DYAAABsGwAAgG0DAADAtgEAAGDbAAAAbBsAAAC2DQAAwLYBAABg2wAAALBtAAAAtg0AAADbBgAAYNsAAACwbQAAANg2AAAA2wYAAIBtAwAAsG0AAADYNgAAAGwbAACAbQMAAMC2AQAAYNsAAABsGwAAALYNAADAtgEAAGDbAAAAsG0AAAC2DQAAANsGAABg2wAAALBtAAAA2DYAAADbBgAAgG0DAACwbQAAANg2AAAAbBsAAIBtAwAAwLYBAADYNgAAAGwbAAAAtg0AAMC2AQAAYNsAAABsmwQAAAC2DQAAANsGAABg2wAAALBtAAAA2DYAAADbBgAAgG0DAACwbQAAANg2AAAAbBsAAIBtAwAAwLYBAADYNgAAAGwbAAAAtg0AAMC2AQAAYNsAAABsGwAAALYNAAAA2wYAAGDbAAAAsG0AAAC2DQAAANsGAACAbQMAALBtAAAA2DYAAABsGwAAgG0DAADAtgEAANg2AAAAbBsAAAC2DQAAwLYBAABg2wAAAGwbAAAAtg0AAADbBgAAYNsAAACwbQAAALYNAAAA2wYAAIBtAwAAsG0AAADYNgAAANsGAACAbQMAAMC2AQAA2DYAAABsGwAAALYNAADAtgEAAGDbAAAAbBsAAAC2DQAAANsGAABg2wAAALBtAAAAtg0AAADbBgAAgG0DAACwbQAAANg2AAAA2wYAAMBL4X+pavn6S0gAAAAASUVORK5CYII="/><div class="t m0 x1 h1 y1 ff1 fs0 fc0 sc0 ls0 ws0">SELEXIP<span class="_ _0"></span>AG </div><div class="t m0 x2 h2 y2 ff2 fs1 fc0 sc0 ls0 ws0">CLINICAL REVIEW</div><div class="t m1 x3 h3 y3 ff3 fs2 fc1 sc0 ls0 ws0"> <span class="_ _1"> </span><span class="ff4">AM J HEAL<span class="_ _5"></span>TH-SYST PHARM<span class="ff3 ws1"> | VOLUME <span class="_ _3"></span>74 | NUMBER <span class="_ _2"></span>15 | AUGUST <span class="_ _3"></span>1, <span class="_ _2"></span>2017  <span class="ff4 fs3 ws0">1139</span></span></span></div><div class="t m3 x3 ha y18a ff8 fs0 fc1 sc0 ls1 ws56">noted that it was anticipated and ac<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y18b ff8 fs0 fc1 sc0 ls1 ws134">counted for in the sensitivity analyses. </div><div class="t m3 x3 ha y18c ff8 fs0 fc1 sc0 ls1 ws21">A long-term, open-label extension of </div><div class="t m3 x3 ha y18d ff8 fs0 fc1 sc0 ls1 wsa5">the GRIPHON study is being conduct<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y18e ff8 fs0 fc1 sc0 ls1 ws11f">ed to further assess the safety and tol<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y18f ff8 fs0 fc1 sc0 ls1 ws135">erability of selexipag and is expected </div><div class="t m3 x3 ha y190 ff8 fs0 fc1 sc0 ls1 ws0">to conclude in 2018.</div><div class="t m3 x84 hb y191 ff8 fs6 fc1 sc0 lsf ws136">21</div><div class="t m2 x3 h3 y192 ff4 fs3 fc2 sc0 ls0 ws0">Safety and adverse effects</div><div class="t m3 x19 ha y15c ff8 fs0 fc1 sc0 ls0 ws137">The adverse-effect prole of selex<span class="ws0">-</span></div><div class="t m3 x3 ha y15d ff8 fs0 fc1 sc0 ls0 ws138">ipag is consistent with those of other </div><div class="t m3 x3 ha y15e ff8 fs0 fc1 sc0 ls0 ws139">prostacyclin therapies<span class="_ _4"></span>, which produce </div><div class="t m3 x3 ha y15f ff8 fs0 fc1 sc0 ls0 ws130">a unique, pr<span class="_ _4"></span>edictable set of dose-</div><div class="t m3 x3 ha y160 ff8 fs0 fc1 sc0 ls0 ws35">dependent adverse effects. <span class="_ _0"></span>There is </div><div class="t m3 x3 ha y161 ff8 fs0 fc1 sc0 ls0 ws86">considerable interpatient variability </div><div class="t m3 x3 ha y162 ff8 fs0 fc1 sc0 ls0 ws13a">in the doses at which these adverse ef<span class="ws0">-</span></div><div class="t m3 x3 ha y163 ff8 fs0 fc1 sc0 ls0 ws13b">fects occur<span class="_ _0"></span>, and tolerance can develop </div><div class="t m3 x3 ha y164 ff8 fs0 fc1 sc0 ls0 ws64">with time.</div><div class="t m3 x6b hb y193 ff8 fs6 fc1 sc0 ls0 ws0">19,20</div><div class="t m3 x85 ha y164 ff8 fs0 fc1 sc0 ls0 ws64"> <span class="_ _4"></span>T<span class="_ _5"></span>able 2 details data on </div><div class="t m3 x3 ha y165 ff8 fs0 fc1 sc0 ls0 ws13c">common or noteworthy adverse ef<span class="ws0">-</span></div><div class="t m3 x3 ha y166 ff8 fs0 fc1 sc0 ls0 ws13d">fects from the GRIPHON study<span class="_ _5"></span>.</div><div class="t m3 x69 hb y194 ff8 fs6 fc1 sc0 ls0 ws0">20</div><div class="t m3 x86 ha y166 ff8 fs0 fc1 sc0 ls10 ws13e"> Ad<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y167 ff8 fs0 fc1 sc0 ls0 ws13f">verse effects more commonly occur </div><div class="t m3 x3 ha y168 ff8 fs0 fc1 sc0 ls0 ws140">during dose adjustment, but with time </div><div class="t m3 x3 ha y169 ff8 fs0 fc1 sc0 ls0 ws141">these often impro<span class="_ _4"></span>ve.</div><div class="t m3 x79 hb y195 ff8 fs6 fc1 sc0 ls0 ws0">19,20</div><div class="t m3 x81 ha y169 ff8 fs0 fc1 sc0 ls0 ws141"> Administering </div><div class="t m3 x3 ha y16a ff8 fs0 fc1 sc0 ls0 ws20">se <span class="_ _13"></span>lex <span class="_ _13"></span>ipag with food decreases the <span class="ff9 ws0">C</span></div><div class="t m3 x71 hb y196 ff8 fs6 fc1 sc0 ls0 ws0">max</div><div class="t m3 x18 ha y16a ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 x3 ha y16b ff8 fs0 fc1 sc0 ls0 ws142">and helps to mitigate adverse effects </div><div class="t m3 x3 ha y16c ff8 fs0 fc1 sc0 ls0 ws89">associated with peak concentrations<span class="_ _4"></span>.</div><div class="t m3 x1a hb y197 ff8 fs6 fc1 sc0 ls0 ws0">16</div><div class="t m3 x19 ha y16d ff8 fs0 fc1 sc0 ls0 ws2a">F<span class="_ _4"></span>ew adverse cardio<span class="_ _0"></span>vascular and </div><div class="t m3 x3 ha y16e ff8 fs0 fc1 sc0 ls0 ws143">hematologic effects have been ob<span class="ws0">-</span></div><div class="t m3 x3 ha y16f ff8 fs0 fc1 sc0 ls0 ws144">served with the use of selexipag. </div><div class="t m3 x3 ha y170 ff8 fs0 fc1 sc0 ls0 ws145">Among clinical trial participants, </div><div class="t m3 x3 ha y171 ff8 fs0 fc1 sc0 ls0 ws146">changes in blood pressur<span class="_ _4"></span>e and rates of </div><div class="t m3 x3 ha y172 ff8 fs0 fc1 sc0 ls0 ws27">symptomatic hypotension were simi<span class="_ _4"></span><span class="ws0">-</span></div><div class="t m3 x3 ha y173 ff8 fs0 fc1 sc0 ls0 ws147">lar between those treated with selexi<span class="ws0">-</span></div><div class="t m3 x3 ha y174 ff8 fs0 fc1 sc0 ls0 ws148">pag and placebo users.</div><div class="t m3 x74 hb y198 ff8 fs6 fc1 sc0 ls0 ws0">19,20</div><div class="t m3 x7e ha y174 ff8 fs0 fc1 sc0 ls0 ws148"> Changes </div><div class="t m3 x3 ha y175 ff8 fs0 fc1 sc0 ls0 wsb0">in cardiac r<span class="_ _4"></span>epolarization were stud<span class="ws0">-</span></div><div class="t m3 x3 ha y176 ff8 fs0 fc1 sc0 ls0 ws112">ied in 91 healthy patients receiving </div><div class="t m3 x3 ha y177 ff8 fs0 fc1 sc0 ls0 ws9">escalating doses of selexipag, and no </div><div class="t m3 x3 ha y178 ff8 fs0 fc1 sc0 ls0 ws7e">signicant change in the Q-Tc inter<span class="ws0">-</span></div><div class="t m3 x3 ha y179 ff8 fs0 fc1 sc0 ls0 wsd0">val was observed.</div><div class="t m3 x78 hb y199 ff8 fs6 fc1 sc0 ls0 ws0">22</div><div class="t m3 x79 ha y179 ff8 fs0 fc1 sc0 ls0 wsd0"> Although selexi<span class="ws0">-</span></div><div class="t m3 x3 ha y17a ff8 fs0 fc1 sc0 ls0 wse9">pag produces an inhibitory effect on </div><div class="t m3 x3 ha y17b ff8 fs0 fc1 sc0 ls0 ws147">platelet aggregation in vitro<span class="_ _0"></span>, no effect </div><div class="t m3 x3 ha y17c ff8 fs0 fc1 sc0 ls0 ws8e">on platelet function was observed in </div><div class="t m3 x3 ha y17d ff8 fs0 fc1 sc0 ls0 ws5c">healthy individuals given selexipag </div><div class="t m3 x3 ha y17e ff8 fs0 fc1 sc0 ls0 wsd9">doses of up to 1,800 </div><div class="t m1 x87 hd y17e ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x14 ha y17e ff8 fs0 fc1 sc0 ls0 ws0">g.</div><div class="t m3 x16 hb y19a ff8 fs6 fc1 sc0 ls0 ws0">23</div><div class="t m3 x7a ha y17e ff8 fs0 fc1 sc0 ls0 wsd9"> N<span class="_ _4"></span>o increase </div><div class="t m3 x3 ha y17f ff8 fs0 fc1 sc0 ls0 ws52">in major bleeding events with selexi<span class="ws0">-</span></div><div class="t m3 x3 ha y180 ff8 fs0 fc1 sc0 ls0 wsae">pag use was observed in clinical trials, </div><div class="t m3 x3 ha y181 ff8 fs0 fc1 sc0 ls0 ws149">although anemia was more common </div><div class="t m3 x3 ha y182 ff8 fs0 fc1 sc0 ls0 ws14a">in patients treated with selexipag. F<span class="_ _0"></span>or </div><div class="t m3 x3 ha y183 ff8 fs0 fc1 sc0 ls0 ws25">reasons not yet identied, hyperthy<span class="_ _0"></span><span class="ws0">-</span></div><div class="t m3 x3 ha y184 ff8 fs0 fc1 sc0 ls0 ws14b">roidism occurred in appr<span class="_ _4"></span>oximately </div><div class="t m3 x3 ha y185 ff8 fs0 fc1 sc0 ls0 wsb3">1% of clinical trial particpants treated </div><div class="t m3 x3 ha y186 ff8 fs0 fc1 sc0 ls0 wsa4">with selexipag and no placebo recipi<span class="ws0">-</span></div><div class="t m3 x3 ha y187 ff8 fs0 fc1 sc0 ls0 ws12d">ents; ho<span class="_ _4"></span>wever<span class="_ _0"></span>, this led to drug discon<span class="ws0">-</span></div><div class="t m3 x3 ha y188 ff8 fs0 fc1 sc0 ls0 ws38">tinuation in only 1 patient. P<span class="_ _4"></span>eriodic </div><div class="t m3 x3 ha y189 ff8 fs0 fc1 sc0 ls0 ws14c">monitoring of thyroid function should </div><div class="t m3 x24 h7 y19b ff4 fs0 fc2 sc0 ls0 ws0">T<span class="_ _5"></span>able 2.<span class="ff3 fc1"> Adverse Effects Observed During GRIPHON T<span class="_ _5"></span>rial</span></div><div class="t m3 x88 h8 y19c ff3 fs6 fc1 sc0 ls0 ws0">20,a</div><div class="t m3 x10 he y19d ff4 fs8 fc1 sc0 ls0 ws0">No. (%) Patients</div><div class="t m3 x89 he y19e ff4 fs8 fc1 sc0 ls0 ws0">Adverse Effect</div><div class="t m3 x8a he y19f ff4 fs8 fc1 sc0 ls0 ws0">Placebo </div><div class="t m3 x8b he y1a0 ff4 fs8 fc1 sc0 ls0 ws0">Group</div><div class="t m3 x8c he y19e ff4 fs8 fc1 sc0 ls0 ws0">(<span class="ffd">n</span> = 577)</div><div class="t m3 x8d he y19f ff4 fs8 fc1 sc0 ls0 ws0">Selexipag </div><div class="t m3 x8e he y1a0 ff4 fs8 fc1 sc0 ls0 ws0">Group</div><div class="t m3 x37 he y19e ff4 fs8 fc1 sc0 ls0 ws0">(<span class="ffd">n</span> = 575)<span class="_ _14"> </span><span class="ffd">p</span></div><div class="t m3 x9 hf y1a1 ff3 fs8 fc1 sc0 ls0 ws0">Headache<span class="_ _15"> </span>189 (32.8)<span class="_ _16"> </span>375 (65.2)<span class="_ _17"> </span>&lt;0.001</div><div class="t m3 x9 hf y1a2 ff3 fs8 fc1 sc0 ls0 ws0">Diarrhea<span class="_ _18"> </span>110 (19.1)<span class="_ _16"> </span>244 (42.4)<span class="_ _17"> </span>&lt;0.001</div><div class="t m3 x9 hf y1a3 ff3 fs8 fc1 sc0 ls0 ws0">Nausea<span class="_ _19"> </span>107 (18.5)<span class="_ _16"> </span>193 (33.6)<span class="_ _17"> </span>&lt;0.001</div><div class="t m3 x9 hf y1a4 ff3 fs8 fc1 sc0 ls0 ws0">Jaw pain<span class="_ _1a"> </span>36 (6.2)<span class="_ _1b"> </span>148 (25.7)<span class="_ _17"> </span>&lt;0.001</div><div class="t m3 x9 hf y1a5 ff3 fs8 fc1 sc0 ls0 ws0">W<span class="_ _0"></span>orsening P<span class="_ _4"></span>AH<span class="_ _1c"> </span>206 (35.7)<span class="_ _16"> </span>126 (21.9)<span class="_ _17"> </span>&lt;0.001</div><div class="t m3 x9 hf y1a6 ff3 fs8 fc1 sc0 ls0 ws0">V<span class="_ _0"></span>omiting<span class="_ _1d"> </span>49 (8.5)<span class="_ _1b"> </span>104 (18.1)<span class="_ _17"> </span>&lt;0.001</div><div class="t m3 x9 hf y1a7 ff3 fs8 fc1 sc0 ls0 ws0">Dyspnea<span class="_ _1e"> </span>121 (21.0)<span class="_ _1b"> </span>92 (16.0)<span class="_ _1f"> </span>0.03</div><div class="t m3 x9 hf y1a8 ff3 fs8 fc1 sc0 ls0 ws0">Myalgia<span class="_ _20"> </span>34 (5.9)<span class="_ _21"> </span>92 (16.0)<span class="_ _17"> </span>&lt;0.001</div><div class="t m3 x9 hf y1a9 ff3 fs8 fc1 sc0 ls0 ws0">Flushing<span class="_ _22"> </span>29 (5.0)<span class="_ _21"> </span>70 (12.2)<span class="_ _17"> </span>&lt;0.001</div><div class="t m3 x9 hf y1aa ff3 fs8 fc1 sc0 ls0 ws0">Anemia<span class="_ _23"> </span>31 (5.4)<span class="_ _21"> </span>48 (8.3)<span class="_ _14"> </span>0.05</div><div class="t m3 x9 hf y1ab ff3 fs8 fc1 sc0 ls0 ws0">Hypotension<span class="_ _24"> </span>18 (3.1)<span class="_ _21"> </span>29 (5.0)<span class="_ _14"> </span>0.1</div><div class="t m3 x9 hf y1ac ff3 fs8 fc1 sc0 ls0 ws0">Major bleeding event<span class="_ _25"> </span>12 (2.1)<span class="_ _21"> </span>14 (2.4)<span class="_ _14"> </span>0.7</div><div class="t m3 x9 hf y1ad ff3 fs8 fc1 sc0 ls0 ws0">Hyperthyroidism<span class="_ _26"> </span>0<span class="_ _27"> </span>8 (1.4)<span class="_ _14"> </span>0.004</div><div class="t m3 x9 hf y1ae ff3 fs8 fc1 sc0 ls0 ws0">Discontinuation due to adverse effects<span class="_ _28"> </span>41 (7.1)<span class="_ _21"> </span>82 (14.3) <span class="_ _29"> </span>&lt;0.001</div><div class="t m5 x55 h10 y1af ff3 fsa fc1 sc0 ls0 ws0">a</div><div class="t m1 x47 h11 y1b0 ff3 fs2 fc1 sc0 ls0 ws0">P<span class="_ _0"></span>AH = pulmonary arterial hypertension.</div><div class="t m3 xa ha y1b1 ff8 fs0 fc1 sc0 ls0 ws14d">be considered in patients r<span class="_ _4"></span>eceiving </div><div class="t m3 xa ha y1b2 ff8 fs0 fc1 sc0 ls0 ws0">selexipag.</div><div class="t m3 x8f hb y1b3 ff8 fs6 fc1 sc0 ls0 ws0">23</div><div class="t m2 xa h3 y1b4 ff4 fs3 fc2 sc0 ls0 ws0">Place in therapy</div><div class="t m3 x9 ha y13a ff8 fs0 fc1 sc0 ls0 ws14e">On the basis of available clinical </div><div class="t m3 xa ha y13c ff8 fs0 fc1 sc0 ls0 ws14f">trial data, selexipag was appro<span class="_ _4"></span>ved by </div><div class="t m3 xa ha y13d ff8 fs0 fc1 sc0 ls0 ws13d">FDA for use in the treatment of P<span class="_ _0"></span>AH </div><div class="t m3 xa ha y13e ff8 fs0 fc1 sc0 ls0 ws57">(either as monotherap<span class="_ _4"></span>y or in combi<span class="ws0">-</span></div><div class="t m3 xa ha y13f ff8 fs0 fc1 sc0 ls0 ws150">nation with an ERA, a PDE5 inhibitor<span class="_ _0"></span>, </div><div class="t m3 xa ha y140 ff8 fs0 fc1 sc0 ls0 ws77">or both) to reduce disease progr<span class="_ _4"></span>ession </div><div class="t m3 xa ha y142 ff8 fs0 fc1 sc0 ls0 ws151">and the risk of hospitalization.</div><div class="t m3 x27 hb y1b5 ff8 fs6 fc1 sc0 ls0 ws0">9</div><div class="t m3 x90 ha y142 ff8 fs0 fc1 sc0 ls11 ws152"> Pa<span class="_ _8"></span><span class="ls0 ws0">-</span></div><div class="t m3 xa ha y143 ff8 fs0 fc1 sc0 ls0 ws44">tients with FC II or III disease should </div><div class="t m3 xa ha y144 ff8 fs0 fc1 sc0 ls0 ws153">be considered for tr<span class="_ _4"></span>eatment with </div><div class="t m3 xa ha y146 ff8 fs0 fc1 sc0 ls0 ws14d">selexipag, and 2015 joint European </div><div class="t m3 xa ha y147 ff8 fs0 fc1 sc0 ls0 ws103">guidelines on treatment of P<span class="_ _0"></span>AH rec<span class="ws0">-</span></div><div class="t m3 xa ha y148 ff8 fs0 fc1 sc0 ls0 ws154">ommend its use in these patients; this </div><div class="t m3 xa ha y1b6 ff8 fs0 fc1 sc0 ls0 ws12b">was a class I recommendation (i.e<span class="_ _4"></span>., use </div><div class="t m3 xa ha y1b7 ff8 fs0 fc1 sc0 ls0 ws14d">is <span class="_ _0"></span>recommended/indicated) based </div><div class="t m3 xa ha y1b8 ff8 fs0 fc1 sc0 ls0 ws155">on level B evidence (data derived </div><div class="t m3 xa ha y1b9 ff8 fs0 fc1 sc0 ls0 ws156">from a single randomized clinical trial </div><div class="t m3 xa ha y1ba ff8 fs0 fc1 sc0 ls0 ws157">or large nonrandomized studies).</div><div class="t m3 x28 hb y1bb ff8 fs6 fc1 sc0 ls0 ws0">6</div><div class="t m3 x29 ha y1ba ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 xa ha y1bc ff8 fs0 fc1 sc0 ls0 ws11b">Guidelines from the American Col<span class="ws0">-</span></div><div class="t m3 xa ha y1bd ff8 fs0 fc1 sc0 ls0 ws3f">lege of Chest Physicians on P<span class="_ _0"></span>AH have </div><div class="t m3 xa ha y1be ff8 fs0 fc1 sc0 ls0 ws158">not been updated since the appro<span class="_ _4"></span>val </div><div class="t m3 xa ha y1bf ff8 fs0 fc1 sc0 ls0 ws102">of selexipag and thus do not pro<span class="_ _4"></span>vide </div><div class="t m3 xa ha y1c0 ff8 fs0 fc1 sc0 ls0 ws63">recommendations for its use<span class="_ _4"></span>. Selexi<span class="ws0">-</span></div><div class="t m3 xa ha y1c1 ff8 fs0 fc1 sc0 ls0 ws159">pag has not been adequately studied </div><div class="t m3 xa ha y1c2 ff8 fs0 fc1 sc0 ls0 ws106">in patients with FC IV symptoms, and </div><div class="t m3 xa ha y1c3 ff8 fs0 fc1 sc0 ls0 ws15a">parenter<span class="_ _4"></span>al prostacyclin analogs re<span class="ws0">-</span></div><div class="t m3 xd ha y1b1 ff8 fs0 fc1 sc0 ls0 ws106">main the standard of car<span class="_ _4"></span>e for patients </div><div class="t m3 xd ha y1b2 ff8 fs0 fc1 sc0 ls0 ws0">with advanced disease.</div><div class="t m3 x91 hb y1b3 ff8 fs6 fc1 sc0 ls0 ws0">5,6</div><div class="t m3 x2a ha y1c4 ff8 fs0 fc1 sc0 ls0 wse">Although selexipag is appro<span class="_ _4"></span>ved for </div><div class="t m3 xd ha y1c5 ff8 fs0 fc1 sc0 ls0 ws85">use in combination with other P<span class="_ _0"></span>AH </div><div class="t m3 xd ha y1c6 ff8 fs0 fc1 sc0 ls0 ws15b">therapies, it is unkno<span class="_ _0"></span>wn at this time </div><div class="t m3 xd ha y1c7 ff8 fs0 fc1 sc0 ls0 ws15c">whether adding selexipag to other </div><div class="t m3 xd ha y1c8 ff8 fs0 fc1 sc0 ls0 ws14f">therapies, such as an ERA or a PDE5 </div><div class="t m3 xd ha y1c9 ff8 fs0 fc1 sc0 ls0 ws5a">inhibitor<span class="_ _0"></span>, provides additional benet </div><div class="t m3 xd ha y1ca ff8 fs0 fc1 sc0 ls0 ws28">relative to the use of selexipag alone<span class="_ _4"></span>. </div><div class="t m3 xd ha y1cb ff8 fs0 fc1 sc0 ls0 ws15d">Prior to the appro<span class="_ _4"></span>val of selexipag, a </div><div class="t m3 xd ha y1cc ff8 fs0 fc1 sc0 ls0 ws15e">trial evaluating the combination of </div><div class="t m3 xd ha y1cd ff8 fs0 fc1 sc0 ls0 ws119">ambrisentan (an ERA) and tadalal </div><div class="t m3 xd ha y1ce ff8 fs0 fc1 sc0 ls0 ws8">(a PDE5 inhibitor) sho<span class="_ _4"></span>wed that com<span class="ws0">-</span></div><div class="t m3 xd ha y1cf ff8 fs0 fc1 sc0 ls0 ws9">pared with use of either agent alone<span class="_ _4"></span>, </div><div class="t m3 xd ha y1d0 ff8 fs0 fc1 sc0 ls0 ws5f">the combined use of these agents re<span class="ws0">-</span></div><div class="t m3 xd ha y1d1 ff8 fs0 fc1 sc0 ls0 ws15f">duced the risk of hospitalization or </div><div class="t m3 xd ha y1d2 ff8 fs0 fc1 sc0 ls0 ws5b">disease progression b<span class="_ _0"></span>y 50%, with only </div><div class="t m3 xd ha y1d3 ff8 fs0 fc1 sc0 ls0 ws1e">a moderate incr<span class="_ _4"></span>ease in nonserious ad<span class="ws0">-</span></div><div class="t m3 xd ha y1d4 ff8 fs0 fc1 sc0 ls0 ws160">verse effects (e.g., edema, headache) </div><div class="t m3 xd ha y1d5 ff8 fs0 fc1 sc0 ls0 ws161">in the combination therap<span class="_ _4"></span>y group<span class="_ _4"></span>.</div><div class="t m3 x92 hb y1d6 ff8 fs6 fc1 sc0 ls0 ws0">24</div><div class="t m3 x93 ha y1d5 ff8 fs0 fc1 sc0 ls12 ws162"> To<span class="_ _12"></span> </div><div class="t m3 xd ha y1d7 ff8 fs0 fc1 sc0 ls0 wsfd">date, ther<span class="_ _4"></span>e have been no trials directly </div><div class="t m3 xd ha y1d8 ff8 fs0 fc1 sc0 ls0 ws163">comparing selexipag with the combi<span class="ws0">-</span></div><div class="t m3 xd ha y1d9 ff8 fs0 fc1 sc0 ls0 ws38">nation of ambrisentan and tadalal. </div><div class="t m3 xd ha y1da ff8 fs0 fc1 sc0 ls0 ws164">Because of the benets of selexipag use </div><div class="t m3 xd ha y1db ff8 fs0 fc1 sc0 ls0 ws165">demonstrated in the GRIPHON trial,</div><div class="t m3 x2d hb y1dc ff8 fs6 fc1 sc0 ls0 ws0">20</div><div class="t m3 x2e ha y1db ff8 fs0 fc1 sc0 ls0 ws0"> </div><div class="t m3 xd ha y1dd ff8 fs0 fc1 sc0 ls0 ws33">as well as the benets associated with </div><div class="t m3 xd ha y1de ff8 fs0 fc1 sc0 ls0 ws166">combination therap<span class="_ _4"></span>y with ambris<span class="ws0">-</span></div><div class="t m3 xd ha y1df ff8 fs0 fc1 sc0 ls0 ws167">entan and tadalal,</div><div class="t m3 x38 hb y1e0 ff8 fs6 fc1 sc0 ls0 ws0">24</div><div class="t m3 x94 ha y1df ff8 fs0 fc1 sc0 ls0 ws167"> clinicians may </div><div class="t m3 xd ha y1e1 ff8 fs0 fc1 sc0 ls0 ws10c">choose a combination of these agents </div></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf6" class="pf w0 h0" data-page-no="6"><div class="pc pc6 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x1 h2 y4b ffb fs1 fc0 sc0 ls0 ws0">CLINICAL REVIEW </div><div class="t m0 x12 h1 y4c ffc fs0 fc0 sc0 ls0 ws0">SELEXIP<span class="_ _0"></span>AG</div><div class="t m1 x3 h3 y3 ff4 fs3 fc1 sc0 ls0 ws0">1140<span class="fs8"> <span class="_ _9"> </span><span class="fs2"> <span class="_ _a"> </span>AM J HEAL<span class="_ _5"></span>TH-SYST PHARM<span class="ff3 ws1"> | VOLUME <span class="_ _3"></span>74 | NUMBER <span class="_ _2"></span>15 | AUGUST <span class="_ _3"></span>1, <span class="_ _2"></span>2017</span></span></span></div><div class="t m3 x3 ha y4d ff8 fs0 fc1 sc0 ls0 ws138">to maximize treatment benets<span class="_ _4"></span>. S<span class="_ _4"></span>ub<span class="ws0">-</span></div><div class="t m3 x3 ha y4e ff8 fs0 fc1 sc0 ls0 ws12f">group analysis in the GRIPHON trial </div><div class="t m3 x3 ha y4f ff8 fs0 fc1 sc0 ls0 ws168">suggested that the benets of selexi<span class="ws0">-</span></div><div class="t m3 x3 ha y50 ff8 fs0 fc1 sc0 ls0 ws28">pag use are consistent irr<span class="_ _4"></span>espective of </div><div class="t m3 x3 ha y52 ff8 fs0 fc1 sc0 ls0 ws169">background therap<span class="_ _4"></span>y<span class="_ _5"></span>. Ther<span class="_ _0"></span>e is an on<span class="ws0">-</span></div><div class="t m3 x3 ha y53 ff8 fs0 fc1 sc0 ls0 ws10c">going trial to evaluate changes in PVR </div><div class="t m3 x3 ha y54 ff8 fs0 fc1 sc0 ls0 wsc7">in patients with newly diagnosed P<span class="_ _0"></span>AH </div><div class="t m3 x3 ha y55 ff8 fs0 fc1 sc0 ls0 ws16a">treated with the ERA macitentan in </div><div class="t m3 x3 ha y56 ff8 fs0 fc1 sc0 ls0 ws132">combination with tadalal and selexi<span class="ws0">-</span></div><div class="t m3 x3 ha y58 ff8 fs0 fc1 sc0 ls0 wsb7">pag or with selexipag plus either maci<span class="ws0">-</span></div><div class="t m3 x3 ha y59 ff8 fs0 fc1 sc0 ls0 ws11f">tentan or tadalal.</div><div class="t m3 x95 hb yf9 ff8 fs6 fc1 sc0 ls0 ws0">25</div><div class="t m3 x96 ha y59 ff8 fs0 fc1 sc0 ls0 ws11f"> Study completion </div><div class="t m3 x3 ha y5a ff8 fs0 fc1 sc0 ls0 ws5f">is not anticipated until 2018 but may </div><div class="t m3 x3 ha y5b ff8 fs0 fc1 sc0 ls0 ws8">pro<span class="_ _4"></span>vide additional insight on the use </div><div class="t m3 x3 ha y5c ff8 fs0 fc1 sc0 ls0 wsc6">of selexipag in combination with other </div><div class="t m3 x3 ha y5e ff8 fs0 fc1 sc0 ls0 ws0">P<span class="_ _0"></span>AH medications.</div><div class="t m3 x19 ha y60 ff8 fs0 fc1 sc0 ls0 ws16b">U<span class="_ _4"></span>ntil additional clinical trial data </div><div class="t m3 x3 ha y61 ff8 fs0 fc1 sc0 ls0 wsf6">are available<span class="_ _4"></span>, the poor prognosis and </div><div class="t m3 x3 ha y62 ff8 fs0 fc1 sc0 ls0 ws16c">limited treatment options for patients </div><div class="t m3 x3 ha y64 ff8 fs0 fc1 sc0 ls0 ws16d">with P<span class="_ _0"></span>AH may favor aggressive upfront </div><div class="t m3 x3 ha y65 ff8 fs0 fc1 sc0 ls0 ws16e">therap<span class="_ _4"></span>y combining selexipag with an </div><div class="t m3 x3 ha y67 ff8 fs0 fc1 sc0 ls0 ws16f">ERA, a PDE5 inhibitor<span class="_ _0"></span>, or both; how<span class="ws0">-</span></div><div class="t m3 x3 ha y68 ff8 fs0 fc1 sc0 ls0 ws3f">ever<span class="_ _0"></span>, the questionable benet of such </div><div class="t m3 x3 ha y69 ff8 fs0 fc1 sc0 ls0 wsf">treatment should be weighed against </div><div class="t m3 x3 ha y6a ff8 fs0 fc1 sc0 ls0 ws15b">the nancial burden and higher r<span class="_ _4"></span>ate </div><div class="t m3 x3 ha y6b ff8 fs0 fc1 sc0 ls0 ws170">of adverse effects that may occur with </div><div class="t m3 x3 ha y6c ff8 fs0 fc1 sc0 ls0 ws0">combination therapies<span class="_ _4"></span>. </div><div class="t m2 x3 h3 y1e2 ff4 fs3 fc2 sc0 ls0 ws0">Cost and access </div><div class="t m2 x3 h3 y1e3 ff4 fs3 fc2 sc0 ls0 ws0">considerations</div><div class="t m3 x19 ha y1e4 ff8 fs0 fc1 sc0 ls13 ws98">Selexipag is only available through </div><div class="t m3 x3 ha y1e5 ff8 fs0 fc1 sc0 ls13 ws64">Accr<span class="_ _4"></span>edo (Accredo H<span class="_ _0"></span>ealth, Inc., M<span class="_ _4"></span>em<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y1e6 ff8 fs0 fc1 sc0 ls13 ws171">phis, <span class="_ _4"></span>TN) and CVS (CVS H<span class="_ _4"></span>ealth, </div><div class="t m3 x3 ha y1e7 ff8 fs0 fc1 sc0 ls13 ws172">W<span class="_ _0"></span>oonsocket, RI) specialty pharma<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y1e8 ff8 fs0 fc1 sc0 ls13 ws54">cies. <span class="_ _0"></span>The average wholesale price for </div><div class="t m3 x3 ha y1e9 ff8 fs0 fc1 sc0 ls13 ws6">a 1-month supply of selexipag 200 </div><div class="t m1 x71 hd y1e9 ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x1a ha y1e9 ff8 fs0 fc1 sc0 ls0 ws0">g </div><div class="t m3 x3 ha y1ea ff8 fs0 fc1 sc0 ls13 ws173">is $11,208, with an average monthly </div><div class="t m3 x3 ha y1eb ff8 fs0 fc1 sc0 ls13 ws174">price of $17,424 for doses of 400 </div><div class="t m1 x71 hd y1eb ff5 fs0 fc1 sc0 ls0 ws0">m</div><div class="t m3 x1a ha y1eb ff8 fs0 fc1 sc0 ls0 ws0">g </div><div class="t m3 x3 ha y1ec ff8 fs0 fc1 sc0 ls13 ws3">and abo<span class="_ _4"></span>ve.</div><div class="t m3 x6b hb y1ed ff8 fs6 fc1 sc0 ls14 ws175">26</div><div class="t m3 x80 ha y1ec ff8 fs0 fc1 sc0 ls13 ws3"> In comparison, ERAs cost </div><div class="t m3 x3 ha y1ee ff8 fs0 fc1 sc0 ls13 ws176">approximately $10,000 per month, </div><div class="t m3 x3 ha y1ef ff8 fs0 fc1 sc0 ls13 ws177">and the oral prostacyclin analogue </div><div class="t m3 x3 ha y1f0 ff8 fs0 fc1 sc0 ls13 wsc7">treprostinil diolamine costs up<span class="_ _0"></span>ward of<span class="ffe ls0 ws0"> </span></div><div class="t m3 x3 ha y1f1 ff8 fs0 fc1 sc0 ls13 wsed">$10,000 per month for a median dos<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y1f2 ff8 fs0 fc1 sc0 ls13 ws178">age of 2.55 mg twice daily<span class="_ _5"></span>.</div><div class="t m3 x97 hb y1f3 ff8 fs6 fc1 sc0 ls14 ws175">26</div><div class="t m3 x1e ha y1f2 ff8 fs0 fc1 sc0 ls13 ws178"> Finan<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y1f4 ff8 fs0 fc1 sc0 ls13 ws179">cial assistance programs for insur<span class="_ _4"></span>ed </div><div class="t m3 x3 ha y1f5 ff8 fs0 fc1 sc0 ls13 ws96">or uninsured individuals ar<span class="_ _4"></span>e available </div><div class="t m3 x3 ha y1f6 ff8 fs0 fc1 sc0 ls13 wscc">through Actelion Pharmaceuticals<span class="_ _4"></span>. At </div><div class="t m3 x3 ha y1f7 ff8 fs0 fc1 sc0 ls13 ws2f">this time, data r<span class="_ _4"></span>egarding the compar<span class="_ _4"></span>a<span class="ls0 ws0">-</span></div><div class="t m3 x3 ha y1f8 ff8 fs0 fc1 sc0 ls13 ws17a">tive cost-effectiveness of se <span class="_ _2a"></span>lex <span class="_ _2a"></span>ipag and </div><div class="t m3 x3 ha y1f9 ff8 fs0 fc1 sc0 ls13 ws0">other therapies for P<span class="_ _0"></span>AH are lacking.</div><div class="t m2 x3 h3 y1fa ff4 fs3 fc2 sc0 ls0 ws0">Conclusion</div><div class="t m3 x19 ha yf3 ff8 fs0 fc1 sc0 ls0 ws9d">Selexipag is an oral pr<span class="_ _4"></span>ostacyclin </div><div class="t m3 x3 ha yf4 ff8 fs0 fc1 sc0 ls0 wse1">IP receptor agonist appro<span class="_ _0"></span>ved for use </div><div class="t m3 x3 ha yf6 ff8 fs0 fc1 sc0 ls0 wscf">as monotherap<span class="_ _4"></span>y or in combination </div><div class="t m3 x3 ha yf7 ff8 fs0 fc1 sc0 ls0 ws8c">with other therapies to slo<span class="_ _4"></span>w P<span class="_ _0"></span>AH pro<span class="ws0">-</span></div><div class="t m3 xa ha y4d ff8 fs0 fc1 sc0 ls0 ws5">gression and r<span class="_ _4"></span>educe the risk of hospi<span class="ws0">-</span></div><div class="t m3 xa ha y4e ff8 fs0 fc1 sc0 ls0 ws5f">talization in patients with FC II or III </div><div class="t m3 xa ha y4f ff8 fs0 fc1 sc0 ls0 ws12f">symptoms. I<span class="_ _4"></span>ts stability and relativ<span class="_ _4"></span>ely </div><div class="t m3 xa ha y50 ff8 fs0 fc1 sc0 ls0 wscb">long half-life offer conveniences o<span class="_ _4"></span>ver </div><div class="t m3 xa ha y52 ff8 fs0 fc1 sc0 ls0 ws0">conventional prostanoid therapies<span class="_ _4"></span>.</div><div class="t m2 xa h3 yc0 ff4 fs3 fc2 sc0 ls0 ws0">Disclosures</div><div class="t m3 xa h12 y1fb ff8 fs8 fc1 sc0 ls0 ws17b">The authors have declared no potential </div><div class="t m3 xa h12 y1fc ff8 fs8 fc1 sc0 ls0 ws0">conicts of interest.</div><div class="t m2 xa h3 y1fd ff4 fs3 fc2 sc0 ls0 ws0">References</div><div class="t m1 x98 h12 y1fe ff8 fs8 fc1 sc0 ls0 ws0">1. <span class="_ _12"> </span>Peacock AJ, M<span class="_ _0"></span>urphy NF<span class="_ _7"></span>, McM<span class="_ _0"></span>urray </div><div class="t m1 x9 h12 y1ff ff8 fs8 fc1 sc0 ls0 ws0">JJ et al. An epidemiological study of </div><div class="t m1 x9 h12 y200 ff8 fs8 fc1 sc0 ls0 ws0">pulmonary arter<span class="_ _8"></span>ial hypertension. <span class="ff9">Eur </span></div><div class="t m1 x9 h12 y201 ff9 fs8 fc1 sc0 ls0 ws0">Respir J.<span class="ff8"> 2007; 30:104-9.</span></div><div class="t m1 x98 h12 y202 ff8 fs8 fc1 sc0 ls0 ws0">2. <span class="_ _12"> </span>Archer SL, <span class="_ _0"></span>W<span class="_ _0"></span>eir EK, <span class="_ _4"></span>Wilkins MR. </div><div class="t m1 x9 h12 y203 ff8 fs8 fc1 sc0 ls0 ws0">Basic science of pulmonary arte-</div><div class="t m1 x9 h12 y204 ff8 fs8 fc1 sc0 ls0 ws0">rial hypertension for clinicians: new </div><div class="t m1 x9 h12 y205 ff8 fs8 fc1 sc0 ls0 ws0">concepts and experimental therapies. </div><div class="t m1 x9 h12 y206 ff9 fs8 fc1 sc0 ls0 ws0">Circulation.<span class="ff8"> 2010; 121:2045-66.</span></div><div class="t m1 x98 h12 y207 ff8 fs8 fc1 sc0 ls0 ws0">3. <span class="_ _12"> </span>Montani D<span class="_ _0"></span>, Gunther S, Dorfmuller P </div><div class="t m1 x9 h12 y208 ff8 fs8 fc1 sc0 ls0 ws0">et al. Pulmonary arterial hyperten-</div><div class="t m1 x9 h12 y209 ff8 fs8 fc1 sc0 ls0 ws0">sion. <span class="ff9">Orphanet J Rar<span class="_ _4"></span>e Dis.<span class="ff8"> 2013; 8:97.</span></span></div><div class="t m1 x98 h12 y20a ff8 fs8 fc1 sc0 ls0 ws0">4. <span class="_ _12"> </span>F<span class="_ _4"></span>arber HW<span class="_ _5"></span>, Loscalzo J. Pulmonary </div><div class="t m1 x9 h12 y20b ff8 fs8 fc1 sc0 ls0 ws0">arterial hypertension. <span class="ff9">N Engl J Med.</span> </div><div class="t m1 x9 h12 y20c ff8 fs8 fc1 sc0 ls0 ws0">2004; 351:1655-65.</div><div class="t m1 x98 h12 y20d ff8 fs8 fc1 sc0 ls0 ws0">5. <span class="_ _12"> </span>T<span class="_ _5"></span>aichman DB, Ornelas J, Chung L et </div><div class="t m1 x9 h12 y20e ff8 fs8 fc1 sc0 ls0 ws0">al. Pharmacologic therap<span class="_ _4"></span>y for pulmo-</div><div class="t m1 x9 h12 y20f ff8 fs8 fc1 sc0 ls0 ws0">nary arter<span class="_ _8"></span>ial hypertension in adults: </div><div class="t m1 x9 h12 y210 ff8 fs8 fc1 sc0 ls0 ws0">CHEST guideline and expert panel </div><div class="t m1 x9 h12 y211 ff8 fs8 fc1 sc0 ls0 ws0">report. <span class="ff9">Chest.</span> 2014; 146:449-75.</div><div class="t m1 x98 h12 y212 ff8 fs8 fc1 sc0 ls0 ws0">6. <span class="_ _12"> </span>Galie N, H<span class="_ _4"></span>umbert M, <span class="_ _4"></span>V<span class="_ _0"></span>achier<span class="_ _8"></span>y JL et </div><div class="t m1 x9 h12 yd8 ff8 fs8 fc1 sc0 ls0 ws0">al. 2015 ESC/ERS guidelines for the </div><div class="t m1 x9 h12 y213 ff8 fs8 fc1 sc0 ls0 ws0">diagnosis and treatment of pulmo-</div><div class="t m1 x9 h12 y214 ff8 fs8 fc1 sc0 ls0 ws0">nary hypertension. <span class="ff9">Eur Heart J.</span> 2016; </div><div class="t m1 x9 h12 y215 ff8 fs8 fc1 sc0 ls0 ws0">37:67-119.</div><div class="t m1 x98 h12 y216 ff8 fs8 fc1 sc0 ls0 ws0">7. <span class="_ _12"> </span>Macaulay <span class="_ _4"></span>TE, Co<span class="_ _4"></span>vell MB, P<span class="_ _4"></span>ogue KT<span class="_ _5"></span>. </div><div class="t m1 x9 h12 y217 ff8 fs8 fc1 sc0 ls0 ws0">An update on the management of </div><div class="t m1 x9 h12 y218 ff8 fs8 fc1 sc0 ls0 ws0">pulmonary arter<span class="_ _8"></span>ial hypertension and </div><div class="t m1 x9 h12 y219 ff8 fs8 fc1 sc0 ls0 ws0">the pharmacist<span class="_ _5"></span>s role. <span class="ff9">J P<span class="_ _4"></span>harm Pract.<span class="ff8"> </span></span></div><div class="t m1 x9 h12 y21a ff8 fs8 fc1 sc0 ls0 ws0">2016; 29:67-76.</div><div class="t m1 x98 h12 y21b ff8 fs8 fc1 sc0 ls0 ws0">8. <span class="_ _12"> </span>V<span class="_ _0"></span>entavis (iloprost) package insert. </div><div class="t m1 x9 h12 y21c ff8 fs8 fc1 sc0 ls0 ws0">San F<span class="_ _4"></span>rancisco<span class="_ _4"></span>, CA: Actelion Pharma-</div><div class="t m1 x9 h12 y21d ff8 fs8 fc1 sc0 ls0 ws0">ceuticals US, Inc.; 2016 O<span class="_ _4"></span>ct. </div><div class="t m1 x98 h12 y21e ff8 fs8 fc1 sc0 ls15 ws17c">9. <span class="_ _6"></span><span class="ws0">Uptr<span class="_ _4"></span>avi (selexipag) prescribing </span></div><div class="t m1 x9 h12 y21f ff8 fs8 fc1 sc0 ls15 ws0">information. San Fr<span class="_ _4"></span>ancisco<span class="_ _4"></span>, CA: </div><div class="t m1 x9 h12 y220 ff8 fs8 fc1 sc0 ls15 ws0">Actelion Pharmaceuticals US, Inc<span class="_ _4"></span>.; </div><div class="t m1 x9 h12 y221 ff8 fs8 fc1 sc0 ls15 ws0">2015 Dec.</div><div class="t m1 xa h12 y222 ff8 fs8 fc1 sc0 ls0 ws0">10. <span class="_ _12"> </span>Kuwano K, H<span class="_ _0"></span>ashino A, Asaki T et </div><div class="t m1 x9 h12 y223 ff8 fs8 fc1 sc0 ls0 ws0">al. 2-[4-[(5,6-diphenylpyr<span class="_ _4"></span>azin-2-yl)</div><div class="t m1 x9 h12 y224 ff8 fs8 fc1 sc0 ls0 ws0">(isopropyl)amino]buto<span class="_ _4"></span>xy]-<span class="ff9">N</span>-</div><div class="t m1 x9 h12 y225 ff8 fs8 fc1 sc0 ls0 ws0">(methylsulfonyl)acetamide (NS-304), </div><div class="t m1 x9 h12 y226 ff8 fs8 fc1 sc0 ls0 ws0">an orally available and long-acting </div><div class="t m1 x9 h12 y227 ff8 fs8 fc1 sc0 ls0 ws0">prostacyclin r<span class="_ _4"></span>eceptor agonist pro-</div><div class="t m1 x9 h12 y228 ff8 fs8 fc1 sc0 ls0 ws0">drug. <span class="ff9">J Pharmacol Exp Ther<span class="_ _5"></span>.<span class="ff8"> 2007; </span></span></div><div class="t m1 x9 h12 y229 ff8 fs8 fc1 sc0 ls0 ws0">322:1181-8.</div><div class="t m1 xa h12 y22a ff8 fs8 fc1 sc0 ls0 ws0">11. <span class="_ _12"> </span>Humbert M, Sitbon O<span class="_ _0"></span>, Simonneau </div><div class="t m1 x9 h12 y22b ff8 fs8 fc1 sc0 ls0 ws0">G. <span class="_ _4"></span>T<span class="_ _0"></span>reatment of pulmonary arterial </div><div class="t m1 x9 h12 y22c ff8 fs8 fc1 sc0 ls0 ws0">hypertension. <span class="ff9">N Engl J Med.</span> 2004; </div><div class="t m1 x9 h12 y22d ff8 fs8 fc1 sc0 ls0 ws0">351:1425-36.</div><div class="t m1 xa h12 y22e ff8 fs8 fc1 sc0 ls0 ws0">12. <span class="_ _12"> </span>Kuwano K, H<span class="_ _0"></span>ashino A, Noda K et </div><div class="t m1 x9 h12 y22f ff8 fs8 fc1 sc0 ls0 ws0">al. A long-acting and highly selec-</div><div class="t m1 x9 h12 y230 ff8 fs8 fc1 sc0 ls0 ws0">tive prostacyclin r<span class="_ _4"></span>eceptor agonist </div><div class="t m1 x9 h12 y231 ff8 fs8 fc1 sc0 ls0 ws0">prodrug, 2-{4-[(5,6-diphenylpyr<span class="_ _4"></span>azin-</div><div class="t m1 x2a h12 y232 ff8 fs8 fc1 sc0 ls0 ws0">2-yl)(isopropyl)amino]buto<span class="_ _4"></span>xy}-<span class="ff9">N</span>-</div><div class="t m1 x2a h12 y233 ff8 fs8 fc1 sc0 ls0 ws0">(methylsulfonyl)acetamide (NS-304), </div><div class="t m1 x2a h12 y234 ff8 fs8 fc1 sc0 ls0 ws0">ameliorates rat pulmonary hyperten-</div><div class="t m1 x2a h12 y235 ff8 fs8 fc1 sc0 ls0 ws0">sion with unique relaxant r<span class="_ _4"></span>esponses </div><div class="t m1 x2a h12 y236 ff8 fs8 fc1 sc0 ls0 ws0">of its active form, {4-[(5,6-diphen-</div><div class="t m1 x2a h12 y237 ff8 fs8 fc1 sc0 ls0 ws0">ylpyr<span class="_ _4"></span>azin-2-yl)(isopropyl)amino]</div><div class="t m1 x2a h12 y238 ff8 fs8 fc1 sc0 ls0 ws0">butoxy}acetic acid (MRE-269), on rat </div><div class="t m1 x2a h12 y239 ff8 fs8 fc1 sc0 ls0 ws0">pulmonary arter<span class="_ _8"></span>y<span class="_ _5"></span>. <span class="ff9">J Pharmacol Exp </span></div><div class="t m1 x2a h12 y23a ff9 fs8 fc1 sc0 ls0 ws0">Ther<span class="_ _5"></span>.<span class="ff8"> 2008; 326:691-9.</span></div><div class="t m1 xd h12 y23b ff8 fs8 fc1 sc0 ls0 ws0">13. <span class="_ _12"> </span>Morrison K, Ernst R, H<span class="_ _4"></span>ess P et al. </div><div class="t m1 x2a h12 y23c ff8 fs8 fc1 sc0 ls0 ws0">Selexipag: a selective prostacyclin </div><div class="t m1 x2a h12 y23d ff8 fs8 fc1 sc0 ls0 ws0">receptor agonist that does not affect </div><div class="t m1 x2a h12 y23e ff8 fs8 fc1 sc0 ls0 ws0">rat gastric function. <span class="ff9">J Pharmacol Exp </span></div><div class="t m1 x2a h12 y23f ff9 fs8 fc1 sc0 ls0 ws0">Ther<span class="_ _5"></span>.<span class="ff8"> 2010; 335:249-55.</span></div><div class="t m1 xd h12 y240 ff8 fs8 fc1 sc0 ls0 ws0">14. <span class="_ _12"> </span>Baldoni D<span class="_ _4"></span>, Bruderer S, M<span class="_ _0"></span>uhsen N </div><div class="t m1 x2a h12 y241 ff8 fs8 fc1 sc0 ls0 ws0">et al. Bioequivalence of differ<span class="_ _4"></span>ent </div><div class="t m1 x2a h12 y242 ff8 fs8 fc1 sc0 ls0 ws0">dose-strength tablets of selexipag, a </div><div class="t m1 x2a h12 y243 ff8 fs8 fc1 sc0 ls0 ws0">selective prostacyclin r<span class="_ _4"></span>eceptor ago-</div><div class="t m1 x2a h12 y244 ff8 fs8 fc1 sc0 ls0 ws0">nist, in a multiple-dose up-titration </div><div class="t m1 x2a h12 y245 ff8 fs8 fc1 sc0 ls0 ws0">study<span class="_ _5"></span>. <span class="ff9 ws17d">Int J Clin Pharmacol Ther<span class="_ _5"></span>.<span class="ff8"> 2015; </span></span></div><div class="t m1 x2a h12 y246 ff8 fs8 fc1 sc0 ls0 ws0">53:788-98.</div><div class="t m1 xd h12 y247 ff8 fs8 fc1 sc0 ls0 ws0">15. <span class="_ _12"> </span>Kaufmann P<span class="_ _2a"></span>, Niglis S, Bruderer S et </div><div class="t m1 x2a h12 y248 ff8 fs8 fc1 sc0 ls0 ws0">al. Effect of lopinavir/ritonavir on the </div><div class="t m1 x2a h12 y249 ff8 fs8 fc1 sc0 ls0 ws0">pharmacokinetics of selexipag an oral </div><div class="t m1 x2a h12 y24a ff8 fs8 fc1 sc0 ls0 ws0">prostacyclin r<span class="_ _4"></span>eceptor agonist and its </div><div class="t m1 x2a h12 y24b ff8 fs8 fc1 sc0 ls0 ws0">active metabolite in healthy subjects. </div><div class="t m1 x2a h12 y24c ff9 fs8 fc1 sc0 ls0 ws0">Br J Clin Pharmacol.<span class="ff8"> 2015; 80:670-7.</span></div><div class="t m1 xd h12 y24d ff8 fs8 fc1 sc0 ls0 ws0">16. <span class="_ _12"> </span>Kaufmann P<span class="_ _2a"></span>, Okubo K, Bruderer S </div><div class="t m1 x2a h12 y24e ff8 fs8 fc1 sc0 ls0 ws0">et al. Pharmacokinetics and toler-</div><div class="t m1 x2a h12 y24f ff8 fs8 fc1 sc0 ls0 ws0">ability of the nov<span class="_ _4"></span>el oral prostacyclin </div><div class="t m1 x2a h12 y250 ff8 fs8 fc1 sc0 ls0 ws0">IP receptor agonist selexipag. <span class="ff9">A<span class="_ _4"></span>m J </span></div><div class="t m1 x2a h12 y251 ff9 fs8 fc1 sc0 ls0 ws0">Car<span class="_ _4"></span>diovasc Drugs.<span class="ff8"> 2015; 15:195-203.</span></div><div class="t m1 xd h12 y252 ff8 fs8 fc1 sc0 ls0 ws0">17. <span class="_ _12"> </span>Bruderer S, Okubo K, M<span class="_ _0"></span>ukai H et al. </div><div class="t m1 x2a h12 y253 ff8 fs8 fc1 sc0 ls0 ws0">Investigation of potential pharma-</div><div class="t m1 x2a h12 y254 ff8 fs8 fc1 sc0 ls0 ws0">codynamic and pharmacokinetic </div><div class="t m1 x2a h12 y255 ff8 fs8 fc1 sc0 ls0 ws0">interactions between selexipag and </div><div class="t m1 x2a h12 y256 ff8 fs8 fc1 sc0 ls0 ws0">warfarin in healthy male subjects. </div><div class="t m1 x2a h12 y257 ff9 fs8 fc1 sc0 ls0 ws0">Clin Ther<span class="_ _5"></span>.<span class="ff8"> 2016; 38:1228,1236.e1.</span></div><div class="t m1 xd h12 y258 ff8 fs8 fc1 sc0 ls0 ws0">18. <span class="_ _12"> </span>Kaufmann P<span class="_ _2a"></span>, Cruz HG, Krause A et al. </div><div class="t m1 x2a h12 y259 ff8 fs8 fc1 sc0 ls0 ws0">Pharmacokinetics of the nov<span class="_ _4"></span>el oral </div><div class="t m1 x2a h12 y25a ff8 fs8 fc1 sc0 ls0 ws0">prostacyclin r<span class="_ _4"></span>eceptor agonist selexi-</div><div class="t m1 x2a h12 y25b ff8 fs8 fc1 sc0 ls0 ws0">pag in subjects with hepatic or renal </div><div class="t m1 x2a h12 y25c ff8 fs8 fc1 sc0 ls0 ws0">impairment. <span class="ff9">Br J Clin Pharmacol.</span> </div><div class="t m1 x2a h12 y25d ff8 fs8 fc1 sc0 ls0 ws0">2016; 82:369-79.</div><div class="t m1 xd h12 y25e ff8 fs8 fc1 sc0 ls0 ws0">19. <span class="_ _12"> </span>Simonneau G, <span class="_ _4"></span>T<span class="_ _5"></span>orbicki A, Hoeper </div><div class="t m1 x2a h12 y25f ff8 fs8 fc1 sc0 ls0 ws0">MM et al. Selexipag: an oral, selective </div><div class="t m1 x2a h12 y260 ff8 fs8 fc1 sc0 ls0 ws0">prostacyclin r<span class="_ _4"></span>eceptor agonist for </div><div class="t m1 x2a h12 y261 ff8 fs8 fc1 sc0 ls0 ws0">the treatment of pulmonary arterial </div><div class="t m1 x2a h12 y262 ff8 fs8 fc1 sc0 ls0 ws0">hypertension. <span class="ff9">Eur Respir J.</span> 2012; </div><div class="t m1 x2a h12 y263 ff8 fs8 fc1 sc0 ls0 ws0">40:874-80.</div><div class="t m1 xd h12 y264 ff8 fs8 fc1 sc0 ls0 ws0">20. <span class="_ _12"> </span>Sitbon O<span class="_ _0"></span>, Channick R, Chin KM et al. </div><div class="t m1 x2a h12 y265 ff8 fs8 fc1 sc0 ls0 ws0">Selexipag for the tr<span class="_ _4"></span>eatment of pulmo-</div><div class="t m1 x2a h12 y266 ff8 fs8 fc1 sc0 ls0 ws0">nary arter<span class="_ _8"></span>ial hypertension. <span class="ff9">N Engl J </span></div><div class="t m1 x2a h12 y267 ff9 fs8 fc1 sc0 ls0 ws0">Med.<span class="ff8"> 2015; 373:2522-33.</span></div><div class="t m1 xd h12 y268 ff8 fs8 fc1 sc0 ls0 ws0">21. <span class="_ _12"> </span>ClincalT<span class="_ _0"></span>rials.gov<span class="_ _5"></span>. Long-term, </div><div class="t m1 x2a h12 y269 ff8 fs8 fc1 sc0 ls0 ws0">single-arm, multicenter<span class="_ _0"></span>, open-label </div><div class="t m1 x2a h12 y26a ff8 fs8 fc1 sc0 ls0 ws0">extension, Phase 3 study<span class="_ _5"></span>, to evaluate </div><div class="t m1 x2a h12 y26b ff8 fs8 fc1 sc0 ls0 ws0">the safety and tolerability of A<span class="_ _4"></span>CT<span class="_ _5"></span>-</div><div class="t m1 x2a h12 y26c ff8 fs8 fc1 sc0 ls0 ws0">293987 in patients with P<span class="_ _0"></span>AH who </div><div class="t m1 x2a h12 y26d ff8 fs8 fc1 sc0 ls0 ws0">participated in the double-blind </div><div class="t m1 x2a h12 y26e ff8 fs8 fc1 sc0 ls0 ws0">study AC-065A302 (GRIP<span class="_ _4"></span>HON). </div><div class="t m1 x2a h12 y26f ff8 fs8 fc1 sc0 ls0 ws0">https://clinicaltrials.go<span class="_ _4"></span>v/ct2/show/</div><div class="t m1 x2a h12 y270 ff8 fs8 fc1 sc0 ls0 ws0">NCT01112306?term=griphon&amp;rank=2 </div><div class="t m1 x2a h12 y271 ff8 fs8 fc1 sc0 ls0 ws0">(accessed 2016 Dec 20). </div><div class="t m1 xd h12 y272 ff8 fs8 fc1 sc0 ls0 ws0">22. <span class="_ _12"> </span>Hoch M, Darpo B<span class="_ _4"></span>, Remeno<span class="_ _4"></span>va <span class="_ _4"></span>T et al. </div><div class="t m1 x2a h12 y273 ff8 fs8 fc1 sc0 ls0 ws0">A thorough QT study in the context of </div><a class="l" href="https://clinicaltrials.gov/ct2/show/NCT01112306?term=griphon&amp;rank=2"><div class="d m4" style="border-style:none;position:absolute;left:473.400000px;bottom:111.600000px;width:127.934000px;height:9.120000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" href="https://clinicaltrials.gov/ct2/show/NCT01112306?term=griphon&amp;rank=2"><div class="d m4" style="border-style:none;position:absolute;left:473.400000px;bottom:99.600000px;width:135.454000px;height:9.120000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf7" class="pf w0 h0" data-page-no="7"><div class="pc pc7 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x1 h1 y1 ff1 fs0 fc0 sc0 ls0 ws0">SELEXIP<span class="_ _0"></span>AG </div><div class="t m0 x2 h2 y2 ff2 fs1 fc0 sc0 ls0 ws0">CLINICAL REVIEW</div><div class="t m1 x3 h3 y3 ff3 fs2 fc1 sc0 ls0 ws0"> <span class="_ _1"> </span><span class="ff4">AM J HEAL<span class="_ _5"></span>TH-SYST PHARM<span class="ff3 ws1"> | VOLUME <span class="_ _3"></span>74 | NUMBER <span class="_ _2"></span>15 | AUGUST <span class="_ _3"></span>1, <span class="_ _2"></span>2017  <span class="ff4 fs3 ws0">1141</span></span></span></div><div class="t m1 x19 h12 y274 ff8 fs8 fc1 sc0 ls0 ws0">an uptitration regimen with selexi-</div><div class="t m1 x19 h12 y275 ff8 fs8 fc1 sc0 ls0 ws0">pag, a selective oral prostacyclin r<span class="_ _4"></span>e-</div><div class="t m1 x19 h12 y276 ff8 fs8 fc1 sc0 ls0 ws0">ceptor agonist. <span class="ff9">Drug Des Devel Ther<span class="_ _5"></span>.<span class="ff8"> </span></span></div><div class="t m1 x19 h12 y277 ff8 fs8 fc1 sc0 ls0 ws0">2014; 9:175-85.</div><div class="t m1 x3 h12 y278 ff8 fs8 fc1 sc0 ls0 ws0">23. <span class="_ _12"> </span>Bruderer S, H<span class="_ _4"></span>urst N, Kaufmann P et </div><div class="t m1 x19 h12 y279 ff8 fs8 fc1 sc0 ls0 ws0">al. M<span class="_ _4"></span>ultiple-dose up-titration study </div><div class="t m1 x19 h12 y27a ff8 fs8 fc1 sc0 ls0 ws0">to evaluate the safety<span class="_ _5"></span>, tolerability<span class="_ _0"></span>, </div><div class="t m1 x19 h12 y27b ff8 fs8 fc1 sc0 ls0 ws0">pharmacokinetics, and pharmacody-</div><div class="t m1 x19 h12 y27c ff8 fs8 fc1 sc0 ls0 ws0">namics of selexipag, an orally avail-</div><div class="t m1 x19 h12 y27d ff8 fs8 fc1 sc0 ls0 ws0">able selective prostacyclin r<span class="_ _4"></span>eceptor </div><div class="t m1 x19 h12 y27e ff8 fs8 fc1 sc0 ls0 ws0">agonist, in healthy subjects. <span class="ff9">P<span class="_ _4"></span>harma-</span></div><div class="t m1 x19 h12 y27f ff9 fs8 fc1 sc0 ls0 ws0">cology<span class="_ _4"></span>.<span class="ff8"> 2014; 94:148-56.</span></div><div class="t m1 x3 h12 y280 ff8 fs8 fc1 sc0 ls0 ws0">24. <span class="_ _12"> </span><span class="ws17d">Galie N, Barbera JA, F<span class="_ _4"></span>rost AE et al. Ini<span class="ws0">-</span></span></div><div class="t m1 x19 h12 y281 ff8 fs8 fc1 sc0 ls0 ws0">tial use of ambrisentan plus tadalal </div><div class="t m1 x19 h12 y282 ff8 fs8 fc1 sc0 ls0 ws0">in pulmonary arter<span class="_ _8"></span>ial hypertension. </div><div class="t m1 x19 h12 y283 ff9 fs8 fc1 sc0 ls0 ws0">N Engl J M<span class="_ _4"></span>ed.<span class="ff8"> 2015; 373:834-44.</span></div><div class="t m1 x3 h12 y284 ff8 fs8 fc1 sc0 ls0 ws0">25. <span class="_ _12"> </span>ClinicalT<span class="_ _0"></span>rials.gov<span class="_ _5"></span>. <span class="_ _4"></span>The efcacy and </div><div class="t m1 x19 h12 y285 ff8 fs8 fc1 sc0 ls0 ws0">safety of initial triple versus initial </div><div class="t m1 x19 h12 y286 ff8 fs8 fc1 sc0 ls0 ws0">dual oral combination therap<span class="_ _4"></span>y </div><div class="t m1 x19 h12 y287 ff8 fs8 fc1 sc0 ls0 ws0">in patients with newly diagnosed </div><div class="t m1 x19 h12 y288 ff8 fs8 fc1 sc0 ls0 ws0">pulmonary arter<span class="_ _8"></span>ial hypertension </div><div class="t m1 x19 h12 y289 ff8 fs8 fc1 sc0 ls0 ws0">(<span class="_ _8"></span>TRITON). https://clinicaltrials.go<span class="_ _4"></span>v/</div><div class="t m1 x19 h12 y28a ff8 fs8 fc1 sc0 ls0 ws0">ct2/show/NCT02558231 (accessed </div><div class="t m1 x19 h12 y28b ff8 fs8 fc1 sc0 ls0 ws0">2016 Dec 20).</div><div class="t m1 x3 h12 y28c ff8 fs8 fc1 sc0 ls0 ws0">26. <span class="_ _12"> </span>Redbook Online [online database]. </div><div class="t m1 x19 h12 y28d ff8 fs8 fc1 sc0 ls0 ws17e">Greenwood Village<span class="_ _4"></span>, <span class="_ _8"></span>CO: <span class="_ _8"></span>T<span class="_ _0"></span>ruven </div><div class="t m1 x19 h12 y28e ff8 fs8 fc1 sc0 ls0 ws0">Health Analytics (accessed 2016 D<span class="_ _4"></span>ec </div><div class="t m1 x19 h12 y28f ff8 fs8 fc1 sc0 ls0 ws0">20).</div><a class="l" href="https://clinicaltrials.gov/ct2/show/NCT02558231"><div class="d m4" style="border-style:none;position:absolute;left:129.124800px;bottom:591.048000px;width:90.750000px;height:9.120000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" href="https://clinicaltrials.gov/ct2/show/NCT02558231"><div class="d m4" style="border-style:none;position:absolute;left:81.000000px;bottom:579.048000px;width:87.783000px;height:9.120000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
</div>
<div class="loading-indicator">
<img alt="" src="data:image/png;base64,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"/>
</div>
</body>
</html>
